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Abstract
Although much has been unravelled with regards to the mechanisms o f  
proteolys is  o f  exogen ous ly  derived antigen for presentation via  
histocompatib il ity  class-II (MHC-II),  key questions remain unresolved.  
The exact role o f  each proteolytic  enzyme in this process  is not 
understood. The aspartic proteinase cathepsin E is hypothes ised  to play  
an important role.  The aim o f  this study is to examine this by the use o f  
novel aspartic proteinase inhibitors based upon the aspartic proteinase  
inhibitor pepstatin A.
The first two inhibitors designed and synthes ised  included a mannose  
sugar m olecu le  to improve solubi li ty ,  a l inker section  and a s ingle  
pepstatin molecule .  The mannose derivat ive 3 ’-succinimidoxycarbonyl-  
propyl 2,3,4,6-tetra-0-acetyl-a-D-mannopyranoside was synthes ised and 
l inked via  an amide bond to either A-^-butyloxycarbonyl) propane-1,3- 
diamine or ^-(/-butyloxycarbonyl) cystamine, the latter o f  these containing a 
cellularly cleavable disulphide bond. After deprotection, the amines o f  these 
two molecules were further reacted with pepstatin succinimide to form the 
precursors to the inhibitors A/'- (3-(a-D-mannopyranosyloxy)  
propylcarbonyl) ,A’ (pepstat- inyl)  propane-1,3-diamine (Mannose  
Pepstatin Conjugate 1, MPC1) and Ar- (3 - (a -D -m an n op yran osy loxy)  
propylcarbonyl) ,A’-(pepstatinyl)  cyst-amine (M PC2),  the final products  
being formed by se lect ive  removal o f  the mannopyranosyl acetyl  
protecting groups. The purified inhibitors were tested in a we l l -  
characterised in v it ro  model o f  antigen process ing ,  in which ovalbumin  
is processed and presented by a B -ce l l  l ine  A 20  to ova lbum in-spec i f ic  T- 
cell s ,  D O 11-10 .
Further studies aimed to address the role o f  cathepsin E within dendritic 
cell s  (DCs) ,  one o f  the key cell s  invo lved  in initiating and propagating  
immune response  to antigen. Further inhibitors were  des igned with the
aim o f  improving solubi li ty  and cellular targeting. These inhibitors  
contained multiple mannose sugars attached either to a protein backbone  
bovine serum albumin (MPC5 and 6 ) or a p o ly - ly s in e  backbone (MPC3 
and 4). As for MPC2, a c leavable  l inker was inc luded in the design o f  
MPC4 and M PC6 , to facil itate intracellular release o f  pepstatin from the 
carrier.
The full synthes is  o f  MPC5 and M PC6 was achieved by the coupling  o f  
either A-(iodoacetyl) ,A’-(pepstatinyl) propane-1,3-diamine (MPC5) or N-  
(iodoacetyl) ,Ar’-(pepstatinyl) cystamine (MPC6 ) to the single free sulfhydryl 
o f  mannosylated bovine serum albumin (BSA) protein. The mannosylated  
BSA protein was achieved by the thiourea bond formation between the 
multiple lysine residues contained within BSA and the amine-reactive  
mannose derivative 4-isothiocyanatophenyl a-D-mannopyranoside.  
Biochemical tests showed that between 22 and 24 mannose units were 
coupled to each BSA protein. The inhibitors MPC5 and M PC 6 were tested  
for their abil ity to block process ing and presentation o f  ovalbumin by  
mouse bone-marrow derived DCs. Since  pepstat in A inhibits not only  
cathepsin E but also the lysosom al  proteinase catheps in D, the inhibitors  
were further tested on DCs prepared from mice  def ic ient  in cathepsin D.  
The results suggest that cathepsin E has an important and non-redundant  
role in antigen processing o f  ovalbumin by dendritic cel ls .
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Chapter 1
From Antigen to Immune Response -  An Antigen 
Processing and Presentation Viewpoint
1.1 Introduction
The recognit ion o f  foreign particles such as proteins,  peptides,  l ipids  
and carbohydrates (known as antigen) by effector cell s  expressing  
specif ic  antigen receptors is paramount to forming a successfu l  
adaptive immune response.  Antigen present ing cell s  (APCs) hold the 
key role o f  internalising, processing and presenting so luble  antigen to 
T lymphocytes  that occurs through the interaction o f  the T-cell  
receptor (TCR) complex with APC presented antigen on surface 
majorhistocompatib il i ty  complex (MHC) c lass-I  or -II molecu les .
The mechanisms involved in the antigen process ing  and presentation  
pathways o f  APCs are complex. These mechanisms are not a set o f  
distinct predictable processes  and have great diversi ty  in their action.  
One protein can be proteolytically  c leaved into numerous fragments,  in 
theory to produce many antigenic peptides .  However  more often than 
not a s ingle  or several immunodominant peptides  are produced. The 
mechanisms that control this process are sti ll  being studied, but it is 
known that the enzymes that proteoly t ica lly  c leave  antigenic  proteins  
play a vital role. A successfu l ly  activated T-cell ,  by interaction with an 
APC peptide / MHC complex, wil l  induce T -ce l l s  to mediate  other  
immune responses,  such as release o f  cytokines  from helper C D 4+ T- 
cell s  or C D 8+ T-cel l  mediated cell  kil l ing.
The mechanisms o f  antigen processing and presentation can be broadly  
divided into two, major histocompatibil ity  c lass-I  (MHC class-I )  and 
major h is tocompatibil ity  class-II (MHC class-II)  mediated antigen  
presentation. The discussion o f  MHC class-I antigen presentation is not  
within the scope o f  this research and wil l  not be discussed  further.
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MHC class-II m olecu les  are expressed on APCs and predominantly  
bind antigen taken in from without the cell .  Antigens derived from 
invading organisms is eff ic ient ly  internalised into APCs by specia l ised  
mechanisms that recognise  common antigenic molecular patterns on 
pathogens.
The poss ib le  role o f  the enzyme cathepsin E (CE) within the formation  
o f  MHC class-II  presented peptidic fragments is the concern o f  this 
thesis.  To gain more insight into its poss ib le  role,  and to highlight  the 
com plex ity  o f  the antigen processing and presentation system, several  
areas w il l  be explained in this chapter. The pathway from antigen entry 
into an APC to antigenic peptide presentation on the surface,  
complexed with MHC class II w il l  be examined. The participation o f  
the proteolytic  enzymes that generate the antigenic pept ides  wil l  also  
be discussed,  in particular the aspartic proteases  cathepsin D and E. An  
overview o f  some inhibitors o f  such proteinases,  fo l low ed  by a 
discussion o f  an approach to study the proteinase cathepsin E wil l  
conclude the chapter.
An understanding o f  these concepts will  highlight  the major obstacles  
in the study and understanding o f  the antigen process ing  pathway.  
Chapter 2 will  highlight some criteria that need to be considered in the 
design o f  aspartic proteinase inhibitors that can be used in the study o f  
antigen processing. Chapter 2 wil l  also propose some synthesis  
procedures and chemical structures o f  aspartic proteinase inhibitors.  
Chapter 3 details  the synthesis o f  these compounds,  with chapter 4 
discussing the results o f  this synthesis .  Chapter 5 explain the materials  
and methods used in the b io logical  study o f  the synthes ised  inhibitors.  
The b io log ica l  data obtained in the test ing o f  the synthes ised  inhibitors  
upon several models  o f  antigen process ing are presented in Chapter 6. 
The conclus ion  to this thesis summarises the information obtained and 
discusses  it in the context o f  current information on antigen 
process ing, and details  improvements that can be made for future work.
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1.2 The ‘professional’ antigen presenting cells
The skin and absorptive epithelia are the first l ine o f  defence to 
intercept many invading organisms. The epithelium and most tissues  o f  
the body contain a class o f  “profess ional” APCs that are w e l l  suited to 
capture, internalise,  degrade and present extracellular antigen.  
Professional APC express a variety o f  cel l  surface receptors that are 
involved  in the internalisation o f  microbial ant igens5,6. They contain 
acidic intracellular ves ic les  containing numerous proteolytic  enzymes  
able to generate antigenic peptides for loading onto MHC class-II  
m o lecu le s7,8. The professional  APCs can also express high levels  o f  
MHC class-II and costimulatory m olecu les  for eff ic ient  CD4+ T-cel l  
activation. The antigen presenting function o f  these  cell s  is 
upregulated when pathogens are recognised by APC cell  surface pattern 
recognition receptors (PRRs) such as the Tol l - l ike  receptors (TLR s)9. 
Epithelial  cell s  themselves  along with ce l l s  such as m onocytes  and 
astrocytes,  do not consti tutively  express  MHC class-II and other 
elements  o f  the antigen processing machinery to a llow presentation to 
activated CD4+ T-cel ls .  These cel ls  usual ly  express  this function only  
when activated by pro-inflammatory factors such as IFN-y. These cel ls  
are sometimes  referred to as “non-profess ional” APCs.
1.2.1 Dendrit ic  Cells
Unlike  the B -ce l l  and the macrophage, the dendritic cell  is mainly  
concerned with the eff ic ient endocytos is ,  degradation and presentation  
o f  antigenic particles to both CD4+ and CD8+ T-cel l s .  Their 
specia l isat ion for this function is ref lected by the fact that DCs are the 
only  cell s  able to activate naive T-cel l s ,  and hence are necessary  for 
the establ ishment o f  the memory T-cell  pool .  There are numerous  
reviews on dendritic cell  im m unob io logy10,11 that can be read for more  
information.
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The DC takes up antigen via receptor-mediated endocytos is ,  
phagocytosis  or macropinocytos is  (see  section 1.3). Receptor mediated  
endocytos is ,  l ike that o f  the macrophage, invo lves  many different types  
o f  receptors including the mannose receptor,  scavenger receptors or via 
FcyRII receptor mediated en d o cy to s i s12,13. Macropinocytosis  is a 
specia l ised form o f  rapid fluid endocytos is ,  a function performed by  
immature dendritic cell s  as a means to sample large volum es o f  
extracellular f lu id14. The antigen sampling abil it ies  o f  peripheral DCs  
can quickly change in the presence o f  microbial signals.  TLRs are 
among a group o f  cellular receptors (PRRs) that play a major role in 
signall ing the presence o f  pathogens to D C s 15. The c lass ica l TLR 
interaction response o f  DCs is to mature and migrate from the tissue  
periphery to the T-cell  zone o f  lymph node or spleen, and to express  
co-stimulation m o le c u le s 16. Transient st imulation o f  antigen 
macropinocytosis  and antigen process ing occurs before the maturation 
events occur17'19. The interaction o f  TLRs on DCs with microbes is a 
key link between innate and adaptive immunity.  Recognit ion  o f  foreign  
particles by DC PRRs induces the secret ion o f  cytokines  and 
chemokines  that causes inf lammation and activation  o f  other immune  
cells ,  or induces  chemotaxis  o f  immune ce l l s  to the infected region. In 
short, the innate recognit ion o f  pathogenic  signals  by immune cell s ,  in 
particular DC, activates the adaptive immune response.
During DC migration and maturation, the cel l  function switches  from 
antigen sampling to antigen presenting. The express ion o f  antigen  
processing enzymes is at its maximum to increase the maximum amount  
o f  antigen presented by MHC class-II m olecu les ,  however  during the 
maturation process,  these enzymes are downregulated. Important c o ­
receptors (such as CD80 / CD86 and CD40) are expressed to de liver the 
“second s ignal” cost imulation that is required along with MHC / TCR / 
peptide to activate T cell s .  In addition, the cell  morphology  changes  
once within a lymphoid organ. DCs mature into cell s  that send out 
many dendrites to form contact with several T-cel l s ,  forming a 
characteristic DC / T-cel l  cluster.
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ha p ie r
1.3 Endocytosis  - mechanisms involved  in antigen uptake
The mechanisms employed by professional APC to endocytose  or to 
phagocytose  microorganisms are highly  specia l ised to ensure maximum  
ef f ic iency  o f  antigen internalisation. Four main mechanisms have been  
described, macropinocytosis ,  phagocytosis ,  clathrin-mediated coated  
pit endocytos is  and caveolae-mediated endocytos is .  These are 
diagrammatically represented in fig. 1.1.
Ciathrin-coated pit Membrane ruffling
Macropinosome
Endosome
ActinPhagosome
Non-coated pit 
or caveotae
Phagocytosis
Figure 1.1: Schematic of pinocytosis mechanisms. Arrows signify movement of antigen towards 
the antigen containing vesicles of endosomes, although other mechanisms may exist to shuttle 
antigen to these or similar vesicles.
1.3.1 M acro p in o cy to s i s
DCs use macropinocytos is ,  which is the abil ity to endocytose  non-  
specif ica l ly  large volumes  o f  extracellular fluid.  Sallusto et al  showed  
that the immature DC can endocytose  approximately  a cell  volume  
within one hour by macropinocytos is14. M acropinosom es form around 
membrane ruffl ing sites,  mediated by a rearrangement o f  the actin 
cytoskeleton and can form large ves ic le s  with a diameter ranging from 
0.5 -  3 pm. Such a large volume o f  internalisation requires that DCs  
also have a high rate o f  ex o cy to s i s12. Some fluid and antigen from 
macropinosomes is routed further into ves ic le s  contain ing MHC class-
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II, proteolyt ic  enzymes such as cathepsin D, and ly sosom al  associated  
markers such as L A M P -1 14.
1.3.2 Phagocytosis
The macrophage is the c lass ical  phagocytic  cel l  playing an important  
part in the removal o f  large pathogens.  DCs can also actively  
phagocytose  microbes such as yeast and bacteria via  the many  
receptors expressed on the cell  surface.  For example,  T-cell  st imulation  
by C ryp tococcus  n e o form ans  was shown to be by DC presentation and 
not by macrophages,  and to be mediated via  the mannose receptor and 
FcyRII20. Similar studies have shown the phagocytos is ,  kil l ing and 
presentation o f  antigen from other types o f  yeast,  invo lv ing  the binding  
o f  mannose,  complement,  Fcyll  and fibronectin receptors among  
others21. It has also been shown that Baci l lus  Calmette-Guerin (BCG)  
mycobacteria are endocytosed by DC and able to induce immune  
responses  in v i v o 12, and numerous examples  o f  DC endocytos is  of, for 
example,  S a lm o n e l la , M. tu b e r c u lo s i s , E. c o l i , C h la m y d i a , have since  
been described6.
1.3.3 Clathrin and non-c lathrin-mediated endocytosis
Ciathrin-coated pits are a major organelle  used by eukaryotic cell s  for 
the endocytos is  o f  receptors and their l igands.  These ve s ic le s  are 
formed by the formation o f  cage- like  structures mediated by the 
formation and assembly  o f  clathrin tr iskelions  . The endosomal  
ves ic le s  formed are small (80 -  120nm) in comparison to
macropinosomes. Many PRRs such as the mannose receptors 14 are 
known to be endocytosed via  ciathrin-coated pits.  Receptors  cluster  
during coated pit formation, internalise and sometimes  release attached  
l igand (usually  triggered by a lowering o f  endosomal pH), a llowing  
receptor recycling  back to the plasma membrane. These features o f  
ciathrin-coated pits can lead to a high quantity o f  antigen  
internalisat ion by APC.
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Non-coated pits,  including caveolae ,  are the least understood o f  the 
endocytos is  mechanisms. It is be l ieved  that caveolae  play a role in the 
endocytos is  o f  certain antigens and bacteria into macrophages  and 
dendritic cell s ,  both o f  which express caveo l in-1 ,  an essential  element  
o f  caveolae  formation24. The size  o f  caveolae  are in the region o f  50 -  
80 nm diameter. The exact role o f  caveolae  and their link to the 
endocytos is  o f  antigen is unknown. However ,  several interesting  
observations  have shown that caveolae  may be important in immune  
functions or immune evasion by bacteria. Caveolae may play  a 
particularly important role in internalisation o f  antigen when clathrin  
coated-pit formation is disrupted .
1.4 Mannose receptor and antigen uptake
The mannose receptor (MR) is a well -characterised receptor for the 
binding o f  mannose-fucose  type sugars by macrophages and dendritic  
cel ls .  Work by Stahl, Ezekowitz,  Taylor, Drickamer and many others  
has elucidated both the structure and binding characteristics  o f  the MR.
1.4.1 Mannose receptor function
The mannose receptor is found on mononuclear phagocytes  such as 
macrophages and liver Kupffer cell s ,  on antigen present ing DCs and on 
endothelial  cell s .  The presence o f  these cell s  in most tissues  leads to a 
wide tissue  distribution o f  the mannose receptor including the l iver, all 
epithelial  surfaces such as the gastrointestinal tract and lungs,  the 
spleen, lymph nodes and other lymphoid ti ssues.  Its express ion on DCs  
has created a lot o f  interest into its poss ib le  im m unolog ica l  function.
The MR is synthes ised in the rough endoplasmic  ret iculum (RER) as an 
inact ive 154 kDa precursor, and on its journey towards the cell  surface  
is 7V-and O-glycosylated ,  maturing to a 162 kDa active form26. The 
location o f  g lycosy lat ion  on the MR is thought to be between the
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carbohydrate recognit ion domains (CRDs) and may function to induce  
conformational changes and affect MR binding.
Endocytos is  o f  the mannose receptor concentrates the receptor mainly  
into early endosomes,  with some also being detectable in late 
endosom es27. This has the effect  o f  concentrating antigen into early  
endosomes,  the first intracellular step where degradation o f  protein  
antigen occurs.  The MR is endocytosed via  ciathrin-coated pits,  as 
suggested by its association with surface a-adaptin27. An estimated
100,000 MR molecules  are found on the plasma membrane o f  GM-CSF  
/ IL-4 cultured DCs, with approximately four times this amount in
2 “I-intracellular pools .  The MR requires 2 Ca ions and a neutral pH to 
internalise attached sugars28. Once the receptor and ligand enter 
endosomes o f  a suff ic ient ly  low pH, the receptor releases  the sugar and
2 Qis recycled back to the plasma membrane . By contrast,  FcyR and 
scavenger receptors on APCs and membrane Ig m olecu les  on B -ce l l s  
are targeted for degradation upon endocytos is ,  p oss ib ly  suggest ing  an 
important role for the MR in antigen endocytos is .  Approximate ly  2 x 
106 m olecules  can be endocytosed by the MR every  hour, suggest ing  a 
turnover o f  15 min for the receptor to recyc le  back to the surface.  In 
DCs, MR internalisation o f  antigen was found to enhance presentation  
to T-cell s  100 fo ld30, compared to antigen internal isation via  fluid
3 1phase uptake. Tan et a l  reported a 2 0 0 - 1 0 ,0 0 0 - fo ld  enhanced potency  
o f  mannosylated versus  non-mannosylated pept ides  in abil ity  to 
stimulate HLA class-II-restricted pept ide-spec if ic  T-cell  c lones .
1.4.2 MR homologues as endocytic  receptors
The DEC-205 receptor is a 205 kDa membrane protein shown to be 
expressed on mouse dendritic and thymic epithel ia l  c e l l s 32 and certain 
subsets o f  D C s 33. Like the MR, DEC-205 is able to endocytose  
g lycosy lated  antigens very e f f ic ient ly32. DEC-205  has a low surface  
expression on human immature monocyte-derived DCs,  with expression  
increasing as the cel ls  mature, the opposite  situation to the M R 33, but 
like the MR, DEC-205 is endocytosed via  ciathrin-coated pits. A C-
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terminal cytoplasmic  sequence within DEC-205 targets DEC-205 to 
MHC class-II pos i t ive  late endosomal / lysosom al  v es ic le s  and not to 
early endosomes as for the MR and most other endocytic  v e s i c l e s 34. 
Recently  Steinman et al  have shown that targeting antigens to maturing 
DCs via  DEC-205 improves T-cel l  vacc inat ion5. The exact type o f  
carbohydrate l igand for DEC-205 is unknown, but is suggested to be 
more complex than simple mannose l igands.  This suggests  a specia l ised  
recognit ion and function o f  DEC-205 that may or may not involve  
antigen endocytosis .
The DC -spec i f ic  ICAM-grabbing non-integrin (DC-SIGN) receptor  
family  have so far only been found to be expressed on DCs, in 
particular DCs in the sub-mucosa and dermis. The yeast Candida  
a lb icans  is known to enter via these tissues ,  and Cambi et a l  have  
proposed that l ike the MR, DC-SIGN is a receptor for C. a l b i c a n s 2"5. 
DC-SIGN has been shown to bind to a w hole  range o f  v iruses,  such as 
H I V - 1/2, Ebola, Hepatitis  C and Dengue virus. It is clear that the 
multitude o f  recently discovered C-type lect ins  expressed by DCs may  
perform various functions including antigen internal isation.  Extensive  
reviews on these and other C-type lect ins  expressed on DCs can be 
found e lsew here36'38.
1.4.3 MR structure and binding characterist ics
Figure 1.2 shows a schematic o f  the macrophage MR structure. The 
cytoplasmic  tail o f  the receptor contains an amino acid sequence  
(FENTLY) that is involved in s ignall ing for internalisat ion via  
ciathrin-coated pits. At the N-terminus are two cyste ine-r ich  domains  
and the fibronectin type II repeat. Neither o f  these  are invo lved  in the
• • "X Q
recognit ion o f  mannosylated targets but are suggested  to perform a 
different function, poss ib ly  also in antigen recognit ion.  After the N-  
terminal domains are eight CRDs that are invo lved  in the recognit ion  
o f  specif ic  types o f  sugars.
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Figure 1.2: Structure of the macrophage mannose receptor. Diagram adapted from Taylor et a/39
At present,  little is known about the relationship between these CRDs  
in terms o f  binding l igands,  although it is be l ieved  that the domains  
cluster together, reinforcing multiple weak interactions with individual  
oligosaccharides  to g ive high-avidity o f  binding. CRD4 is the only  MR 
domain that is able to bind mannose l igands on its own 39 and is 
essential  for binding to many carbohydrate co m p le x e s39'41. CRD4-8  
shows the same binding as the whole  receptor and CRD1-3  do not  
appear to be needed for binding. In complex  carbohydrates,  CRD5-7  
also show binding activity. It is clear that binding o f  complex  
ol igosaccharides  is dependent on many o f  the CRDs.
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1.5 Endosom al vesicles and antigen transport
Early endocytic  ves ic le s  containing antigen do not contain all the 
molecules  required for proteolysis  and MHC class-II loading. Antigen  
must therefore be transported through the cel l  and brought into contact  
with these molecules  by vesicular  fus ion7. A simpli fied scheme for the 
transport o f  ves ic le s  through a typical APC is shown in figure 1.3.
Endosome
RE
Golgi
Early ' 
Endosome, MHC
Late ' 
Endosome,
Lysosome
Figure 1.3: Schematic of endosomal vesicular transport. Solid lines denote vesicle maturation, 
fusion or membrane / solute transport. The existence of what are termed MHC class-II 
compartments is also included with dotted arrows denoting possible links with other vesicles. 
MIIC = MHC class-II compartment, RE = Recycling Endosome, TGN = Trans-Golgi Network
1.5.1 E n dosom e transport
An important early step o f  endosome transport is the fusion o f  new ly  
created endosomes with the pre-exist ing early endosome. Early 
endosomes have a pH o f  - 6 . 0 ,  and poss ib ly  contain the first enzymes  
involved in the proteolysis o f  antigen such as asparaginyl  
endopeptidase (AEP) and thio reductases such as y- interferon-like  thiol 
reductase (GILT) (see section 1.7, page 47).  Early endosomes  can then 
form late endosomes and then lysosom es ,  a process called vesicular  
maturation. However,  ves ic le  maturation is also accompanied by the 
shuttling o f  membrane and / or intravesicular contents throughout all
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endosomal  pathways.  This f luidity o f  endosomal  movement makes it 
diff icult  to associate  some important cellular functions to particular 
organel les,  such as the location o f  acid proteases required for antigen  
processing, or the loading o f  MHC class-II  molecules .  R ecyc l ing  or 
sorting endosomes have also been described in the l iterature42 which  
adds to the overall  complexity .  The movement and maturation o f  
different ves ic le s  is controlled by a whole  series o f  GTP-binding Rab 
GTPases,  information on l ies outside the scope o f  this thesis 42.
Targeting o f  receptors to specif ic  ve s ic le s  or pathways by signal  
sequences  in their cytoso l ic  terminal (as has been described for the MR 
and D E C - 2 0 5 )  may subject antigen to different proteolyt ic  
environments,  containing different proteolytic  enzymes and altered 
vesicular  pH, and as such, may have important consequences  for the 
generation o f  antigenic determinants.
1.5.2 MHC class-II  containing compartments
The e f f ic iency  o f  antigen presentation in APCs has been attributed in 
part to the existence  o f  specia l ised MHC class-II  containing  
compartments, called MIICs43. These compartments,  along with a 
similarly described class-II ves ic le  (CIIV),  exhibit  all the properties  
expected o f  a ves ic le  involved in the e ff ic ient  loading o f  MHC class-II  
molecules .  MIICs contain MHC class-II and H LA-DM  for exchange o f  
invariant chain (Ii) with antigen peptides  (see  section 1.6), have an 
acidic pH which allows proteolyt ic  degradation o f  Ii and antigen, are 
accessib le  to endosomes and allow export o f  antigen loaded MHC  
class-II m olecu les  to the cel l  membrane. Although such organelles  have  
been described as multivesicular or multilaminar late endosomes,  it is 
still  unclear i f  MIIC are specia l ised or conventional endocyt ic  
compartments,  these issues being high lighted by several groups43,44. 
The role o f  these multivesicular endosomes is sti ll  not fu lly  
understood, but it is clear from recent reports that they are important in 
antigen presentation7,45.
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1.5.3 Antigen transport within APC endosomes
Vesicular kinetics within dendritic cell s  have been analysed, and 
compartments posit ive  for MHC class-II,  LAMP-1, antigen and 
cathepsin D are present in D C s 14,46. Similar studies within  
macrophages47 and B -c e l l s 48,49 have also shown the co- loca l isat ion  o f  
antigen with lysosomal markers, MHC class-II associated m olecules  
and proteolytic  enzymes. DCs however,  display a dif ference to 
macrophages and B -ce l l s  in the speed upon which they are able to 
present MHC class-II / antigen complexes  to responder T-cel ls .  
Kleijmeer et a l  showed that presentation o f  hen egg-white  ly sozym e  
protein (HEL) antigen to HEL-specif ic  T hybridomas by mouse  spleen  
dendritic cell s  occurred after only  2 hours,  with a maximal response  
after 6 hours50. Studies with an immature DC cel l  l ine (FSDC) showed  
that macropinocytosed and clathrin coated-pit endocytosed antigen  
displayed a long- last ing retention o f  unprocessed antigen for up to 24 
hours within large, mildly acidic v e s i c l e s 51. Similar long-last ing  
antigen retention has recently been reported in v i v o 52.
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1.6 MHC class-II molecules and antigen presentation
The major histocompatibil ity  class-II complex  (MHC class-II) is a set 
o f  h ighly  polymorphic  cell  membrane proteins that bind antigen for 
presentation to T-cell s .  They play a major role in all o f  the steps from 
antigen proteolysis  to presentation o f  antigen on the cel l  surface to T- 
cel ls ,  and as such, have an their important role in the antigen  
processing and presentation pathway. Class-II MHC m olecu les  and 
their role in antigen processing and presentation have been reviewed  
e lsewhere53,54.
1.6.1 MHC class-II structure
MHC class-II molecules  are comprised o f  the g lycoprote in  chains a  (34  
kDa) and p (29 kDa).  A crystal structure drawing o f  the MHC class-II  
m olecule  I -Ad in complex with the ovalbumin pept ide 323 -  339 is 
shown in figure 1.4. These two chains each contain two domains ( a i ,  
ot2, and Pi, P2), and the chains are non -cova len t ly  bound to form the 
full MHC class-II molecule  as a heterodimer55. The a i  and pi domains  
form the peptide binding cleft  where ant igenic  pept ides  are bound  
allowing presentation to the TCR. The binding groove is l ined at the 
base by eight strands o f  anti-parallel P-sheets (four from each chain)  
with two sides l ined by long a -h e l i ce s  (one from each chain).  The 
binding groove has “open-ends”, a l lowing  binding o f  pept ides  o f  
differing lengths,  typically between 12-20 amino ac ids56. It has been  
suggested that this al lows for MHC-guided process ing  o f  antigen by  
allowing the binding o f  long antigenic fragments that can later be 
trimmed at the ends by proteases57. B inding o f  peptides  occurs by 
hydrophobic,  electrostatic and Van der Waals forces ,  by interacting  
with both invariant and polymorphic parts o f  the binding cleft .  There 
are many different variations o f  the MHC class-II genes ,  such that each 
individual may express a different set o f  a l le les  (a term that refers to 
each individual gene variation) within a population. The combination  
o f  MHC po ly g en y  (a human can express four different MHC class-II
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genes) and polymorphism leads to great variat ions  in the expression of  
MHC class-II genes  within a population.  The potent ia l  to respond to 
antigens  differently  depends on the abili ty of  di fferent MHC to bind an 
antigen.
a chain
P chain peptide
Figure 1.4: MHC class-II molecule I-Ad in complex with ovalbumin peptide 323 -  339. The 0- 
sheets of the two chains (a  and P chains) are shown in yellow and blue, respectively, with a -  
helices shown in red. A) Side view of the molecules, B) A top-down view of the a! and Pi domains 
showing the peptide binding groove with bound peptide. Some amino acid side chains of the a -  
helices are also shown to display possible interactions of MHC class-II with peptide. Diagram  
drawn from PDB file (PDB accession number 1IAO)''8.
1.6.2 MHC class -II  and the in v a r ia n t  chain
Empty MHC class-II molecules  that arrive within  the ER are unstable  
without the binding of  a special ised prote in  cal led  the invar iant  chain 
(Ii). The invar iant  chain fulfils several funct ions;  s tabi l isa t ion o f  MHC 
class-II molecules ,  provision o f  a target ing signal to help t ransport  
MHC class-II molecules  towards appropriate endosomal vesic les ,  and 
prevention o f  peptides  binding to MHC class-II  with the ER. The 
invariant  chain is a non-polymorphic type II integral membrane 
protein,  with a short 30 amino acid cytosolic domain,  24 amino acid 
t ransmembrane region and - 1 5 0  amino acid luminal  domain  (fig. 1.5). 
Ii exists as a tr imer  and is able to bind three MHC class-II  molecules  
o f  any allele type (referred to as an ( a p l i ) 3  complex)^9. Within the ER, 
a region o f  Ii, called the class-II -associated Ii chain peptide (CLIP) fits 
into the MHC class-II peptide-binding groove and stops binding o f  any 
other ant igen peptide fragments.  Ii faci li tates  the targeting of  the
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( a p l i ) 3  complex into low pH late endosomes such as MIICs. Targeting 
towards these vesic les is mediated by the cytoplasmic tail o f  the Ii.
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Figure 1.5: Stages of invariant chain degradation leading to the release of the class-II-associated 
Ii chain peptide (CLIP). Figure adapted from Matza et af°.
1.6.3 In var ian t  chain proteo lys is
During transpor t  or upon arrival into vesicles  where antigen loading 
occurs,  Ii is degraded by a stepwise process .  Aspart ic,  cysteine and 
possibly other  prote inases are implicated in this process ing ,  but the 
exact details remain unclear  (fig. 1.5). Blum and Cresswell  were first 
to analyse the proteolysis o f  I i61. They found that the Ii degradation 
during passage through the endosomal  pathway was inhibited  by the 
cyste ine proteinase  inhibitor leupeptin , resul t ing  in an accumulat ion  o f  
Ii fragments dubbed LIPs ( leupept in induced po lypept ides)  and SLIPs 
(small leupeptin induced polypeptides) .  Marie  et al found that the 
formation o f  these LIP / SLIP fragments  was a two stage process  that 
required a cyste ine prote inase to generate  the final CLIP / MHC class- 
II complex,  but that also required an aspart ic pro te inase  to perform 
initial  Ii degradat ion62. It has been shown using cathepsin  D (CD) 
knockout mice that degradation o f  Ii still occurs,  suggest ing that CD is 
not involved, or its activi ty can be replaced by another  p ro te inase63. 
The cysteine prote inase  cathepsin S has been shown to be a major 
enzyme involved in the generation of  CLIP fragments .  However ,  this is
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MHC class-II haplotype dependent,  and other prote inases  such as 
cathepsin B are also involved63. Cathepsin L has been shown to be 
important in Ii degradation within cortical thymic epithel ial  c e l l s64. 
Section 1.7.3 (page 49) d iscusses  the cysteine  proteinases that may be 
involved in Ii chain proteolysis.
It is generally accepted that because  o f  the importance o f  Ii 
degradation and the different proteinase expression patterns that exist  
in cell s ,  redundancy in proteolyt ic  process ing exists  to ensure eff ic ient  
Ii degradation.
1.6.4 HLA-DM mediated antigen loading onto MHC class-II  
molecules  and cell surface presentation
To facil itate the removal o f  the CLIP fragment,  an MHC class-II  
encoded protein called HLA-DM (H-2M in the mouse)  cata lyses  the 
removal o f  the CLIP protein and replacement by antigen. HLA-DM is a 
non-polymorphic  MHC class-II l ike m olecu le  that does not bind 
peptide, and is found predominantly in v e s ic le s  that contain MHC 
class-II molecules .  HLA-DM can catalyse  the removal  o f  antigen from 
MHC class-II molecules  containing weakly  assoc ia ted antigen. Higher  
aff inity antigen peptides and longer antigenic  pept ides  are more  
resistant to HLA-DM induced dis soc ia t ion65. H LA-DM  may funct ion by  
binding to unstable conformations o f  MHC class-II  m olecu les .  L-cell s  
(which do not contain HLA-DM) transfected with genes for MHC class-  
II and Ii were able to present one dominant epitope o f  HEL and elic it  a 
T-cel l  response,  but also two cryptic epitopes  o f  HEL (i .e . ,  ant igenic  
peptides that can be generated by proteolys is  but not presented).  
However , L-cel ls  also transfected with H LA-DM  were  unable to 
present the cryptic epitopes and only e lic ited a T-cel l  response  to the 
dominant epitope o f  HEL66.
The morphology o f  MIICs as being mult ivesicular  or multilaminar is 
thought to provide the segregation and controlled association o f  the 
large array o f  molecules  involved in antigen p rocess in g8. It has been
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suggested that this may be the reason why immature  DCs are able to 
store antigen for long periods o f  t ime by segregat ing the machinery 
that is required to effic iently load and present  an t igen43. The transport 
o f  MHC class-II molecules  to the cell surface is bel ieved to occur via 
vesicular  budding from MUC-derived tubules,  which are thought to 
fuse with the outer  cell  m em brane8. Figure 1.6 summarises  the 
pathways that are involved in MHC class-II transport  through to the 
cell surface.
Antigen /  MHC class-II 
presentation
Antigen
loading (a(3Ii>3
transport
MIIC
compartments
.Ii processing 
rby cathepsins
^  D  r^ote'nases
MHC class-II Antigen
I Invariant Chain 
HLA-DM ,f CLIP
CLIP removal and 
MHC stabilisation 
by HLA-DM
Figure 1.6: Schematic representation of the process of MHC class-II transport to the cell surface. 
The processes of Ii degradation, MHC class-II stabilisation by HLA-DM, CLIP removal for 
loading of antigen and MHC class-II presentation on the surface of APCs are represented.
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1.7 Antigen proteolysis
Fol low ing  capture o f  antigen via  one o f  the endocyt ic  mechanisms  
previously  mentioned, an APC needs to proteoly t ica lly  degrade antigen  
to generate class-II speci f ic  peptide MHC class-II complexes  for 
recognition by CD4+ T-cel ls .  Proteins may require disulphide bond 
reduction, denaturation as well  as c leavage to generate small  peptide  
fragments. In addition, the invariant chain Ii also requires c leavage.  
The degradative environment o f  the lysosom e  may be too aggress ive  
for the l imited proteolysis  needed to generate antigenic  fragments.
Instead, proteolys is  and antigen loading may occur within early or late 
endosomes, or the special ised MIIC compartments.  Peptidic antigens  
may also bind to MHC class-II and then be further trimmed by
exoprote inases57. Mechanisms such as this may be important for the
survival o f  some or many antigenic determinants. An alternative  
possib il ity ,  extracellular antigen process ing  by DCs, may ex is t67. 
Immature DCs have been shown to have empty cell  surface MHC class-  
II and HLA-DM molecules ,  as well  as d isplaying extracellular  
proteolysis  o f  peptide antigens68. The scale  and importance o f
extracellular antigen processing and presentation is not known,  but is 
not expected to be on a large scale  in comparison to the intracellular  
mechanisms that exist  within DCs, and may exis t  to fulfi l  a specia l ised  
function.
Several proteolytic  enzymes have been implicated in antigen  
processing, with most having broad substrate spec i f ic i ty  and an acidic  
pH optimum, consistent with their distribution within endocytic  and 
ly sosomal compartments o f  APCs69,70. However ,  there are except ions  to 
these rules,  and proteolytic expression can differ between APC cell  
types or different T-cel l  activation / maturation stages.
The cathepsin family  forms the major group o f  proteins involved in 
antigen processing. Dependent on the proteinase active site amino acid 
required for the catalytic cleavage, the enzymes in the cathepsin family  
can be c lass i f ied  as either aspartic proteinases,  such as cathepsin D and 
E, or cyste ine  proteinases,  such as cathepsins B, L, and S. Although
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other  classes o f  hydrolases  exist within lysosomal  compartments  such 
as serine prote inases  and metalloprote inases,  no evidence exists for 
their involvement in antigen processing within APCs. Figure  1.7 shows 
the stages of  antigen proteolysis  that occurs within  APCs as it is 
currently  understood.  Several techniques  have been used to identify  
proteinase  enzymes and their  specifici ties ,  such as mutagenesis  of  
processing sites, the use o f  specific inhibitors ,  gene-knockout  mice, 
and more recently  techniques ut il is ing f luorescent  act ive-si te  di rected  
probes71.
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Figure 1.7: Antigen and Invariant chain (Ii) processing within a typical APC. Antigen is first 
unfolded by the action of y-interferon-inducible thiol reductase (GILT), then an initiating 
proteinase (AEP) and then further degraded by the cathepsins to produce small antigenic 
peptides for loading onto MHC class-II molecules. At the same time, MHC class-II / Ii processing 
occurs to allow removal of stabilising Ii.
1.7.1 y - in te r fer o n - in d u c ib le  th io l  r ed u c ta se  (G IL T)
The reduction o f  disulphide bonds may be required  to open up a prote in  
suff ic ient ly  to allow proteolysis  and release  o f  immunodominant  T-cell  
epitopes. Most  studies on antigen processing that look at the role of  
disulphide  bond reduction shows this to be an essential  s tep72,73. The 
identif icat ion o f  y- inter feron-inducible thiol reductase (GILT) resolved
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the problem o f  the protein involved in disulphide reductive c leavage74. 
GILT is consti tutively  expressed in APCs and expression can be 
induced in other cell s  by IFN-y, suggest ing the enzyme has an immune  
function. It is expressed as a 35 kDa precursor that is transported to 
endosomal compartments where N-terminal and C-terminal propeptides  
are c leaved to generate the 30 kDa mature form75. The importance o f  
GILT in immune responses  was shown by generation o f  GILT-def ic ient
76mice which displayed defective  antigen process ing  .
1.7.2 Asparaginyl  Endopeptidase
Asparaginyl endopeptidase (AEP) is a cysteine  proteinase that c leaves  
antigen specif ica l ly  after asparagine residues.  It is synthes ised as a 
preproprotein that is auto-catalytical ly  processed to y ie ld  the mature 
form. Many tissues  express AEP, with particularly high express ion in 
the kidney. AEP shows some interesting properties in relation to the 
control o f  T-cel l  immunity.  A single  amino acid change (A sn-1219)  
introduced into tetanus toxin C fragment blocks  degradation by AEP
• • • • 7  7and severely  impairs T-cel l  recognit ion . AEP can also destroy 
potentia lly  important T-cel l  epitopes.  For example ,  an HLA-DR2-  
restricted encephalitogenic  myelin  basic protein (MBP) epitope (MBP  
85-99)  contains an AEP cleavable  site (A sn-94) .  Thymic APCs,  which  
express AEP, poss ib ly  destroy this epitope during thymic T-cell  
development ,  l imiting negative se lect ion  o f  se l f -react ive  T -ce l l s  to this 
epitope78 and allowing potentially  autoreactive  T-cel l s  to survive.  
Another study has shown with OVA and myel in  o l igodendrocyte  
glycoprotein antigens containing asparagine within or near to relevant  
epitopes that presentation were not impaired in AEP-def ic ient  m ic e 79.
Manoury et a l  have recently shown that the init iat ion o f  Ii degradation  
in B -ce l l s  can be performed by AEP, as inhibit ion o f  AEP s lows (but 
does not stop) the processing o f  Ii80. The generation o f  AEP-def ic ient  
mice has shown that the generation o f  the two-chain mature forms o f  
cathepsins B, H, and L are impaired, suggest ing  AEP is important in 
processing the immature forms o f  these enzym es79. At least in the case
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o f  cathepsin L, this does not necessarily  lead to impairment o f  its 
function79. A review by Watts et al  describes more information on 
AEP81.
1.7.3 Cysteine cathepsins
There are numerous cysteine cathepsins within lysosom es  o f  cel ls ,  that 
play a part in “house-keeping” protein degradation. Cathepsins B, L 
and S are the most characterised cysteine  cathepsins  involved in 
antigen processing, and along with other cysteine  cathepsins have been  
located within endosome / lysosom e compartments o f  A PC s69. They are 
synthes ised in the endoplasmic  reticulum as pro-enzymes, with a 
propeptide occupying the active-s ite ,  which is removed  
autocatalytically  or by another en zym e82. Like other c lasses  o f  
proteinases,  cysteine proteinases can act as endoproteinases (cathepsin  
L, S, F) or exoproteinases  (cathepsin H, Z )83, cathepsin B may act as 
both.
1.7.3.1 Cathepsin B
Cathepsin B, a lysosomal papain-like proteinase,  is a potent  
carboxypeptidase,  involved in cellular protein turnover,  that may havea a
a role m antigen processing . Cathepsin B is synthes ised  as a pro­
enzyme, and targeted to late endosomes / ly so so m es  by the mannose-6-  
phosphate receptor. The mature single  chain form is generated in these  
compartments by autocatalysis.  The administration o f  the cathepsin B-  
specif ic  inhibitor CA-074 2 hours before and after HBV vaccination o f  
mice suppressed anti-HBV IgG production84. In the same study, CA-  
074 was shown to suppress antigen process ing  and presentation by  
macrophages o f  rabies antigens to specif ic  T-cell  c lones .  In contrast to 
these inhibitor studies,  analysis o f  cathepsin B defic ient mice  
suggested that cathepsin B (as well  as cathepsin D) is d ispensib le  for 
process ing and presentation o f  antigens85.
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1.7.3.2 Cathepsin L
Another lysosomal  cysteine proteinase,  cathepsin L, has been shown to 
be important in Ii degradation within cortical thymic epithelial  cel ls ,  
the cel ls  which mediate pos it ive  se lect ion  o f  CD4+ T -ce l l s64. There is 
evidence that cathepsin L is regulated by a degradation product o f  the 
p41 isoform o f  Ii, which binds to, and inhibits specif ica l ly ,  the 
proteolytic  abilit ies o f  cathepsin L86. This degradation product has no 
effect  on cathepsin B or S. Although there is no direct evidence  for the 
involvement o f  cathepsin L within antigen process ing  by direct antigen
Q A Q n
cleavage, its involvement has been suggested ’ . A study by Hsieh et 
al  showed that fibroblasts expressing either cathepsin L or S generated 
signif icantly  altered levels  o f  some peptide antigens compared with  
fibroblasts not expressing cathepsin L / S. The antigenic pept ide levels  
expressed were also different between these two fibroblasts expressing  
either o f  these Ii degrading enzymes,  an observation that may suggest  
an involvement in more than I i-process ing a lone87. The authors do 
point out, however,  that it cannot be d ismissed  that this e ffect could be 
related to di fferences  in the rate o f  Ii degradation, and as such antigen  
loading and proteolysis  within different T-cel lular compartments.
1.7.3.3 Cathepsin S
Cathepsin S has been identified in APCs such as B -ce l l s ,  macrophages,  
DCs and epithelial  cells .  It is known to be essent ia l  in the degradation
u
o f  Ii in some alleles,  particularly I-A . Cathepsin S def ic ient  mice  have  
B-ce l l s  and DCs with accumulated MHC class-II  / LiplO com plexes ,  
and it is suggested that in these cell s  cathepsin S is essential ,  although  
as mentioned,  this is dependent on the alle lic  type as some alle les  are 
less dependent on invariant chain p rocess in g88. In human epithelial  
cells ,  cathepsin S is the only  cysteine proteinase able to degrade the Ii- 
plO fragment89. Cathepsin S may contribute a role in autoantigen  
generation within several immunological diseases .  In mouse models  o f  
Sjogren’s Syndrome, a specific  inhibitor o f  cathepsin S (CLIK-60)  
dramatically reduced the signs o f  symptoms84. In another study, the N-
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terminal generation in vitro  o f  a major autoantigen from Myelin  basic  
protein,  was w h o l ly  controlled by cathepsin S90
1.7.3.4 Other cysteine cathepsins
In recent years some additional cysteine cathepsins which could be
7 0implicated in antigen processing have been identi fied . Cathepsin H 
for example,  is an aminopeptidase shown to loca l ise  within early  
endosomal compartments and has a near neutral pH optimum. However  
no data yet associates  it to antigen processing.  Cathepsins F and Z are 
expressed in many cell  types,  but among APCs this distribution is 
restricted to macrophages.  In v i t r o , Cathepsin F is able to generate the 
IilO fragment o f  Ii as e f f ic ient ly  as cathepsin S, and in cathepsin S 
defic ient  mice,  macrophages were shown to c leave Ii fragments as wel l  
as wild-type mice.  These observations suggest cathepsin F may  
substitute for cathepsin S in degradation o f  Ii in cathepsin S defic ient  
m ic e 91, highlight ing the redundancy that exists  in proteolyt ic  enzymes.
1.7.4 Aspartic proteinases
The aspartic proteinase family is a diverse  fam ily  o f  enzymes,  involved
Q 9in a whole  range o f  important b io log ica l  functions , and implicated in
0 ^a number o f  diseases  . Many pathogens rely on aspartic proteinases to 
function correctly,  and the interest in spec i f ic  aspartic proteinase  
inhibitors is therefore huge94. O f  particular interest in this study is 
their role in antigen process ing. The distribution o f  the aspartic 
proteinases within cells  or tissues  varies.  Some recently  discovered  
human aspartic proteinases may not be relevant to antigen process ing  
within antigen presenting c e l l s 92. The napsins are a family  o f  aspartic 
proteinases so far shown to be predominantly expressed within lung 
and k idney95. Another family recently discovered,  called the p-site  
amyloid precursor protein-cleaving enzyme (BACE),  has been  
suggested to have a role in antigen processing as low leve ls  are found  
within most  human organs. However,  BACE is insensi t ive  to the 
aspartic proteinase  pepstatin A 96, and as wi l l  become apparent
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throughout this section, suggests  that BACE is not implicated in 
antigen processing.
Cathepsin D (CD) and cathepsin E (CE) are the only  two aspartic 
proteinases ident ified to date expressed within the endosomal  / 
ly sosom al  compartments o f  APCs, and have been implicated in several  
studies o f  antigen process ing69,97,98. They are w ide ly  distributed in 
many tissues,  and in particular APCs, o f  most mammalian species .  
Human CD and CE are 51 % hom ologous  at the amino acid level ,  
however the two enzymes have different tissue distributions and sub-  
cellular localisation,  and are therefore l ikely  to perform different
i 9 9roles .
1.7.4.1 Cathepsin D
CD is a ubiquitous proteinase that primarily functions as a “h o u se ­
keeping” enzyme, degrading intra- and extracellular proteins.  It is 
usually expressed in lysosom es and late endosom es,  but can also be 
found in early endosomes o f  macrophages where it is membrane-  
bound100. Its express ion varies with dif ferent cell  t y p e s 101. CD has a 
wide distribution amongst various mammalian tissues ,  but it is 
particularly high in adrenal, spleen and lung t i s s u e s 102.
The transport o f  CD from the ER is mediated by the N-terminal pre 
sequence o f  CD. The 44-residue propeptide o f  CD stabil ises  the 
enzyme until its transport to endosome or ly so so m e  compartments via
i n ^mannose-6-phosphate targeting , where it is c leaved to generate an 
active 44kDa cathepsin D en zym e104. The crystal structures o f  CD 
identi fied the active site within a deep c left  that is f lanked by an N-  
l inked o l igosaccharide103,105.
A wide variety o f  proteins have been shown to be degraded by CD in 
v i t r o , including extracellular matrix components  such as pro-collagen  
106, hormones such as P-endorphin, P-lipoprotein and parathyroid 
hormone, and inactivation o f  the cysteine  proteinase inhibitor cystatin.
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Over-expression o f  CD has been associated with inflammation,  tumour 
progression, and P-amyloid peptide release from amyloid  precursor 
protein in A lzhe im er’s d i sease107. Recent work has associated CD with  
the caspase cascade in apoptosis,  essential  for homeostas is .  CD has 
been shown to be involved in the programmed cel l  death induced by  
IFN-y, Fas and T N F - a 108. Ceramide, a second messenger in the 
transduction o f  apoptotic s ignall ing has been shown to interact with  
preprocathepsin D and induce its autocatalytic c leavage  to 
enzymatically  active i so form s109.
1.7.4.2 Cathepsin D deficient mice
The cathepsin D defic ient mouse ( C D - / - )  generated by hom ologous  
gene targeting has given some interesting insights  into the role and 
importance o f  CD. C D - / -  mice develop a progress ive  atrophy o f  the 
intestinal mucosa and lymphoid tissue.  These mice  develop normally  
within the first few weeks,  but stop thriving and decrease weight  in the 
third week, and usually die at 25 + / -  2 days o f  a g e 110. They also 
display neurological  seizures near terminal stages,  with ce l l s  o f  the 
central nervous tissue displaying autophagosome / auto lysosom e- l ike  
b od ies99. The Balb/c C D - / -  mice generated as part o f  the present study 
(see  sect ion 6.5,  page 213)  displayed a similar abnormalities and die 
around weaning.
General lysosomal proteolysis is not impaired in C D - / -  mice .  
Stimulation o f  antigen-specific  T - c e l l s 110 and the degradation o f  
invariant chain in MHC class-II expressing A P C s 85 are not affected.  
This suggests  that CD is not essential  for antigen process ing  in the 
mouse. A recent study looked at the aspartyl proteinase  substrate 
m yoglobin  presentation to T-cel ls  by DCs. Presentation o f  two 
different myoglobin  T cell  epitopes was enhanced rather than hindered 
in C D - / -  m i c e 111. This was concluded to be due to the destructive  
process ing o f  cathepsin D. It was also shown that pepstatin-sensitive  
myoglobin  process ing  activity persists in lysosom es  from C D - / -  mice,  
being l ikely  due to cathepsin E. A role for CD in antigen processing
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cannot be ruled out however,  as the complex ity  and degeneracy  
inherent in antigen processing may allow adequate antigen processing  
o f  certain antigens to occur by any o f  the proteolytic  enzymes found 
within APCs, but this may not be the case for all antigens. The 
presence o f  another aspartic enzyme,  cathepsin E, that has similar  
cleavage specif ic i ty ,  may provide a large contribution to antigen  
proteolysis  in the absence o f  CD. Indeed in the murine B 
lymphoblastoid  cell  l ine A20,  cathepsin E is the main aspartic 
prote inase112. Species  other than mice,  including humans, may rely  
more on CD.
1.7.4.3 Cathepsin E
Cathepsin E has a l imited distribution compared with that o f  CD, be ing  
found in lymphoid tissues,  gastrointestinal tracts, urinary organs,  some
113red blood cell s  in some species ,  and microglia  . Of  particular interest  
is its expression in APCs, including DCs, B -ce l l s  and epithelial  
c e l l s 114-116. The CE gene has been shown to be expressed in many  
mammalian s p e c ie s117 and has been cloned from many s p e c i e s 118-120.
CE, unlike CD and other aspartic proteinases  such as pepsin,  renin, 
napsin, and BACE, is neither secreted nor lysosom al .  CE has been  
shown to be localised to endosomal compartments and the E R 113. CE is 
synthes ised as a preproenzyme in the RER. A signal pept ide o f  17 
amino acids in length is c leaved upon entry into the ER, where an 
intracellular pool o f  procathepsin E is retained. This is mediated by a
region o f  48 amino acids at the N-terminus o f  the mature cathepsin
121E . Entry into the endosome is associated with autocatalytic  
activation o f  the mature enzyme. Posit ion 4 o f  the mature enzyme  
contains a cysteine residue that forms a disulphide bond with another  
CE chain to form a homodimer o f  85 kDa in size ,  although the 
monomeric form is also found. The cysteine  residue is h ighly  
conserved amongst various mammalian s p e c i e s 122. This residue may  
also play a role in the retention o f  CE within the ER, poss ib ly  via  
interaction o f  the homodimer with a membrane bound receptor within
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the ER. The monomeric form o f  CE is less stable to pH and 
temperature changes123. Unlike CD, CE can retain activ ity  at sl ightly  
acidic or even neutral pH, when in the presence o f  A T P 124. N-Linked  
glycosy lat ion  was also shown to be essential  for CE to remain stable to 
changes in pH and temperature125. In human cel ls  and mouse  
lymphoblasts ,  the sub-cellular locali sation o f  CE has been shown to be 
l imited to endosomal compartments with a higher pH than late 
endosom es112,121.
Recently  the structure o f  cathepsin E in complex  with its pro-sequence  
was so lved at 2 . 3 5 A 126. Unlike other aspartic proteinases,  cathepsin E 
does not appear to c leave its pro-sequence, which remains attached to 
the mature enzyme as a p-strand. In addition, the N-terminal section  
from a different,  nearby cathepsin E pro-sequence,  b locks  the active  
s i te126. Cathepsin D is inactive at neutral pH, due to the N-terminal  
sect ion o f  mature enzyme blocking the active  site. In cathepsin E, the 
active site is blocked by the bound pro-sequence.  This dif ference may  
help to explain the reason for the d if ferences  in pH optima between  
cathepsin D and E. A combination o f  crystal structure data and a model  
o f  substrate binding for cathepsin D and cathepsin E show that the 
binding sites o f  both enzymes are almost  ident ical.  As such both 
enzymes,  as appears so far from substrate binding s tu d ies127, are l ikely  
to have very similar substrate binding preferences ,  making it very  
difficult  to design cathepsin D or E specif ic  inh ibitors126.
There are a number o f  b io log ica l ly  important m olecu les  shown to be 
c leavable  by CE in v i t r o , although this does not necessar i ly  imply a 
bio log ica l  s ignificance .  ot2-Macroglobulin ,  an important plasma  
glycoprotein,  is involved in the capture and cellular targeting o f  a 
range o f  molecu les ,  including cytokines,  growth factors and hormones.  
Recent ev idence has shown that CE, and not CD, is able to c leave (X2-
1 J  o
macroglobulin into three major proteins . In l ine with the expression  
o f  CE within the brain and gastrointestinal t issue,  the hormones  
substance P, neurokinin A, eledois in and neurotensin have also been  
shown to be s e lec t ive ly  or more eff ic iently  c leaved by CE, compared to
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££>120,129,130 g  chain 0 f  oxid ised insul in and big endothelin-1 have  
both been reported to be cleaved by CE131,132. There are two potential  
processing sites within human invariant chain that can be cleaved by  
cathepsin E 133, suggest ive  o f  a poss ib le  role in Ii chain degradation.
The substrate specif ic i ty  o f  CE has been explored and, as predicted  
from crystal structure, shares many similarities in substrate preference  
with other aspartic proteinases.  CE prefers hydrophobic bulky amino  
acids at Pi and P i ’,+ examples being Phe and Nph (4- 
nitrophenylalanine).  However,  CE is also able to c leave  peptides  
containing Phe-X, Tyr-X and Leu-X (where X = any amino acid)  
around the sc iss i le  bond131,134. Val and l ie  are not tolerated at the Pi 
position, and there is a preference for Pro at the P4’ p o s i t io n 135. The S4 
subsite'5' o f  CE prefers proline or leucine,  whereas  the S3 subsite prefers 
large a .a . ’s. The S2 and S2’ subsite can accommodate  hydrophobic  
amino acids (S 2 also accepts hydrogen bonding residues).  When l ie  is 
present at P3, the influence o f  the P2 residue becom es  less  important134. 
Recent work by Liu et al  have shown through mutational analysis  o f  
specif ic  residues o f  CE, that the amino acids A sp -98 ,  A sp-283  and Thr- 
284 are critical for the catalysis  o f  peptide c l e a v a g e 136.
1.7.4.4 Cathepsin E def icient  mice
The cathepsin E deficient mouse ( C E - / - )  has recently  been generated
1 'l n
by homologous  gene targeting . The funct ion and study o f  a potential  
role in antigen processing by CE was not explored, however  a change  
in immune function was noted. CE def ic ient  mice  primarily develop  
severe atopic dermatitis (AD) when bred under conventional condit ions  
but not under specif ic  pathogen free (SPF) condit ions.  CE defic ient  
mice have a higher express ion o f  the cytokines  IL-18 and I L - ip ,  both
+ Nomenclature for naming peptide substrate for proteolytic enzyme is:
substituent -  NH -  Pi -  P f  -  CO -  substituent
where the bond between Px -  is the scissile bond. The next residue in the direction o f the amino 
terminal is the P2 residue, and P2’ for the next residue towards the carboxy terminal and so on 
* The enzyme subsite that is involved in the binding of the corresponding peptide residue, e.g. S2 is the 
subsite for the peptidic P2 residue
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important in the polarisation o f  naive T-cell s  to T h2 cel ls .  Such 
cytokines  can induce the production o f  IL-4 and IL-5 by TH2 cells ,  and 
increased levels  o f  IgE, all o f  which were observed in the CE deficient  
mice. These results suggest that the turnover o f  IL-18 and IL - ip  is 
reduced, and as such may implicate CE in the deactivation o f  these  
cytokines.  It is noted that humans with AD have an observed decrease  
in CE expression.
1.7.4.5 Role of  CE and CD in antigen and Ii processing
The expression o f  CE within APC, given its l imited expression in other 
cell  types is suggest ive  o f  a role in antigen processing. M cel ls  o f  
fo l l ic le  associated epithelium in the gut express CE but do not express  
MHC class-II. Such cells  are the main, i f  not the only  way, for complex  
antigens to gain access to the intestinal immune system, and may
13 8function to pass on antigen to intestinal APCs . CE express ion in 
HeLa cel ls  can be induced by IFN-y via  a c lass II transactivator 
(CIITA) independent manner (CIITA induces  the express ion o f  MHC 
class-II,  HLA-DM and Ii) 139. It is thought that CIITA independent  
IFN-y action is required for the generation o f  an antigen presenting  
phenotype in non-professional A P C s140. R ecent ly  it has been shown  
that an isoform o f  CIITA negat ive ly  regulates  CE ex p ress io n 141. CE is 
also the major aspartic proteinase in a human B -ce l l  lymphoblastoid
119 ♦ •cell  l ine . Its expression in DC is particularly signif icant,  and CE has 
been shown to be expressed in human Langerhans and interdigitating  
reticulum c e l l s 115, and murine m icrog l ia142.
Both CD and CE have been shown to generate known T-cell  epitopes  
by in vi tro  protein digestion. Tetanus toxin contains  numerous CD / CE 
cleavage sites and several previously  described T-cell  epitopes ,  such as 
between residues  1273 and 1284, which are flanked by CD and CE 
cleavage s i t e s 143. The generation o f  H -2d-restricted OVA epitopes ,  in 
particular O V A 323-339, as recognised by the D O 11-10  hybridoma has 
been shown to be mediated by CD and CE144,145. This model forms the 
basis o f  the work presented within this thesis.
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More direct evidence for the role o f  CE in APC comes from several  
studies. In the A20 B-cel l  l ine,  70 % o f  the aspartic proteinase activity  
could be blocked by the CE-specif ic  A sc a r i s  pepsin inhibitor-3 or by  
pre-incubation o f  cell  lysates with anti-CE ant ibody112. Processing o f  
OVA by A20 cel ls  for presentation to the DO 11-10 T-cell  l ine was  
dramatically reduced by the A sca r i s  inhibitor,  but the presentation o f  
peptide was unaffected. The responses  o f  T-cell s  primed in v ivo  by  
administration o f  OVA were also reduced (63%) by the addition o f  the 
inhibitor to A20 c e l l s 112. The approach used and presented within this 
thesis has also recently been applied e lsewhere.  The inhibitor pepstatin  
A s ignif icantly  inhibited the interleukin-2 (IL-2) production from an 
O V A -(2 6 6 - 2 8 l ) - s p e c i f i c  T helper cell  hybridoma upon stimulation with  
native OVA presented by IFN-y-treated microglia  isolated from C D - / -  
m i c e 113,142. IL-2 production was not inhibited by OVA pept ide 266 -  
281. Microglia  from CD deficient  mice retained the ability for antigen  
presentation when not in the presence o f  pepstatin A. Another study 
confirmed that CD was dispensable for antigen process ing  as APCs  
from spleens o f  CD deficient mice were able to generate T-cel l  
epitopes from a number o f  antigens,  including OVA, hen egg lysozym e,
o c
pigeon cytochrome C, and myelin  basic protein . This study did not 
spec if ica l ly  address the role o f  CE. As prev ious ly  mentioned, cathepsin  
E has been suggested to play a role in m yoglob in  presentation by  
murine DCs in C D - / -  mice,  with better m yog lob in  antigen presentation  
by C D - / -  mice than wildtype cathepsin D -express ing  m i c e 111.
Other studies have implicated endosomal aspartic proteinases  in the 
processing o f  Ii . Zhang et al  found mice  in fected with L e i s h m a n ia  
m ajor  were more susceptible  to disease when treated with pepstatin A 
in v i v o 91, and attributed this to a CD-l ike  proteinase mediat ing  
processing o f  Ii. In the presence o f  pepstatin A, LIP and SLIP Ii 
fragments accumulate within A20 c e l l s 97, this e ffect being mainly  
attributed to the inhibition o f  CE112. The same group showed that 
Pepstatin A was found to inhibit the processing o f  a 28kDa fragment o f  
soluble le ishmania antigen within splenocytes  from naive mice  in vitro.
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They also attributed the degradation o f  Ii by an aspartic proteinase  
with the observation that pepstatin A suppressed the degradation o f  Ii 
in OVA immunized mice in vivo  and in v i t r o 146. Riese  et a l  however,  
showed that the culture o f  a B-cel l  lymphoblastoid cel l  l ine with an 
aspartic proteinase inhibitor (CGP 53437)  did not lead to the 
accumulation o f  Ii fragments from a p l i  MHC class-II dimers,  
suggest ing Ii processing by aspartic proteinases was not e ssen t ia l147. 
The specif ic i ty  o f  this inhibitor for all c lasses  o f  aspartic proteinase  
was not ment ioned other than to say it inhibits cathepsin D at 
nanomolar concentration, so other proteinases such as CE may still  
participate. An alternative is that the process ing  o f  Ii by cysteine  
proteinases within this B-cell  lymphoblastoid cel l  l ine is suff ic ient  
such that aspartic proteinase-mediated Ii degradation is redundant.  
Different APCs express different levels  o f  proteolytic  enzymes or even  
different enzymes,  making it difficult  to derive general principals  from 
the confl icting data.
1.7.5 Aspartic  proteinase inhibitors
Ideally, the design o f  a cathepsin E spec if ic  pept ide inhibitor would  
allow for the discrimination between cathepsin  D and E. Such an 
approach however is not within the scope o f  this project. This problem  
can be addressed in other ways with the use o f  cell  l ines containing a 
s ignif icantly  larger expression o f  CE than C D 112, or with the use o f  
cathepsin D knockout m ic e 110.
Initial studies into protease inhibitors concentrated on screening  
microorganisms for inhibitors that were re la t ive ly  small  and generally  
resistant to animal metabol ism148. One particular inhibitor from 
S t rep to m yces  te s taceus  n.sp. ,  called pepstat in A, is a particularly  
potent inhibitor o f  a broad range o f  aspartic proteases  including CD 
and CE. Pepstatin wil l  be used as the most  readily  available,  h ighly  
potent broad-spectrum aspartic proteinase specif ic  inhibitor.  Its small  
size and ease o f  chemical  modification is attractive from a synthesis
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point o f  v iew. The use o f  pepstatin and pepstatin analogues will  be 
discussed further, along with some other inhibitor options.
1.7.5.1 Pepstatin A
Several variants o f  pepstatin (differing in the molecule  attached to the 
N-terminal amide group) are synthesised by S trep to m y c es  specie s ,  the 
most studied and well  known o f  which is the pepstatin A molecu le  
containing the isovaleryl  residue (from here onwards just referred to as 
pepstatin). Pepstatin is a pentapeptide,  the structure o f  which  is shown  
in figure 1.8. The availabili ty o f  a s ingle  C-terminal carboxylic  acid  
and a lack o f  other highly reactive m olecules  makes pepstatin an highly  
attractive target for chemical conjugation.
Figure 1.8: Structure of pepstatin from Streptomyces testaceus n.sp. containing isovaleryl residue
Pepstatin is a very potent inhibitor with a K t value in the 1-10 nM 
range. The unusual amino acid statine provides  pepstatin with its high  
potency. The proposed mechanism for aspartic protease c leavage  o f  a 
sc iss i le  peptide bond involves  a tetrahedral intermediate (fig.  1.9).  
Structure-based subsite specif ic i ty  o f  aspartic proteases  with pepstatin  
analogues149'151 and crystal structures o f  cathepsin D bound to 
pepstatin105 and R h izo p u s  aspartic proteinase bound to pepstat in152 has 
lead to the proposed cathepsin D -  peptide binding and bond c leavage  
mechanism as shown in figure 1.9. The acidic  environment in which  
aspartic proteases  optimally  work allows two aspartic acid residues to 
hydrogen bond to, and hydrolyse ,  a carboxyl o f  a suitable peptide bond 
(fig.  1.9a). This leads to an equilibrium involv ing  a tetrahedral
HO
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intermediate (fig. 1.9b) and subsequent bond c leavage (fig.  1.9c) to 
yie ld  two separate peptide fragments (fig.  1.9d).  It is be l ieved that all 
aspartic proteases exhibit  a mechanism similar to that shown in figure  
1.9, and that the statine residue mim ics  the tetrahedral intermediate.  
More information on the structure and mechanism o f  pepsin- like
9 2aspartic proteinases can be found e lsewhere . 
a)
d)
Figure 1.9: Proposed mechanism of peptide bond cleavage by cathepsin D as deduced from the 
cathepsin D -  pepstatin crystal structure of Baldwin e t  a/.105. The separate stages of peptide 
binding, intermediate formation and cleavage of peptide bond are represented from a) to d). 
Diagram adapted from Bott e t al152.
1.7.5.2 Pepstatin inhibitor analogues
Many groups have also used the C-terminal carboxy group o f  pepstatin  
to synthesis analogues with varied properties.  For example ,  Hamdaoui
153et al  synthes ised mannose-6-phosphate  pepstatin analogues that 
showed anti-proliferative activity on breast-cancer cel l  strains by  
targeting pepstatin to mannose-6-phosphate  receptors and subsequent  
inhibition o f  cathepsin D within lysosomes.  The work o f  Brygier et  
a l 154 showed that a methoxypoly  (ethylene g lyco l)  conjugate o f
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pepstatin inhibited hog pepsin in vi tro  with a Ki  400 times higher than 
pepstatin. A similar idea was adopted by Campbell  et a l 155 who  
conjugated pepstatin to poly  (L-lysine) to show increased inhibition o f  
protein degradation within Balb/c 3T3 fibroblasts. The label l ing o f  
pepstatin has been used previously  to probe for the locali sation o f  
cathepsin D. Knight et a l 156 conjugated pepstatin to dinitrophenyl and 
used an anti-dinitrophenyl antibody to locali se  cathepsin D. The same
157group synthes ised a fluorescent bimane-labelled pepstatin . It should  
be noted however that these studies do not mention cathepsin E 
inhibition, which is equally l ikely in all cases mentioned.  The crystal  
structure o f  cathepsin E, recently solved at 2 .35A,  suggests  that it 
would be difficult  to design a substrate specif ic  for either cathepsin D 
or E 126.
1.7.5.3 Statine-related aspartic proteinase inhibitors
Pepstatin is by far the most wel l -known and studied aspartic proteinase  
inhibitor,  but its active component,  the amino acid statine,  has been  
derivatised to synthesise  new aspartic protease-spec if ic  inhibitors.  The 
variation in binding pockets o f  different aspartic proteases and 
subsequent binding or steric hindrance o f  particular statine inhibitor  
analogues makes this poss ible ,  and this has been achieved for some  
aspartic proteases such as p lasm eps in158, B A C E 159 and cathepsin  
D 15i ,i 60-i63  ^ although t0 hate there is no data to suggest that these CD-  
specif ic  inhibitors are not also CE inhibitory. A compound orig inally  
tested as a BACE inhibitor was found to be more potent towards CE 
than pepstatin,  however no data was shown o f  its ef fects  upon C D 164. 
Very recently,  two bis-trifluoromethyl analogues  o f  pepstatin displayed  
good inhibition o f  CD and CE, the inhibit ion ( I C 5 0 ,  nM) o f  CE being  
10-fold lower than that for C D 165.
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1.7.5.4 Ascaris  pepsin inhibitor-3
The A sca r i s  pepsin inhibitor-3 (PI-3) along with inhibiting porcine  
pepsin, also inhibits the function o f  cathepsin E, but not cathepsin 
D 166 p j _3 jias untii recently been dif ficult  to obtain in suff icient  
quantities for functional studies o f  antigen processing. Structural 
studies have shown that PI-3 uses the N-terminal P-strand to block  
several binding pockets o f  porcine pepsin,  and that approximately 17%
167o f  its surface interacts with porcine pepsin . The mechanism o f  
inhibition o f  cathepsin E is l ikely to be similar, and it may therefore be 
difficult  to synthes ise  a smaller peptidic vers ion o f  PI-3 comparable to 
pepstatin.
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1.8 Aims for studying antigen processing using inhibitors
There is a great potential  for the use o f  aspartic proteinase inhibitors,  
such as pepstatin,  in the study o f  antigen processing. However,  the use  
o f  pepstatin is l imited due to its poor solubi li ty  and inabili ty to cross  
the cell  membrane at concentrations that do not affect cel l  viabi lity.  
The aim o f  this research is to chemically  modify  the structure o f  the 
proteinase inhibitor pepstatin to overcome some o f  the restrictions o f  
the use o f  pepstatin in v itro  and in vivo  (d iscussed in chapter 2).
Several options are available that could help to address the role o f  
cathepsin E in antigen processing. A wel l  understood model  o f  antigen
• • •  • 1 1 9 *processing, in which the A20 B-cell  murine lymphoma is used to 
process and present a specific  peptide epitope o f  ovalbumin to D O l l -  
10 T-cel ls ,  has been used to assess the role o f  cathepsin E within  
antigen proteolysis.  A20 cel ls  have been shown to express most ly  
cathepsin E as their aspartic proteinase.
Another approach is to study antigen process ing  by cathepsin E 
defic ient  mice .  Such a model would not only  address the role o f  
cathepsin E within antigen processing but also help to address i f  it also  
has an importance for other critical cel lu lar processes ,  as has been  
suggested by its enzymatic c leavage o f  a number o f  key endocrine  
mediators. Work towards the generation o f  a cathepsin E defic ient  
mouse has been achieved (sect ion 1.7 .4 .4 ,  page  5 6 ) 137. An alternative  
option would be to use a cathepsin E spec if ic  protease inhibitor.  As  
previously  mentioned, the ascar is  inhibitor is cathepsin E and not 
cathepsin D s p e c i f i c 166. However  it is d if f icult  to obtain suff icient  
quantities for in vi tro  or in vivo  studies.  Alternatively ,  the chemical  
synthesis  o f  a cathepsin E specif ic  inhibitor could help to address this 
problem. A different approach, and one used within this study, is the 
use o f  mice  defic ient  in cathepsin D. Antigen presenting cell s  from 
such mice  should express cathepsin E, but not cathepsin D. Inhibitors  
such as pepstatin,  or pepstatin derivatives,  which do not distinguish
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between cathepsin D and E could be used to probe se lec t ive ly  the 
function o f  cathepsin E.
Published functional studies o f  antigen processing using the aspartic 
proteinase inhibitor pepstatin (see  section 1.7.5.1 ,  page 60) suffer from 
a number o f  limitations: Pepstatin is insoluble  in most solvents  except  
DMSO, a solvent that can i t se l f  markedly affect T-cellular act ivi ties.  
The concentrations o f  pepstatin required to achieve b io log ica l  effects  
is often extremely high (up to 100 pM) raising the poss ib i l i ty  o f  non­
specif ic / toxic  activity.  At these concentrations,  pepstatin is l ikely  to 
target any cell  and cellular compartment present in the culture (or in 
vivo) ,  further complicating the interpretation o f  the results.  Chapter 2 
details  these problems and introduces a series o f  chemical strategies  
that could be used to address the aforementioned problems and lists a 
series o f  modif ied pepstatin inhibitors that may improve both the 
so lubi li ty  and cell  / compartmental targeting.
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Chapter 2
Design of aspartic proteinase inhibitors for use within 
antigen presenting cells
2.1 Introduction
There are a number o f  studies in which inhibitors o f  proteolytic  
enzymes,  including those o f  the aspartic proteases cathepsin D and E, 
have shown an involvement o f  cathepsins in the MHC class-II  process ing  
pathway (refer to section 1.7). However,  several major problems have  
l imited the value and interpretation o f  these studies,  and have in 
particular precluded any in vivo  pharmacologica l analysis  o f  these  
inhibitors in processing activity.
i) There is no low molecular weight inhibitor that discriminates  
between cathepsin D and E. As both enzym es  are found within the 
cellular ves ic le s  upon which antigen may travel during its process ing  
l ifetime, interpretation o f  any data invo lv ing  a non -spec i f ic  aspartic 
proteinase inhibitor cannot be entirely attributed to one or the other 
cathepsin.
ii) Almost all aspartic proteinase inhibitors are poorly  soluble  in 
aqueous medium, l imiting their potential use in v ivo  and in culture.
iii) Many inhibitors are poorly  access ib le  to the correct intra-cellular  
compartment and rely on fluid-phase uptake alone. Attachment via  a 
membrane speci f ic  molecule  would both aid uptake into an appropriate  
cel l  compartment (i.e. the endosome as opposed to the cytoplasm which  
could lead to non-specif ic  effects on other enzymes)  and increase  
cellular availabili ty  o f  the inhibitor.
iv) Inhibitors usual ly  have no ce l l - sp ec i f i c  targeting, leading to 
systemic  distribution o f  inhibitor. This would  g ive  rise to unfavourable
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inhibition within non-antigen presenting cell s  and a greatly reduced  
availabili ty  o f  inhibitor.  The higher doses o f  inhibitor needed in this 
case could produce toxic  effects within any in vivo  model.
There is a need to design inhibitors that are soluble in aqueous medium,  
speci f ic  for cathepsin E, and that are ce l l - sp ec i f ic  and specif ic  for an 
appropriate intracellular compartment. Such inhibitors would help to 
obtained data on the effect  o f  cathepsin E within the class  II MHC 
antigen processing pathway o f  professional antigen presenting cel ls .  
These problems are explored further in this chapter, and an approach to 
help solve  these problems is discussed. A rational chemical design  
strategy based upon these ideas is presented with the des ign o f  some  
appropriate c lasses  o f  inhibitors. The chemistries  available  to achieve  
the synthetic goals wil l  also be discussed.
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2.2 The choice of  cathepsin inhibitor -  pepstatin  A
As mentioned in section 1.7.5,  there are a few choices  for the inhibitor  
moiety  that can be used, however it is clear from the research that has 
been previously  been done in relation to cathepsin D / E inhibitors,  that 
the best and easiest option is to use pepstatin A itself .  There are several  
advantages o f  using pepstatin A. Firstly,  it is available in suff ic ient  
quantities for chemical synthesis procedures. Secondly ,  the presence o f  a 
single  terminal carboxylic acid and no other h ighly  reactive chemical  
groups means that derivatives o f  pepstatin can be eas i ly  achieved  
without the need for complex side chain protection strategies for the rest 
o f  the compound (fig. 2.1).
H
N
H
N
N
OH
N
H
OH
HO'
Figure 2.1: Structure of pepstatin from Streptomyces testaceus n.sp. containing isovaleryl residue
Two disadvantages o f  using pepstatin A is that it is not spec if ic  to either  
cathepsin D or E, and that it is a very insoluble  inhibitor in aqueous  
solutions.  The first problem, in the context o f  this research, wi l l  be 
accomplished by selecting a model o f  antigen process ing  that can 
overcome the need to distinguish the difference between cathepsin D and 
E. Two models  are to be used for this; the use o f  B -ce l l  hybridomas that 
have a very high expression o f  cathepsin E and low express ion o f  
cathepsin D, and the use o f  cathepsin D knockout mice.  Both o f  these  
approaches wil l  be described elsewhere in the chapters 5 and 6. The 
second problem o f  pepstatin solubility can be overcome by chemically  
synthes is ing derivatives o f  pepstatin that have a so lubi l i s ing  compound  
attached.
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2.3 Inhibitor solubility and cellular targeting
Solubil i ty  is an essential  criterion in the design o f  a modif ied  pepstatin  
inhibitor. The presence o f  hydrophobic residues  in pepstatin (fig.  2.1)  
explains its insolubil ity.  For its use in v i t r o , the inhibitor is usually  
disso lved in DMSO and then diluted into aqueous solution. DMSO is 
toxic  to cell s  at high concentrations,  and from data presented (see  
section 6 .1 .2 ,  page 185),  may directly inhibit the function o f  aspartic 
proteinases.  The usual method for increasing solubi li ty  is to attach 
hydrophilic molecules  such as sugars or certain peptides as discussed  
below. Another consideration given the poor so lubi li ty  o f  pepstatin is its 
bioavai labili ty .  The insolubi lity  characteristics o f  pepstatin mean that it
is l ikely to be poorly endocytosed into ce l l s ,  in fact this has been shown
168 • to be the case in vi tro  and in v ivo  . The selection criteria for
overcoming these problems are thus to improve the b ioavai labil ity  o f
pepstatin by improving its solubil ity  and p o s s ib ly  cell  targeting.
Synthetic derivatives o f  pepstatin attached to either carbohydrates or 
hydrophilic peptides are two good choices  for improving solubil ity  and 
bioavai labil ity  o f  any pepstatin analogues.  Carbohydrates, however,  have  
some advantages.  Certain carbohydrates can promote cell  targeting via 
their recognit ion by cell  surface lectins.  As discussed in section 1.4, the 
mannose receptor provides a way to a llow endocytos is  into some types o f  
APCs, and into the ves ic les  that are l ikely  to fuse with aspartic 
proteinase containing vesic les .  Carbohydrates are also less  l ikely  to 
interact with target proteinases than peptides.  The sugar mannose fulf i l s  
the requirements o f  improving so lubi li ty  and cel l  targeting in this  
context.
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2.4 Initial aspartic proteinase inhibitor design
From the requirements  mentioned above, it is clear that a synthetic 
conjugate  containing a single mannose and peps ta t in  molecule  linked 
together  are the minimum requirement for the design o f  a more potent  
aspartic protease  inhibitor with improved solubi l i ty  in aqueous solution. 
It is expected however  that this will not be suff ic ient  to overcome the 
problems described, and a more flexible design would need to allow the 
addition of  multiple mannose sugars to be at tached to a pepsta tin  
molecule.  The inclusion of  a f ramework with a higher  amount of  
mannosyla t ion introduces the potential  for steric hindrance between the 
mannosylat ion unit and the binding o f  pepsta tin  to an aspartic 
proteinase.  Therefore,  the design o f  a soluble aspartic prote inase  needs 
to also include the possibil i ty to allow cleavage be tween the two halves 
o f  the soluble aspartic proteinase  inhib itor  molecule .  In addi tion,  the 
aspartic prote inase  inhibitor  should include careful design that would 
allow for the inclusion o f  a label to improve the usefulness  of  such an 
inhibitor.  Figure 2.2 il lustrates these des ign requirements .  Fur ther 
considera t ion o f  the mannosylation unit  and the linker  section is required 
to aid in our final synthetic design.
Simplest Aspartic Proteinase Inhibitor
fluorescent label
cleavable
Mannose
Multiple
Mannosylation
Pepstatin
PepstatinLinker
reduces steric interaction 
Modified Design Aspartic Proteinase Inhibitor 
Figure 2.2: Schematic of aspartic proteinase design
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2.5 Mannosylation design considerations
Improving aqueous solubil ity  using multiple mannose units is quite 
straightforward, however the ideal l igands for binding to the mannose  
receptor have to be considered.
2.5.1 Mannose receptor binding
Many oligosaccharides  and glycodendrimers have been studied for 
binding characteristics to l e c t in s169. It was through such studies that the 
“cluster g lycos id e” effect was established, i .e. that the aff inity o f  
multivalent g lycos ides  for polyvalent binding l igands is s ignif icantly  
higher than that o f  the individual g ly c o s i d e s 170. There has been much  
research on the structure and sugar binding characteristics o f  the 
mannose receptor. There is still  uncertainty as to the “idea l” l igand for 
the MR and how the multiple carbohydrate recognit ion domains (CRDs)  
cooperate in the binding. There are however  a whole  series o f  natural 
and artificial l igands with good binding to the MR.
Mannose is not the only  sugar monomer that is able to bind to the 
mannose receptor (fig.  2.3).  As shown in table 2.1,  sugars such as 
mannose and L-fucose  have the highest  aff inity  for the MR, the presence  
o f  two equatorial hydroxyls  being important in its binding (the C-2 and 
C-3 hydroxyl groups in the case o f  mannose) .  Hydrophobic ity in the C- l  
posit ion l inked to a-m annos ides  appears to be an important factor in its
171binding to the MR . Biantennary and triantennary oligosaccharides  
show increased binding to the MR than s ingle  sugars (with typical IC50 
values  in the hundreds o f  pM). Branched o l igosaccharides  show an even  
higher binding affinity. M a n a l ,6  [ M a n a l , 3 ] M a n a l - O M e  and other 
similar o l igo-mannos ides  containing a - 1 - 3 -  and/or a - 1 - 6 -  l inkages  (i.e.  
not a - 1-2- and/or a - 1 - 4 -  l inkages) showed the highest  aff inity  
characteristics o f  simple branched or straight o ligosaccharides .  a -Linked
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• 171sugars showed higher affinity than P- lmked sugars . Mannose has the 
added advantage o f  being a reasonably easy  carbohydrate upon which to 
do chemical synthesis  in comparison to some other sugar monomers.
Su g a r  L ig a n d I C 50 (mM)
L-Fucose 3,200
D-Mannose 5,500
D-Glucose 6,000
a -M a n l - O M e 1,000
D-Man-6-P 13,500
D-G lcNAc 13,000
D-Galactose 19,000
D-GalNAc 60,000
Table 2.1: Inhibition (IC50, mM) of 
MR binding to mannan coated micro- 
plates by sugar monomers. Diagram  
adapted from Kery et al111.
D-Mannose D-Glucose
HO 
HO
Me
OH
HO^^
H O ^ ^ ^ ° \
ho—^
NH
OH
L-Fucose
Ac'
N-Acetylglucosamine
Figure 2.3: M R binding sugars
2.5.2 Natural and synthetic MR ligands
There are a whole  range o f  pathogens that are able to bind to the MR,  
including yeas t s14,172 and mycobacteria27,173. Yeast  mannan is the most  
well  understood microbial l igand for the MR. Mannan is the name for a 
mannosylated structure found in yeast cel l  walls ,  with a conserved oc- 
(l ->  6)- l inked polymannosylated backbone with varied length a - ( l - > 2 ) -  
linked mannoses.  Strategies to synthes ise  such l igands have been  
developed by Ley and co-workers using novel one-pot synthesis  
m eth o d o lo g ie s174,175. Others have also synthes ised mannan derivatives  
using trichloroacetimidate,  thiophenyl  and / or «-pentenyl
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m eth od o log ie s176'179. There is however a simpler w ay  to achieve  
mannose receptor binding by using the cluster g lycos ide  effect .
Several different approaches have been used to synthes is  high mannose  
containing glycosynthons with good binding aff inity  for lect ins  such as 
the MR. These approaches have either incorporated multiple copies  o f  
single  mannosyl structures, or multiple copies  o f  o ligosaccharides ,  such  
as mannan structures. The dendritic structures o f  the g lycosynthons  have  
in general been based upon either well  known dendrimeric structures 
such as poly(amidoamine) (PAMAM) or f3-cyclodextrin, or based upon  
peptides such as poly lysine ,  or even upon proteins such as bovine  serum 
albumin (BSA).  These latter two approaches wi l l  be considered in more  
detail.
2.5.3 Peptide-based carriers
The first attempts to design small  g lycopeptide  substrates for 
endocytosis  by macrophage MR came from Robbins et a l l , who  
developed mannosyl analogues such as that shown in figure 2.4.  These  
contained multiple  mannose groups l inked to the a  and s amino group o f  
lysine,  dilys ine (Man3Lys2) and trilysine (Man4L ys 3) with inhibition  
constants (AT*) in the pM range. For comparison, Man43-BSA is quoted as 
having a K& o f  between 0.5-4  nM180.
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Figure 2.4: Mannosylated polyiysines as synthesised by Robbins et all,z and Biessen et a?
Subsequent research lead to the development o f  cluster mannosides  such  
as M 6L5 (f ig. 2 .4 )3. Competition studies showed an increase in 
mannoside binding for mannosides ranging from M2L to M 6L53, the 
mannoside M 6L5 is reported as the most potent synthet ica lly  des igned  
mannoside with nanomolar affinity. The aff inity  o f  the M 6L5 is 
comparable with mannosylated BSA.
The improved affinity o f  the M 6L5 o l igo lys ine  mannoside l igands over  
those designed by Robbins et a l x is due to the length o f  the spacer  
connecting the mannose sugars to the po ly ly s in e  backbone and in the
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nature o f  the spacer. M 6L5 mannosides  contain an aromatic group, which  
may help the binding affinity to the CRD protein res idu es181.
2.5.4 Protein-based carriers
Over the last 20 years, two neoglycoprote ins  have been used a great deal,  
these being Man23-B S A 39,180,182 and Man4o-HSA (Human Serum 
A lbum in)183. The advantage o f  these protein conjugates  is that they are 
easy to prepare and can be labelled with fluorescent probes or 
radio labelled184.
As a choice  o f  protein carrier, bovine serum albumin (BSA) contains  
between 30 -  35 free lys ine side chains for conjugation. Another useful  
feature o f  BSA is that it contains one free cysteine  sulfhydryl side  
chain185, that can be used for attachment o f  a pepstatin molecule .  One 
concern with the conjugation o f  proteins to pepstatin is solubi lity.  Given  
the dramatic difference o f  solubi li ty  between a protein and pepstatin,  it 
will  be essential  to use a protein that a llows the use o f  some pepstatin  
so lubi li sing solvent,  such as DMSO. B SA  has a tolerance towards  
precipitation at up to 35 % DMSO.
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2.6 Linker design considerations
The poss ib i l i ty  o f  steric interactions between the mannosyl unit and 
pepstatin is an important consideration in the des ign o f  an aspartic 
proteinase inhibitor. Considering the initial  design o f  inhibitor (fig.  2.2,  
page 70),  the inclusion o f  a spacer unit would  help to reduce this risk. 
An improvement on this idea is to allow inhibitor c leavabi l i ty  within an 
APC, thus avoiding the steric interaction altogether.  Ensuring that the 
design is f lexib le  enough to incorporate other m olecu les  i f  needed (i.e.  
fluorochrome or radio-label)  would greatly increase the usefu lness  o f  
any synthesised inhibitors that may appear potentially  useful after 
bio logical testing (i.e. due to high solubi lity,  high targeting to 
appropriate cel ls  / compartments,  or high potency).  All  o f  these  
considerations for linker design are d iscussed below.
2.6.1 Reducing steric interaction
In the synthesis  o f  anti-adhesion agents, Toyokuni and Hakomori used  
several different length benzyl esters to provide space between various  
carbohydrate molecules  and a ly sy l ly s in e  framework4. This kind o f
1 8 f\approach, or iginally  designed by Lemieux et al  , is useful for attaching  
an activated carbohydrate at one end to an amino compound at the other 
end while  providing extra space to reduce steric interactions (fig.  2.5a).  
An alternative approach is to conjugate mannose monomers  to a suitable  
carrier via  a 4-nitrophenol spacer,  as used in the M 6L5 (f ig. 2.5b)  
synthesis o f  B iessen  et al  . This approach would  have the advantage o f  
improving aff inity  for the mannose receptor.
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benzyl 4-hydroxybutanoate 
O 1) hydrogenation
2) active ester formation
AcO" React with amine
R
R = good chemical leaving group
b) A rCl
AcO' React with amineAcO-
R
4-nitro phenol
1) hydrogenation
2) isothiocyanate formation
Figure 2.5: Use of a) benzyl ester4 or b) 4-nitrophenol3, as a molecular spacer to reduce steric
interactions
2.6.2 Intracellular cleavable linker
Cleavable linkers have been used in prodrug design and can contain  
either acid-labi le  bonds or enzyme c leavable  bonds (c leaved by enzymes  
such as esterases,  l ipases and proteinases) .  Endocytosis  o f  l igands via 
the mannose receptor introduces an endocytosed l igand into a vesicular  
environment that has a decreased pH towards lysosom al  ves ic le s ,  using  
acid-labi le  bonds in a c leavable  l inker would  be a good choice.  
Examples o f  intracellular acid-labi le  bonds include vinyl ethers187, aryl 
esters188 hydrazone l inkages189’190, and disulphide bon d s191,192.
Disulf ide  bond reduction plays a key role in the production o f  antigenic  
peptides by  antigen process ing72,73,193,194. Recently  an enzyme involved  
in disulphide reduction within APCs has been identif ied (GILT ) 74 and 
shown to be consti tu tively  expressed within endosomes  and lysosom es  o f  
APCs such as macrophages and dendritic c e l l s 195. A disulphide wil l  be 
considered in our design o f  c leavable  linkers. A full review o f  the use o f
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cellular reduction o f  disulfide linked conjugates is provided by Saito et  
a l 196.
Based upon the information o f  mannosylated carrier that wi l l  be used in 
the inhibitor design, and upon an inclusion o f  a spacer section, and upon  
the reactivity o f  pepstatin (i.e. a terminal carboxylic  acid) then a good  
choice for desired functionality on either side o f  the linker is provided  
by the use o f  a diamine linker. A diamine l inker can be attached to 
carboxy groups via  active esters,  or to other amines via  a thiourea  
l inkage. A diamine disulfide (cystamine, fig.  2 .6) is readily available as 
a convenient c leavable  linker. It is proposed that a non-cleavable  linker  
is also chosen to allow for the potential comparison o f  inhibition potency  
with cleavable  linkers. For simplicity ,  this was selected to be 1,3-  
diaminopropane (fig.  2.6).
H2N\ / XSs\ ^ NH2
1,3-diaminopropane
H2N\ S 'NH,
cystamine
Figure 2.6: Cleavable (cystamine) and non-cleavable (1,3-diaminopropane) linkers
2.6.3 Flexibil ity for further chemical modif ication
In the situation whereby a particular inhibitor has proven to be valuable  
in terms o f  cell  targeting, so lubi li ty  or inhibitor potency, it would be 
useful to include a design that would  allow for modif ications.  This is 
particularly important with the testing in DCs,  whereby various labell ing  
studies could be extremely useful with success fu l ly  tested inhibitors.  
The ideas so far discussed using pept ide and protein-based carriers 
(sect ions  2.5.3 and 2 .5 .4)  would  use the side chain o f  lys ine  to introduce
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the mannosylation unit. There is no reason why the 8-amino group o f  
lysine  could not also be used for the potential  to introduce extra 
inhibitor functionality.
For a protein carrier, there are a suff ic ient number o f  lys ine  side chains  
on the protein BSA to accommodate  both mannose m oiet ies  and any 
additional functionality.  For po ly -L- lys ine  pept ides,  the synthesis o f  
which is most l ikely  to be by standard pept ide synthes is  procedures,  
introduction o f  a single  orthogonally protected lys ine  group is possible .  
Standard peptide synthesis uses Boc-protected lys ine groups. Literature 
shows that the lysine side chain protecting group ivDde is stable under a 
large range o f  reaction condit ions but is easily  c leaved by the use o f  2 % 
hydrazine so lut ion197, and would be compatible with the use o f  Boc-  
protected lysine.
79
2.7 Final aspartic proteinase inhibitor design
With all o f  the considerations mentioned so far in this chapter ,  it is 
possible to propose a series o f  separate modules  that could be 
synthesised and conjugated together  to provide  dif ferent  aspartic 
proteinase  inhibitors ,  from here onwards referred to as Mannose 
Pepstatin Conjugates (MPCs). Three classes  o f  inhibi tors  will  be 
synthesis,  the simplest being a l ink between a single mannose and 
pepstatin,  with or without  a c leavable  l inker  (MPC1 and MPC2 
respectively, fig. 2.7). The other  two classes will incorporate  a larger  
number  o f  mannose units,  a pept ide-based  (MPC3 / 4) or prote in-based 
carrier  (MPC5 / 6), and a cleavable  or non-c leavable  l inker  (fig. 2.8).
MPC1
MPC2
HO.
HO"
HO-
OH
cleavable
OH
- l 'Q
Mannose
Mannose
Pepstatin
Pepstatin
Spacer
Spacer
Linker
Linker
Figure 2.7: Design of MPC1 and MPC2 inhibitors
MPC3 and MPC5
Multiple mannosylation 
provided by multiple copies
PepstatinSpacer LinkerMannose Peptide or Protein Carrier
I i
MPC3 / 4 = Poly-L-lysine H2Nn 
noz MPC5 / 6 = BSA protein
\\ cleavable
nh2
MPC4 and MPC6
Figure 2.8: Design of MPC3 to MPC6 inhibitors
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2.8 Chemical strategy for inhibitor synthesis
Within the previous sections are clear sets o f  defined chemical bui lding  
blocks  that wil l  lead to the final structures o f  the inhibitors MPC1 to 
MPC6. Coupling modules  together requires methods that are simple,  
selective  and likely  to work under various synthes is  situations.  For this, 
three types o f  bond formation methods were chosen: peptide,  isothiourea  
and thioether bonds. In addition, mannose sugar derivatives  need to be 
activated so that they are able to react with suitable targets (i .e. the 
hydroxyl o f  the spacer sections) .
2.8.1 Peptide bond formation using NHS esters
There are a number o f  ways that peptide bonds can be formed198’199, 
often by the reaction o f  an activated ester with an amine. A ct ive  esters  
are formed by the action o f  an activating group upon a carboxylic  acid. 
For this work, the synthesis o f  an A-hydroxysucc in im ide  (NHS) active  
ester was chosen (fig. 2.9).
O-Acylisourea
H
+
0
H H
EDU
00 p o
+
peptide bond 
formation
O
Figure 2.9: (i) NHS ester synthesis and (ii) coupling of amine and an NHS active ester to form a 
peptide bond between R and R'
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Figure 2.9 shows the synthetic steps required for making NHS esters.  It 
is poss ib le  to make a peptide bond by reacting an amine directly with an 
O-acylisourea, however,  at the stage o f  0 -acyli sourea  formation, there is 
a competing reaction o f  intramolecular acyl transfer to nitrogen, to form 
an A-acylurea. As the reactivity o f  an amine (e spec ia l ly  i f  using a 
sterically hindered amine) cannot be assured, it would be wiser  to choose  
an attacking nucleophile  (such as NHS) that would  rapidly attack the O- 
acylisourea and reduce the poss ib il ity  o f  any side reactions occurring.
There are several carbodiimides to choose  from including the more
1 o  c
widely  used dicyclohexylcarbodiimide (DCC) and many poss ibi l i t ies  
for the active ester (including 1-hydroxybenzotr iazole )200. The choice  o f  
EDCI and NHS was mainly based on the need for water solubi lity.  The 
urea by-product o f  DCC (DCU) is partially soluble  in most solvents ,  and 
as such dif ficult  to remove by filtration. EDCI is more water-soluble  
than DCC, and EDU and NHS are both removable by an aqueous workup 
after a reaction. As the NHS ester derivatives are soluble in organic 
solvents ,  this allows for easy removal o f  starting materials and the urea 
biproduct.
2.8.2 Isothiourea bond formation using isothiocyanates
Isothiocyanates  are made by the reaction o f  an amine with thiophosgene .  
Although not as reactive as isocyanates  (where sulphur is replaced by  
oxygen),  they are still  h ighly  reactive towards nucleophiles ,  much more  
stable, and avoid the use o f  the h igh ly  toxic  phosgene  gas. 
Isothiocyanates  react with amines to form an isourea bond. This is 
particularly useful for reaction with the 8 -terminal o f  ly s in e 201 and can 
be used for the attachment o f  mannose derivat ives to MPC3 -  M PC6 . 
This is il lustrated in figure 2.10.  The reaction is simple,  and involves  the 
attack o f  an amine towards the highly  electrophil ic  carbon o f  the
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isothiocyanate.  The resulting electron shift and proton loss  results in a 
very stable thiourea l inkage202,203.
thiourea bond
formation Isothiocyanate
Figure 2.10: Isothiocyanate formation and reaction with amine
2.8.3 Thioether bond formation with iodoacetamides
Thioether bonds may be formed by the reaction o f  a haloacetamide with 
a sulfhydryl group. The most reactive haloacetamide is iodoacetamide;  
these can be synthesised by the reaction o f  an amine with iodoacetic  
anhydride. This method was selected for attachment o f  pepstatin -  linker 
intermediates to a single cysteine sulfhydryl group found on the surface
185o f  bovine serum albumin (BSA) for the formation o f  MPC5 and 
MPC6 204.
Iodoacetic anhydride
Iodoacetam ide th ioe ther bond
form ation
Figure 2.11: Formation of iodoacetamide and reaction with a sulfhydryl to create a thioether bond
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2.8.4 Act ivat ion of  mannose C-l  hydroxyl  group
Mannose,  like other aldopyranose sugars,  contains five  hydroxyl groups.  
In order to activate the C - l  hydroxyl for reaction with for example the 
hydroxyl group o f  a spacer element (sect ion 2 .6 . 1 , page 76),  it is 
necessary to protect the others from reaction. Mannose derivatives  
containing acetyl protecting groups in these other pos it ions  are highly  
stable and often crystall ine.  In addition, these  protecting groups are 
removable under mild reaction condit ions.  a -A nom er  derivatives  o f  
mannose have higher affinity for the mannose receptor than
• 171corresponding p-anomer derivatives , and conveniently ,  reactions  
involving the anomeric C- l  posit ion o f  mannose derivatives containing  
acetyl protection mostly prefer a-anomer compounds due to the 
inf luence o f  both the anomeric effect  and neighbouring group 
participation.
2.8.4.1  The anom er ic  e f fec t  and  n e ig h b o u r in g  g ro u p  p a r t i c ip a t io n
The anomeric e f fect205 is due to two main in f luences206’207, a favourable 
interaction between the lone pair o f  the ring oxygen and the antibonding  
a*-orbital  o f  the C- l  -  C-X bond (fig. 2 .12 i ) ,  and an electrostatic effect  
favouring formation o f  an axial substituent,  with less repulsive  
interactions between the oxygen lone pairs and Xa than with Xe (fig.  
2.12ii ) .  Taken together, the anomeric affect inf luence on mannose is to 
favour the a-anomer.
(i)
Xa
Figure 2.12: Factors that lead to the anomeric effect
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The neighbouring group effect occurs when the C-2 hydroxy group o f  
aldopyranose sugars are protected by an acetyl group. For reactions that 
involve  removal o f  a leaving group from the C - l  pos i t ion  (as would  
occur for the reaction o f  a spacer group with a mannose derivative,  
sect ion 2 .6 .1 ,  page 76), a C-2 acetoxy group helps  to stabi lise the 
intermediate oxonium ion formed by the formation o f  an acetoxonium  
ion (fig. 2.13).  The acetoxonium intermediate,  be ing more stable than an 
oxonium ion, is the species under attack by a nucleophile ,  and as such,  
effect ive ly  blocks the (3-face o f  the sugar from nucleophil ic  attack, and 
forces the incoming nucleophile  to approach the a - face .
Me,OAc
OAq
h o
,OAc
AcO' 1-0
AcO-AcO-
AcO-
L
L = leaving group 
R = attacking nucleophile
,OAc
OAc
-l-QAcO-
AcO-
Figure 2.13: Neighbouring group effect on a-anomer formation
2.8 .4 .2  B rom o  and  t r ic h lo ro a c e t im id y l  a c t i v a te d  m a n n o p y ra n o s id e s
Two choices  for the formation o f  activated mannopyranosides wi l l  be 
used in the synthesis o f  activated mannopyranosides,  these being
“7 0 8 9 0 0  9 1 0bromo ’ and acetimidate activated mannopyranosides.  The 
formation o f  mannosyl bromides208,209 is e f f ic ient  with the use o f  per-O-  
acetylated mannopyranose.  The process  invo lves  the displacement o f  the 
acetoxy group by halide ion to give e x c lu s iv e ly  the a-anomer in high  
yields.  The synthesis o f  a -m annosyl  trichloroacetimidates  is used to
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obtain pure, readily isolable and highly  react ive  g lycosy la t ion  
intermediates. They can be formed easi ly  by the reaction o f  2,3 ,4 ,5 -tetra-  
O-acety l-a-D-mannopyranose  with trichloroacetonitrile.  The a-anomer  
trichloroacetimidate is formed as reaction invo lves  the deprotonation o f  
the hydroxyl group by a base and then attack o f  the nucleophi l ic  oxygen  
on the carbon o f  the electron defic ient nitrile group o f  tr ichloro­
acetonitrile.
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2.9 Structure of  MPC1 -  MPC6 inhibitors
The chemical strategies mentioned throughout this chapter have led to 
the design o f  the inhibitors MPC1 to M PC 6 , the structure o f  which are 
shown in figure 2.14.  Chapter 3 details the chemical syntheses  used to 
make these inhibitors and chapter 4 discusses  the results o f  the 
syntheses.
MPC1
,  Pepstatin
MPC2
Pepstatin
MPC3 MPC4
HN— PepstatinPepstatin
MPC5
Pepstatin
MPC6
•OH
.Pepstatin
Figure 2.14: Structure of the inhibitors MPC1 to MPC6
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Chapter 3
Chemical Synthesis
All abbreviations used in the experimental sect ion are l isted on page 25.  
Unless  specif ied , all reagents were purchased from commercia l suppliers  
and were used without further purification. Pepstatin was obtained from 
Calbiochem and Bachem. Hydrazine acetate and 4-nitrophenyl a -D -  
mannopyranoside were supplied by Acros.
*H and 13C NMR spectra were recorded on Bruker AC 300, 400 and 500  
instruments. The chemical shift data for each signal is g iven in units o f  8 
relative to tetramethylsilane (TMS) where 8 (TMS) = 0. The mult ip l ic ity  
o f  the signals is indicated as: br -  broad, s -  singlet,  d -  doublet,  t -  
triplet, m -  multiplet,  quin -  quintet, dd -  doublet o f  doublets.  Cl and 
FAB mass spectra (MS) were recorded using a VG ZAB SE mass  
spectrometer. APCI and ES mass spectra were recorded on a Micromass  
Quattro mass spectrometer. Most acetylated sugar compounds gave some  
or all o f  the fragmentation ions o f  169, 229,  289 and 331. These  
correspond to fragmentations o f  tetraacetyl mannoside.  Table 3.1 shows  
the major fragment ions for [2] (RMM 348)  (see  section 3 .1 .2 ,  page 92).
Structure
OAc
OAc
. 1-0AcO
AcO
OH
Ion Fragmentation
169 compound [2] -  3 x Acetate
229 compound [2] -  2 x Acetate
289 compound [2] -  Acetate
331 compound [2] -  OH
T a b le  3 .1 :  C o m p o u n d  [2] s tr u c tu r e  an d  a c e ty la te d  su g a r  
fr a g m e n ta t io n  io n s
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Optical rotation was recorded using an A A -10  automatic polarimeter  
(Optical Act iv i ty  Ltd, UK) and a 5cm length, 1.5ml cell  (d = 0.5).  
Melt ing point determination was carried out using a Gallenkamp melt ing  
point apparatus. Infra-red (IR) spectroscopy ( v max) was carried out using  
a Shimadzu FTIR-8700 Fourier transform infra-red spectrometer and 
analysed with Shimadzu FT IRS software. Abbreviations used in 
reporting IR data are: w -  weak, m -  moderate,  s -  strong, br -  broad. 
Characteristic absorptions are seen across many compounds with minor  
changes o f  approx. + / -  15 cm'1. These are l isted be low for brevity:
3500 -  3000 (br, -OH, N H 2 or H 20 ) ,  3030 -  2830  (s, C-H), 1780 -  1720  
(s, C = 0 ) ,  1660 (m, amide C = 0 ) ,  1595 (s, aromatic),  1530 -  1510 (m, 
amide N-H),  1500 (s, aromatic), 1450 -  1430 (w, C-H), 1370 (m, C-H),  
1255 - 1230 (acetyl C-O-COMe) cm '1.
Analytical  HPLC (f low rate 1 ml/min) was carried out using a Mill ipore  
Waters 600E system controller and pump system, Pye Unicam PU4025  
UV detector, Shimadzu C-R6 A chromatopac and a Vydac 218TP54  
protein & peptide C l 8 column, 4.6 mm x 25 cm. Preparative HPLC (f low  
rate 15 ml/min) was carried out using a Mill ipore Waters 600E system  
controller and pump system, Gilson Holochrome UV detector,  Mill ipore  
Waters 745B data module and a Vydac 218TP1022  protein & peptide C18 
column, 21 .4  mm x 25 cm. Samples applied to preparative HPLC were  
dissolved at a maximum o f  20  mg / ml and disso lved in the starting 
HPLC solvent or the c losest equivalent i f  so lubi li ty  was a problem. T.l .c.  
was carried out on pre-coated 0.25 mm thick Merck 60 F254 s i l ica plates.  
Reverse phase si l ica plates used were Merck RP -8 F254s. Si l ica for 
chromatography was obtained from BDH. In some instances  (where  
mentioned) plates were pre-soaked in t .l .c.  solvent.  Visuali sation o f  t .l .c .  
plates was either by absorption o f  U.V. l ight, anisaldehyde or 
phosphomolybdic  acid (PMA) stains for sugars,  ninhydrin for amines,  
bromocresol green for organic acids,  or permanganate solution as a 
universal reagent.
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Dialys is  was performed using 12,000 molecular  weight  c u t -o f f  dialysis  
tubing. Before  use,  the tubing was prepared by first bo i l ing  for 10 mins  
in a large vo lume o f  2% (w/v) sodium bicarbonate and I m M  EDTA (pH 
8.0),  then rinsing the tubing thoroughly in I m M  EDTA (pH 8.0),  before  
boil ing again for 10 minutes in I m M  EDTA (pH 8.0).  The tubing was  
allowed to cool  before use,  and was stored in solution (water or buffer)  
at 4°C. Centrifugal filtration devices  used were either Mill ipore  
centriplus YM-30 (Mill ipore (UK) Ltd) with a maximum 15 ml capacity  
and used within a Beckman J2-21 swing bucket centrifuge,  or Mill ipore  
ultrafree-4 filtration unit (5 ml maximum capacity) using a fixed 35° 
angle centrifuge (Jouan MR 1812, Jouan S. A.,  France).
Tetrahydrofuran (THF) was dried by dist i l lat ion from a suspension o f  
THF with sodium and benzophenone. Dimethyl formamide (DMF) was  
dried by disti l lation from a suspension o f  DMF and calcium hydride.  
Acetic  anhydride was purified by a three step process  o f  drying with  
P 2 O 5  (added very s lowly)  until no more P 2 O 5  turned from white to 
brown/black. Then this was dried over potassium carbonate for a few  
hours, and then disti l led into a flask under N 2 containing anhydrous  
activated molecular s ieves  (4A) for storage. Dichloromethane,  
triethylamine and ethanol were dried over CaH2 powder and stored over 
molecular sieves .  Where used as drying agents,  sodium sulphate or 
magnesium sulphate are anhydrous.  With all reactions that used dry 
solvents,  an inert atmosphere o f  nitrogen or argon was used. Where  
reaction stirring is required, it is assumed that a stirrer bar is included at 
the beginning o f  the reaction unless otherwise stated. All  reaction 
vesse ls  used were round-bottomed flasks o f  a volume at least twice the 
capacity o f  the solvent  used for the reaction. Ether refers to diethyl  
ether. Pet. ether refers to petroleum spirit 40 -  60 °C. Brine refers to a 
saturated solution o f  sodium chloride,  and as such an aqueous brine 
solution refers to 50 % ddH2 0 , 50 % saturated sodium chloride solution.  
Bicarbonate refers to a saturated solution o f  sodium bicarbonate.
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3.1 Sugar Derivatives
3.1.1 1,2,3,4 ,6-Penta-O-acetyl-or/^-D-mannopyranose [ l ] 211
OAc
OAc
.1-0AcO'
AcO-
'OAc
Anhydrous TEA (46 ml) and anhydrous acetic anhydride (15.7  ml, 166 
mmol, 5 equiv.) were added to D-mannose  (6.03 g, 33.5 mmol) .  The 
reaction was stirred overnight under anhydrous conditions .  The TEA and 
unreacted acetic anhydride were removed in vacuo  to obtain a sticky  
viscous orange oil. This oil was dispersed in a mixture o f  iced-water  
(200 ml) 1 C H C I 3  (200 ml) and then sol id potass ium bicarbonate was  
added until the aqueous layer reached neutral pH, ensuring careful  
mixing o f  the two layers upon addition o f  the bicarbonate.  The aqueous  
layer was separated and then washed with C H C I 3  (3 x 30 ml). The 
combined C H C I 3  extracts were combined with the original organic layer,  
and dried over MgSCU overnight. The C H C I 3  was removed in vacuo  to 
obtain the title compound as a v iscous  ye l low/orange  oil  (12.6  g, 33.2  
mmol, 99 %) identical by NMR to the literature211, and used without  
further purification.
Rf 0.8 [1:2 e thano l  -  C H C I 3 ; an i sa ld eh y d e  and p e rm a n g an a te  stain].
MS (FAB+): m/z  = 169 (17 %), 331 (5 %), 413 (100 %, [ M  + Na ] +). 
v max ( C H C I 3 ) :  3500 -  3200 (br s), 3028 (m), 3005 (s), 2945 (s),  2833
(m), 1774 -  1726 (s),  1448 (m), 1429 (m), 1371 (s) cm '1.
'H NMR (C D C b,  300 MHz): 8 1.94 (3H, s), 1.95 (3H, s), 2.0 (3H, s),
2.02 (3H, s), 2.03 (3H, s), 2 .10  (3H, s), 2.11 (3H, s), 2 .14  (3H, s), 3.75
(1H, ddd, J  2.4,  5.0 & 9.8 Hz, H-50) ,  3 .96  -  4 .04  (2H, m, H -5 a  & H- 
6 ap),  4 .08 (1H, dd, J 6a>5 2.4 J 6a,6b 12.2 Hz, H -6 aa) ,  4.21 (1H, dd, J 6b;5
4.8 J 6b,6a 12.2 Hz, H-6 b ’cc), 4 .24  (1H, dd, J 6b,5 5.3 J 6b,6a 12.5 Hz, H -6 bP),
5.08 (1H, dd, J  3.3, 10.0 Hz, H-p),  5 .19 -  5 .32  (4H, m, H-P, H -2 a ,  H -3 a
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& H -4a) ,  5.42 (1H, dd, J 2,i 1.1 J i ,3 3.3 Hz, H-2P),  5.81 (1H, d, J , ,2 1.1 
Hz, H - l p ) ,  6 .02 ( 1H, d, J U2 1.9 Hz, H - l a ) .
13C NMR ( C D C I 3 ,  75.4 MHz): 8 20.0 ,  20 .2 ,  20 .31 ,  20 .33 ,  20 .35 ,  20 .38 ,  
20.39,  20 .42, 20 .44,  20.5 ,  53.3 ,  61.7,  65 .1 ,  65.2 ,  67 .9 ,  68 .0 ,  68 .4 ,  70.3 ,
70.3,  72.8 ,  90.2,  90.3 ,  167.8,  168.0,  169 .2 ,  169.3 ,  169.4 ,  169.5 ,  169.6,  
169.9,  170.2,  170.3.
3.1.2 2,3,4,6-Tetra-O-acetyl-ar-D-mannopyranose [2]2I2;213
OAc
AcO
AcO
OH
1 ,2 ,3 ,4 ,6-Penta-0-acetyl-o' / /?-D-mannopyranose [1] (17 .04  g, 43 .7  mmol)  
was added to anhydrous DMF (300 ml) in a three necked flask equipped 
with a Youngs tap, Suba-seal and stopper. Hydrazine acetate (4 .82 g, 
87.4 mmol,  2 equiv.)  was added portionwise to the reaction mixture and 
then stirred for 4 hours under N 2 or until the starting material was  
judged to have been consumed by t .l .c.  The reaction mixture was diluted  
with ethyl acetate (100 ml) and then washed with water (3 x 100 ml).  
The organic layers were dried overnight with N a 2SC>4, fi ltered and then 
concentrated in vacuo.  Purification by flash chromatography (4 cm, 
gradient, 100 % C H C I 3  to 50 % acetone in C H C I 3 )  gave the title 
compound as a ye l low  oil (11.77 g, 33.8 mmol,  77 %) spectroscopically  
identical to the literature213,214 with less than 1 % o f  the P-anomer by lR
NMR. With time, pure samples crystall ised at -  20 °C.
Rf 0.35 [1:2 ethanol -  C H C I 3 ;  anisaldehyde and permanganate stain],
m.p. 93 -  95 °C (lit. ref. 95 -  97 °C)215.
[«£' + 21.0° (c 1 , C H C I 3 ) ,  (lit. ref. + 19 .8°)213.
MS (FAB+): m/z = 169 (92 %), 331 (93 %), 349 (8  %, [ M  + H ] +). 
v max (KBr): 3500 -  3100 (br), 3030 -  2830  (s) ,  1780 -  1720 (s),  1371 
(m), 1255 (s) cm '1.
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'H NMR (CDCI3, 400 MHz): 5 1.96 (3H, s), 2.01 (3H, s),  2 .07  (3H, s),
2.12 (3H, s), 3.98 (1H, d, J  4.2 Hz), 4 .18  -  4.23 (2H, m),  5.19 -  5.20  
(1H, m, H-5) ,  5.22 (1H, dd, J  1.9 & 3.3 Hz),  5.26 (1H, t, J  9.9  Hz, H-4) ,
5.37 (1H, dd, J  3.3 & 10.1 Hz).
13C NMR (100.6  MHz, CDCI3): 8 20 .6 ,  20 .7 ,  20 .9 ,  62 .5 ,  66 .1 ,  68.3,  6 8 .8 ,
70.0 ,  92.1,  169.8,  170.1,  170.3,  170.9.
Missing 1 CH3 13C signal,  overlapping with 20 .7  ppm.
3.1.3 2 ,3 ,4 ,6-Tetra-O-acety l-a-D-mannopyranosyl  
trichloroacetimidate  [3] 212;214
O . . C C I 3
T
NH
2,3 ,4 ,6-Tetra-0-acetyl-o'-D-mannopyranose  [2] (11 .04  g, 31.7  mmol) was  
dissolved in a flask with anhydrous CH2CI2 (200 ml). Potassium  
carbonate (5 .26 g, 38 mmol,  1.2 equiv.)  was added and stirred for 10 
mins. The reaction mixture was cooled to 4 °C and covered with foil  to 
exclude light.  Trichloroacetonitrile (15 .8  ml,  158 mmol,  5 equiv.)  was  
dissolved in anhydrous CH2CI2 (50 ml) and s low ly  added to the reaction 
vesse l .  The reaction was stirred overnight and monitored by t. l.c. After 
the reaction was judged complete ,  the mixture was filtered and the 
CH2CI2 and trichloroacetonitrile were removed in vacuo  to obtain the 
title compound as a ye l low  oil  (15.01 g, 30.5 mmol,  96 %) identical by  
N M R  and I R  to the literature212,214.
R f  0.7 [1:2 ethanol -  C H C I 3 ;  anisaldehyde and permanganate stain].
[org + 49.0° (c 1 , CHCI3), (lit. ref. + 5 0 .00) 216.
MS (FAB+): m/z  = 169 (100 %), 331 (62 %), 514.5  (92 %, [ M  + N a ] +). 
v max (CHCls): 3026 (s),  1761 -  1732 (s),  1678 (m, C=N), 1369 (s),  1255 
(s) cm .
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'H NMR (400 MHz, CDCI3): 8 1.96 (3H, s), 2 .02 (3H, s), 2 .04  (3H, s),
2.15 (3H, s), 4.11 ( 1H, dd, J 6a>5 2.2 J 6a,6b 11.9 Hz, H -6 a), 4 .13 -  4.16  
(1H, m, H-5) ,  4.23 ( 1H, dd, J bb,5 4.7 J 6b ,6 a  12.0 Hz, H - 6 b), 5 .34  -  5.36  
(2H, m, H-3 & H-4),  5.42 (1H, dd, J 2,1 1.9 J 2,3 3.0 Hz, H-2) ,  6.23 (1H, d, 
J U2 1.9 Hz, H - l ) ,  8.76 (1H, s, C=NH).
13C NMR (100.6  MHz, C D C I 3 ) :  8 20.5 ,  20.6 ,  20 .7 ,  61.9 ,  65.3 ,  67.7 ,  68 .7 ,
71.1,  90 .4 ,  94.4 ,  159.6,  169.5,  169.6 ,  169.7,  170.5.
Miss ing  1 CH3 13C signal,  overlapping with 20 .6  ppm.
3.1.4 2 ,3 ,4 ,6-Tetra-O-acetyl-a-D-mannopyranosyl  bromide [4] 217
OAc
AcO
A cO
Br
1 ,2 ,3 ,4 ,6 -Penta-O-acetyl-ar-D-mannopyranose [1] (3 .112 g, 8 mmol) was  
placed into a round-bottomed flask and d isso lved  with acetic acid (9 ml).  
Hydrogen bromide (45 % solution in acetic acid,  9 ml) was added s low ly  
while  stirring and the reaction stirred for a further 3 hours. The reaction  
mixture was diluted with CH2CI2 ( 1 0 0  ml) and washed with cold 1 % 
HBr solution (3 x 100 ml) and then dried over N a 2S 0 4 . Filtration and 
removal o f  the solvent in vacuo  gave a brown oil containing some acetic  
acid. The acetic acid was removed azeotropically  with toluene to obtain  
the title compound as an orange oil (3.22  g, 7.8 mmol,  97 %) identical by  
NMR to the literature217.
[org + 123.0° (c 1, CHCI3). lit. ref. +123.5°  (c 1 , CHC13).
'H NMR (CDCI3, 300 MHz): 8 1.98 (3H, s), 2.05 (3H, s), 2.08  (3H, s),
2.15 (3H, s), 4.11 (1H, dd, J 6a,5 2.1 J6a>6b 12.3 Hz, H - 6 a), 4 .16  -  4.22  
(1H, m, H-5) ,  4 .30  (1H, dd, J 6b.s 4.8 J 6b,6a 12.4 Hz, H -6 b), 5 .34  (1H, t, J
10.1 Hz, H-4) ,  5.42 ( 1H, dd, J 2,1 1.3 J 2,3 3.4 Hz, H-2) ,  5 .69 (1H, dd, / 3,2
3.4 J 3j4 10.2 Hz, H-3) ,  6 .27  (1H, d, J U2 1.3 Hz, H - l ) .
94
13C NMR (CDCI3, 75.4 MHz): 8 20 .5 ,  20.6 ,  20 .7 ,  20 .7 ,  61 .4 ,  65 .2 ,  67.9,
72.1,  72.8 ,  83.0,  169.5,  170.5. Missing 2 C = 0  13C signals .
3.1.5 4 -Nitrophenyl 2 ,3 ,4 ,6-tetra-O-acetyl-P-D-mannopyranoside
[5] 218;251
n o 2
To a flask containing 2 ,3 ,4 ,6 -tetra-O-acety l- tf -D-mannopyranosyl  
bromide [4] (968 mg, 2.3 mmol)  and 4-nitrophenol (650 mg, 4.6 mmol ,  2 
equiv.)  was added anhydrous MeCN (5 ml). V 7, A^A^A^-tetramethyl-  
guanidine (442 pi , 3.5 mmol,  1.5 equiv.)  was added s low ly  and the 
reaction stirred continually overnight. The solvent was removed in vacuo  
at room temperature and the residue redisso lved in ethyl acetate. This  
was washed with water / 1 % sodium carbonate solut ion (2  x 2 0 0  ml),  
aqueous brine / 1 % sodium carbonate solution (2  x 2 0 0  ml) and aqueous 
brine (2 x 200 ml).  Drying over N a 2S 0 4  for 2 hours and then removal o f  
the solvent in vacuo  (at room temperature) gave a white crystall ine  
product. The product was su ccess ive ly  recrystal l ised from EtOH and 
C H C I 3  to give the title compound (628 mg, 1.34 mmol ,  57 %) as 
yel lowish  crystals, identical by NMR to the literature251.
Rf 0.5 [1:9 acetone -  toluene + 1 % acetic acid; PMA stain and UV].  
m.p.: 182 -  184 °C (lit. ref. 183 °C)218.
[a£ 3 + 24.0°  (c 1, MeOH), (lit. ref. + 2 4 .5°)218.
Found: M+Na,  492 .1121 .  C20H23N O 12 requires M+Na, 4 9 2 .1118  (ES).  
v max (KBr): 3600 -  3100 (br), 1749 (s),  1596 (s) ,  1519 (s, C -N O 2), 1500  
(s),  1371 (s), 1340 (s, C-NO2), 1229 (s) cm '1.
‘H NMR (CDCI3, 500 MHz): 8 1.87 (3H, s), 2 .04  (3H, s), 2 .06  (3H, s),
2.11 (3H, s), 3.70  (1H, ddd, J 5M  2.9  J 5,6b 5.3 J 5A 9.4 Hz, H-5) ,  4 .15 (1H,
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dd, J 6a,5 2 .8  y 6a,6b 12.2 Hz, H-6a),  4.22 (1H, dd, J 6b,5 5.4 J 6b;6a 12.2 Hz,  
H-6b), 4.45 (1H, dd, J 2,i 2.8 / 2,3 4.0 Hz, H-2),  5.13 (1H, dd, J 2,2 4.0 J 3,4
9.4 Hz, H-3),  5.29 (1H, t, J  9.4 Hz, H-4) ,  5.48 (1H, d, J U2 2.7 Hz, H - l ) ,  
7.22 (2H, d, J  9.3 Hz, phenyl),  8.15 (2H, d, J 9 . 3  Hz, phenyl).
13C NMR (CDC13, 125.7 MHz): 8 20.6 ,  20 .68 ,  20 .7 ,  23 .5 ,  62 .4 ,  65.4 ,
69.7,  71.8,  76.0,  97.3,  121.2, 125.3,  143.8,  158 .4 ,  169.5,  170.1,  170.6.  
Missing 1 13C signal, poss ib ly  quaternary.
3.1.6 4-Nitrophenyl 2 ,3 ,4 ,6 -tetra-O-acety l-a-D-m annopyranos ide
r / : i 2 1 9 ; 2 2 0
loJ
OAc
AcO'
AcO.
O.
NO.
l ,2 ,3,4,6-Penta-<9-acetyl-or-D-mannopyranose [1] (334 mg, 860 pmol)  
and 4-nitrophenol (179 mg, 1.29 mmol,  1.5 equiv.)  were added to a flask 
and any water present was removed azeotropical ly with anhydrous  
MeCN. The reagents were d isso lved into anhydrous CH2CI2 (10 ml) and 
cooled to ~ 0 °C. BF3.Et20 (325 pi, 2 .56 pmol,  3 equiv.)  was dropped 
s lowly  into the reaction mixture while  stirring. The reaction was then 
stirred and allowed to reach room temperature over 16 hours, t. l .c.  o f  the 
reaction mixture showed approximately 50 % o f  the starting material  
remaining. An extra portion o f  B F 3.Et20  (0.5 ml,  4.6 equiv.)  was added 
s lowly  and the reaction stirred at r.t. for a further 24 hours. The reaction  
was washed with water / brine / sodium bicarbonate solution (7 x 50 ml),  
until all o f  the ye l low  4-nitrophenol had been removed from the organic  
layer. The product was dried over MgSC>4, f iltered and the solvent  
removed in vacuo.  The final crude product was recrystall ised from 
CH2CI2 / cyclohexane to obtain the tit le compound as a pure ye l low ish
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crystalline compound (359 mg, 764 mmol,  89 %) with approximately 5 % 
o f  the incorrect anomer present as shown by N M R 220.
Rf 0.5 [1:9 acetone -  toluene + 1 % acetic acid; PMA stain and UV],  
compound [1] Rf 0.4,  4-nitrophenol Rf 0.45.  
m.p. 159 -  161 °C, (lit. ref. 154 -  156 °C)220.
[org + 72.0° (c 1, MeOH), (lit. ref. + 103° [c 1 , CHC13] ) 252.
MS (ES+): m/z = 169 (84 %), 331 (100 %), 470  (12 %, [ M  + H]*),  492  
(6 8  %, [M  + Na]*).
v max (CHC13): 3025 (w), 1751 (s),  1594 (m), 1521 (m, C-NOj) ,  1495 (m),  
1370 (m), 1346 (m, C -N O 2), 1235 (s) c m 1.
'H NMR (CDCI3, 400 MHz): S 1.99 (3H, s), 2.01 (3H, s), 2.02  (3H, s), 
2.18 (3H, s), 3.94 (1H, ddd, J 5M 2.3 / 5,6b 5.4 J 5,4 10.0 Hz, H-5) ,  3.98  
(1H, dd, J 6a,5 2.3 Jea,6b 12.3 Hz, H -6 a), 4 .19  (1H, dd, Jeb ,5 5.4 Jeb,6& 12.3 
Hz, H-6 b), 5.30 (1H, t, J  10.0 Hz, H-4) ,  5.38 (1H, dd, J 2,i 1.7 J 2t3 3.5 Hz,  
H-2),  5.45 (1H, dd, J 3t2 3.5 J 3,4 10.0 Hz, H-3) ,  5.57 (1H, d, J U2 1.7 Hz,  
H - l ) ,  7.18 (2H, d, J  12.5, phenyl),  8.19 (2H, d, J  12.6, phenyl).
13C NMR (CDC13, 125.7 MHz): 6 20 .57 ,  20 .58 ,  20 .6 ,  20 .7 ,  61.9 ,  65.5,
68.5,  68.9 ,  69.8,  95.6,  116.4,  125.8,  143.1,  160.1 ,  169.6,  169.9,  170.0,
170.3.
3.1.7 Conversion of  4-nitrophenyl 2 ,3 ,4 ,6-tetra-0-acetyl- /?-D-manno-  
pyranoside [5] to 4-nitrophenyl 2 ,3 ,4 ,6-tetra-0-acetyl-ar-D-  
mannopyranoside [6 ]
4-Nitrophenyl 2,3,4,6-tetra-(9-acetyl-/?-D-mannopyranoside [5] (113 mg,  
241 pmol)  was placed in a flask and dis so lved  in anhydrous CH2CI2 (5 
ml). The flask was cooled  to ~ 0 °C and B F 3.Et2 0  (92 pi, 726 pmol,  3 
equiv.)  was added s low ly  drop-wise with stirring. After 4 hours, t. l.c.  
(40 % ethyl acetate / hexane) showed the presence o f  the nitrophenol (Rf 
0.6, UV and strong ye l low  colour) implying that anomerisation was  
occurring. The solvent was removed in vacuo  and the residue redissolved
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in ethyl acetate.  The organic layer was washed with water / 1 % brine / 1 
% bicarbonate solution (6 x 50 ml). The organic layer was  dried over  
N a 2S0 4 , the solvent  removed in vacuo  and the crude product re­
crystall ised from ethanol to obtain the a -anom er mannoside [6 ] ( 2 2  mg,  
48 pmol,  20 %) as identified by N M R 220.
3.1.8 4 -Aminophenyl 2 ,3 ,4 ,6 -tetra-O -acety l-a-D-m annopyranos ide  [7]
A A n
4-Nitrophenyl 2,3,4,6-tetra-O-acetyl-or-D-mannopyranoside [6 ] (199 mg,  
420 pmol) was dissolved in anhydrous THF (5 ml) and 10 % Pd / C (100  
mg) was added. Hydrogenation was carried out under standard conditions  
using an atmospheric pressure hydrogenator over 4 hours in the presence  
o f  an excess  o f  H2 gas. The mixture was filtered through Celite and the 
solvent removed in vacuo.  Flash column chromatography (4 cm,  
isocratic, 5 % ethanol in C H C I 3 )  gave the title compound as a ye l lowish  
oil (185 mg, 336 pmol,  85 %), identical by NMR to literature
Rf 0.2 [1:19 acetone -  toluene + 1 % acetic acid, ninhydrin, PMA stain 
and UV].
[ a g  + 71.0° (c 1, CHCI3), (lit. ref. + 7 1 .2 0)221.
MS (APCI): m/z = 169 (100%), 331 (34%), 440 (14%, [ M  + H ] +). 
v max (neat): 3460 (s),  3373 (s),  3230 (w),  3045 (w),  2960 (m), 1733 (s),  
1627 (s),  1511 (s),  1435 (s),  1372 (s),  12220 (s br) cm '1.
'H NMR (CDCI3, 400  MHz): 5 1.97 (3H, s), 1.99 (3H, s), 2.0 (3H, s),
2.13 (3H, s), 3.51 (2H, br s, N H 2), 4.03 (1H, dd, y 6a,5 2.3 J 6a,6b 12.1 Hz,  
H-6 a), 4 .10  (1H, ddd, J 5M  2.2 J 5i6h 5.0 J 5A 10.0 Hz, H-5) ,  4.23 (1H, dd,
values220-22'
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. / 6 b , 5 5.3 J 6 b , 6 a  12.1 Hz, H-6b),  5.29 (1H, t, J  10.1 Hz, H-4) ,  5.30 (1H, d, 
J l>2 1.7 Hz, H - l ) ,  5.37 (1H, dd, </2)i 1.8 ^2,3 3.4 Hz, H-2) ,  5 .47 (1H, dd, 
J 3 ,2 3.5 J 3,4 10.0 Hz, H-3),  6.56 (2H, d, J  8.8 Hz, phenyl),  6.82 (2H, d, J
8.8 Hz, phenyl).
13C NMR (CDCI3, 100.6 MHz): 5 20 .4 ,  20 .6 ,  20 .8 ,  20.9 ,  62 .1 ,  6 8 .8 , 76 .7 ,
77.0,  77.3,  96 .8 ,  115.6,  116.1,  117.6,  118.2,  142.1 ,  148.4,  170.5,  169.7 ,
169.8,  169.9.
3.1.9 4-Isothiocyanatophenyl 2,3,4,6-tetra-O-acetyl-ar-D-manno- 
pyranoside [8]222
OAc
AcO'
AcO'
NCS
Extreme caution was taken with this procedure due to the toxic ity  and 
volati l ity  o f  the th iophosgene  reagent.  A 250 ml,  single  neck, round 
bottomed flask containing a stirrer bar and fitted with a pressure 
equalised dropping funnel under argon was prepared before the 
procedure was started. A continuous flow o f  argon through the vesse l  
and out into a mild bleach solution was used for ventilation and 
quenching o f  gaseous th iophosgene and hydrogen chloride produced in 
the reaction. All  equipment and removed solvents  were deactivated by  
the addition o f  methylamine for several hours.
Thiophosgene (286 pi, 3.75 mmol,  5 equiv.)  was d isso lved in anhydrous  
THF (10 ml) and added to a flask containing a pressure equal ised  
dropping funnel under argon. Anhydrous TEA (1 ml) and 4-aminophenyl
2 ,3 ,4 ,6 -tetra-0 -acetyl-<2-D-mannopyranoside [7] (329 mg, 750 pmol) in 
anhydrous THF (9 ml) were added to the dropping funnel.  The mixture
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was s lowly  added to the flask with vigorous  stirring. During the course  
o f  the reaction, the mixture turned cloudy, producing hydrogen chloride  
gas. After several hours the mixture turned dark brown and the gaseous  
layer disappeared. By 4 hours, t.l .c. showed complete  formation o f  
product. The solvent was removed in vacuo  and the reaction redissolved  
in ethyl acetate ( 1 0 0  ml), washed with water (2  x 1 0 0  ml) and with brine 
(1 x 100 ml).  The partitions during workup showed a brown membrane in 
between, which was included in each subsequent ethyl acetate wash  
fraction. The organic layer was dried over anhydrous MgSC>4 for 2 hours  
and the solvent removed in vacuo  to obtain a crude brown crystall ine  
product (358 mg). Further purification by d isso lv ing  the product in ethyl  
acetate and refluxing for 1 minute with some decolouris ing charcoal,  and 
removal o f  the solvent in vacuo  gave the title compound as a lighter  
brown crystall ine product (333 mg, 690 pmol ,  92 %) identical to the 
literature222.
Rf 0.7 [1:1 ethyl acetate -  hexane].
m.p.: 134 -  136 °C (lit. ref. = 134 -  136 °C)222.
[ a g  + 56.0° (c 1 , MeOH) (lit. ref. = + 55 .0°)222.
MS (ES+): m/z = 169 (100 %), 331 (19 %), 504 (54 %) [ M  + N a ] +). 
vmax (CHCb): 3025 (w), 2170 -  2 0 0 0  (br, -N=C=S),  1751 (s),  1502 (s),  
1370 (m), 1234 (s) cm '1.
*H NMR (CDCI3, 300 MHz): 6 1.93 (3H, s), 1.94 (3H, s), 1.96 (3H, s), 
2.10  (3H, s), 3.93 -  4.02 (2H, m, H-5 and H-6 a), 4 .17  (1H, dd, J 6bj5 5.7 
J6b,6a 12.4 Hz, H -6 b), 5.27 (1H, t, J  10.1 Hz, H-4),  5.35 (1H, dd, 1.8 &
3.5 Hz, H-2),  5.42  -  5.46 (2H, m, H - l  & H-3) ,  7.0 (2H, d, J  9.1 Hz,  
phenyl),  7.11 (2H, d, J  9.1 Hz, phenyl).
,3C NMR (CDCI3, 75.4  MHz): 8 18.7, 21.0 ,  21.1 ,  62 .5 ,  66.2 ,  69.1 ,  69.6 ,
69.8 ,  96.3 ,  117.9,  127.4,  135.8,  154 .7 ,  169.9 ,  170.0,  170.2 ,  170.7.  
Missing 1 CH3 13C signal,  overlapping.
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3.1.10 4-Nitrophenyl a-D-mannopyranoside [9]223
OH
HO'
HO.
O.
4-Nitrophenyl 2,3 ,4 ,6-tetra-O-acetyl-or-D-mannopyranoside [6 ] (1 .125 g,
2.4 mmol) and methanol (10 ml) were added to a flask. LiOH (1M, aq) 
was added drop-wise with stirring until pH 11 was reached. During this 
time the starting material s low ly  d isso lved to form a ye l low  solution,
which was then stirred for a further 2 hours during which time a ye l low
precipitate was formed. The solvent was removed in vacuo  to give a off-  
white solid.  This was then purified by flash chromatography (2cm,  
isocratic, 20% methanol in C H C I 3 )  to g ive  the title compound as a off-  
white powder (0 .502 g, 1.68 mmol,  70%). This was recrystall ised from 
hot methanol to give e longated y e l low ish  needles ,  identical by NMR  
to reference compounds.
Rf 0.5 [1:4 methanol -  CHCI3, PMA stain and UV].  
m.p. 175 -  177 °C, (lit. ref. 182 -  184 °C)223.
[ a g  + 160.0° (c 1, MeOH), (lit. ref. + 155 .0°)223.
MS (ES+): m/z = 323 (100%, [ M  + Na] +).
v max (KBr): 3500 -  3100 (br), 2960 -  2850  (m), 1600 (s),  1520 (s, C- 
N 0 2), 1500 (s) ,  1350 (s, C - N 0 2), 1150 -  995 (s) cm '1.
'H NMR (C D 3OD, 500 MHz): 8 3 .49  (1H, ddd, / 5,6a 2.4 J 5,6b 5.7 J 5A 9.7 
Hz, H-5) 3.68 (1H, dd, J 6„,5 5.8 J 6b,6a 12.1 Hz, H -6 b) 3.69 -  3 .72 (1H, m,  
H-4) 3.75 (1H, dd, J 6a,5 2.3 J6a,6b 12.1 Hz, H -6 a) 3.88 ( 1H, dd, J 3>2 3.4  
1/ 3,4 9.5 Hz, H-3) 4 .02  (1H, dd, / 2,t 1.8 J 2,3 3.4 Hz, H-2) 5.64 (1H, d, J u2
1.8 Hz, H - l )  7 .29  (2H, d, J  9.3 Hz, phenyl)  8.21 (2H, d, J  9.3 Hz,  
phenyl).
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13C NMR (CD 3OD, 125.7 MHz): 5 62.6 ,  68 .1 ,  71 .6 ,  72 .2 ,  76 .0 ,  100.1,
117.8,  126.7,  143.8,  162.8.
3.1.11 4-Aminophenyl a-D-mannopyranoside  [ 10 ]223
OH
OH.1-0HO'
HO.
NH-
4-Nitrophenyl or-D-mannopyranoside [9] (1 g, 3.3 mmol) and 10 % Pd / 
C (200 mg) were added to a flask with anhydrous MeOH (50 ml). The 
flask was attached to an atmospheric pressure hydrogenator over 4 hours  
in the presence o f  an excess  o f  H2 gas. The flask contents were filtered  
through Celite and the solvent removed in vacuo  to obtain a ye l lowish  
solid.  This was then d isso lved in CH2CI2 with a small  amount o f  MeOH  
until soluble and filtered through a pad o f  si l ica.  The s i l ica  was washed  
with 40% EtOH / CH2CI2 and the filtrates combined. The solvent was  
removed in vacuo  to obtain the title compound as an off -white  powder  
(0 .89 g, 3.26 mmol,  99 %). NMR data as literature223.
m.p. 147 -  149°C (lit. ref. 158°C)224.
[ a g  + 124.0° (c 1, MeOH) (lit. ref. + 128 .0°)223.
MS (ES+): m/z = 272 (37%, [ M  + H ] +).
v max (KBr): 3600 -  3000 (br), 2940 -  2890 (w), 1630 (m), 1514 (s) cm'1.
*H NMR ( C D C I 3 ,  300 MHz): 6 3.67 -  3 .80  (4H, m, H-4, H-5 & H -6 ) 3.88  
(1H, dd, J  3.3 & 8.7 Hz, H-3) 3.98 (1H, m, H-2) 5.29 (1H, s, H - l )  6.71 
(2H, d, J  8.8  Hz, phenyl) 6.92 (2H, d, J  8 .8  Hz, phenyl).
13C NMR ( C D C I 3 ,  75.4  MHz): 6 62 .7 ,  68 .5 ,  72 .2 ,  72 .5 ,  75.1 ,  101.4,
117.9,  119.3,  144.0,  151.1.
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3.1.12 4-Isothiocyanatophenyl a-D-m annopyranoside  [ H ] 201?225
OH
OH.1-0
HO'
HO'
O.
4-Aminophenyl  a-D-mannopyranoside [10] (800 mg, 2.95 mmol) was  
added to a flask with ethanol (80 ml) and water ( 2 0  ml) and a dropping  
funnel attached. Thiophosgene (1.7 ml, 14.76 mmol,  5 equiv.)  was  
carefully added dropwise via the dropping funnel to the flask while  
vigorously  stirring. After 1 hour the reaction appeared to be complete.  
T.l.c.  UV visualisation and ninhydrin were used to ensure that the 
starting material had been consumed. Removal o f  the so lvent in vacuo  
gave a brown semi-solid that was purified by flash chromatography (6  
cm, isocratic, 2 0  % methanol in C H C I 3 )  to g ive  the desired product as a 
white solid (0 .90 g, 2 .86 mmol,  97 %). This was recrystall ised from 
C H C I 3  / cyclohexane to obtain a crystall ine white  sol id o f  the title 
compound. All  equipment and removed solvent were deactivated by the 
addition o f  methylamine for a period o f  2 hours. Literature does not 
contain analytical data.
Rf 0.5 [1:4 methanol -  C H C I 3 ,  PMA stain and UV],  amine compound [10] 
at baseline.
[ar]£ + 12.0° (c 1, MeOH).  
m.p. 168 -  170°C.
MS (ES+): m/z = 336 (20%, [ M  + N a ] +).
vmax (KBr): 3650 -  3150 (br), 2980 -  2880 (s),  2800  -  2430  (s),  2133  
(br, -N=C=S),  1475, 1444 cm-1.
*H NMR (CD 3OD, 300 MHz): 5 3.53 (1H, ddd, J  2.7 ,  5.0 & 9.7 Hz, H-5),  
3.66 -  3 .80  (3H, m, H-4, H-6 ), 3.86 (1H, dd, J 3j2 3.4 J 3A 9.4 Hz, H-3),
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3.99 (1H, dd, J 2,i 1.9 J 2,3 3.3 Hz, H-2),  5.48 (1H, d, J U2 1.8 Hz, H - l ) ,
7.15 (2H, d, J  9.1 Hz, phenyl) 7.23 (2H, d, J  9.1 Hz, phenyl) .
13C NMR (CD 3OD, 75.4 MHz): 5 62.7 ,  68 .3 ,  71.8 ,  72.4 ,  75 .6 ,  100.3,
114.5,  119.0,  127.9,  157.0.  Missing 1 13C.
3.2 Linker Synthesis
3.2.1 Benzyl 4-hydroxybutanoate  [12]226
HO'
O
To a flask containing y-butyrolactone (4 .20  g, 48.8  mmol)  was added 
sodium hydroxide (1M, 1.95g in 49 ml water,  48.8  mmol) .  A condenser  
was attached and the mixture was stirred and heated at 70 °C overnight.  
Water was azeotropically removed with toluene or alternatively by  
freeze-drying for between 24 and 48 hours.  The salt was loosened from 
the sides o f  the reaction vesse l  and made as fine a powder as poss ib le  
with a mortar and pestle.  To the sodium salt were added anhydrous  
acetone (40 ml),  tetrabutylammonium bromide (1.57 g, 4.87 mmol,  0.1 
equiv.) ,  and benzyl  bromide (3 .30 ml,  27 .7  mmol,  0.6 equiv.) .  This 
mixture was refluxed under a nitrogen atmosphere for 24 hours. The 
reaction mixture was cooled and concentrated in vacuo  to remove the 
acetone. The reaction contents were partitioned between ethyl acetate  
( 2 0 0  ml) and 0.4M NaHSC>4 ( 2 0 0  ml). The organic layer was washed with  
aqueous brine (3 x 200 ml) and then with saturated brine (3 x 200 ml)  
and dried over MgSCN. Removal o f  the solvent in vacuo  gave the title 
compound as a ye l low  oil (5.81 g, 29 .9  mmol,  61 %) identical by NMR  
to the literature226.
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Rf  0.3 [2:3 ethyl acetate -  hexane; UV and permanganate stain],  benzyl  
bromide Rf 0.7 (UV only).
MS (APCI+): m/z = 195 (100%, [ M  + H ] +).
v max (CHCI3): 3550 -  3100 (br), 3010 -  3008 (s) ,  3050  -  2900 (w),  1780  
-  1700 (s),  1454 (m), 1377 (m), 1229 (s) cm '1.
‘H NMR (CDCI3, 300 MHz): 8 1.86 (2H, m, H-3) ,  2.27 (2H, t, J  7.2 Hz,  
H-2),  3.60 (2H, t, J  6.1 Hz, H-4),  5.08 (2H, s, benzyl) ,  7.31 (5H, m).
13C NMR ( C D C I 3 ,  75.4 MHz): 5 27.5 ,  30 .8 ,  61 .7 ,  66 .5 ,  128.1 ,  128.4,
135.7,  173.7.  Missing 1 13C, may be quaternary.
2273.2.2 A'-(f-Btityloxycarbonyl) propane-1 ,3-d iam m e [13]
Anhydrous THF (20 ml) was added to a flask containing diaminopropane  
(4 ml, 47 .4  mmol,  4 equiv.)  and stirred vigorously .  Di-J-butyl  
dicarbonate (2 .56 g, 11.8 mmol)  was d isso lved in anhydrous THF (2 ml)  
and added s lowly .  The mixture was stirred v igorous ly  for 3 hours, by  
which time the Boc  anhydride had complete ly  reacted (t . l.c.  20 % MeOH  
/  C H C I 3  + 1 % TEA, Boc  anhydride R f  0.9,  product R f  0.2).  The THF was  
removed in vacuo  and the crude product redisso lved in 100 ml ether. The 
ethereal layer was washed with water (1 x 100  ml),  water / 1 % brine / 1 
% 0.2M sodium acetate buffer (2 x 100 ml) and then with brine (1 x 100 
ml).  The organic layer was dried with M g S 0 4 , and the solvent removed  
to give 389 mg o f  a white powder. This gave,  not the tit le compound, but 
V,V-(di-£-butyloxycarbonyl) propane-1,3-diamine. To the aqueous layer  
was added 80 ml (i.e.  20 %) o f  50 % saturated brine / 50 % o f  saturated 
bicarbonate solution, and organic material  was extracted with C H C I 3  
(200 ml, then 3 x 50 ml).  The solvent was removed in vacuo  from the 
combined C H C I 3  layers to g ive  1.175 g (6.73  mmol ,  57 %) o f  the title  
product as a ye l low  oil  identical by N M R  to the l iterature153,227.
H
O
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Rf 0 .5  [ 1:1 ethyl acetate -  hexane; ninhydrin stain].
MS (APCI+): m/z  = 175 (65 %, [ M  + H ] +).
v max (CHC13): 3454 (w, N-H), 3009 -  2870  (s),  1711 -  1691 (s),  1512 (s) 
cm'1.
!H NMR (CDCI3, 300 MHz): 6 1.36 (9H, s, t-butyl) ,  1.54 (2H, q, J  6 .6  
Hz, H-2),  1.72 (2H, s, N H 2), 2.68 (2H, t, J U2 6.5 Hz, H - l ) ,  3.12 (2H, q, 
J 3,2 6.4 Hz, H-3),  4.97 (1H, br s, NH).
3.2.3 7V-(*-Butyloxycarbonyl) cystamine [14]250
o
To a flask containing water (5 ml) and dioxane (4 ml) was added 
cystamine dihydrochloride (1.29  g, 5.7 mmol ,  4 equiv.)  and sodium 
bicarbonate (0.48 g, 5.7 mmol,  4 equiv.)  with vigorous stirring. Di-£- 
butyl dicarbonate (313 mg, 1.43 mmol) was d isso lved  in dioxane (1 ml)  
and added slowly .  The mixture was stirred vigorously .  By 2 hours a 
residue had formed which was re-dissolved by the addition o f  MeCN (5 
ml). After 4 hours the organic solvents  were removed in vacuo  to g ive  an 
insoluble  mixture in water. To the mixture was added a few drops o f  
acetate buffer (0.2 M) and the solid filtered and washed several times  
with 10 % saturated brine and 10 % saturated bicarbonate solution (50  
ml total). All  organic products were removed from the filtrate by 
extraction with CH2CI2 (4 x 50 ml) and the combined organic layers  
dried over M g S 0 4 . Removal o f  the solvent in vacuo  gave the title  
compound as a v iscous  ye l low  oil (154 mg, 0.61 mmol,  43 %), similar to 
the literature by NMR.
R f  0 .2  [1:4 ethanol -  CH2CI2; ninhydrin stain].
MS (APCI+): m/z = 252 .9  (56%, [ M  + H J +).
Found: M+H, 253.1010. C9H20N 2O2S2 requires M+H, 253.1044 (F.A.B.).
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Vmax (CHCI3 ): 3454 (w), 3000 -  2900 (w),  1720 -  1680 (s) ,  1506 (s) cm'
1
lH NMR (C D C h,  400 MHz): 5 1.39 (9H, s, t-butyl) ,  1.78 (2H, s, N H 2), 
2.72 (2H, t, J  6.2 Hz, H-2 or H-3),  2.73 (2H, t, J  6.3 Hz, H-2 or H-3) ,  
2.96 (2H, t, J  6.1 Hz, H - l ) ,  3.38 -  3.44 (2H, m, H-4) ,  5.03 (1H, br s, 
NH).
13C NMR (CDC13, 100.6 MHz): 6  28 .3 ,  38 .4 ,  39.3 ,  40 .4 ,  42 .5 ,  155.7.  
Missing 1 1 3 C, may be quaternary.
3.3 Mannose Linker Conjugates
3.3.1 3 ’-Benzyloxycarbonylpropyl 2 ,3 ,4 ,6-tetra-O-acety l-a-D-  
mannopyranoside [15]
.OAc
OAc
-1-0AcO'
AcO-
Benzyl 4-hydroxybutanoate [12] (2 .68 g, 5.4 mmol) and 2,3 ,4 ,6-tetra-O-  
acety l-a-D-mannopyranosyl trichloroacetimidate  [3] (2.11 g, 10.8 mmol,  
2  equiv.)  were added to a flask, and azeotroped with anhydrous toluene  
(4 x 10 ml). Anhydrous CH2 CI2 (30 ml) was added and the mixture  
stirred v igorous ly  and cooled to -40 °C using an MeCN / CO2 (s) bath. 
BF 3 .Et2 0  (1.4 ml, 10.9 mmol,  2 equiv.)  was added s low ly  to this reaction  
mixture over 1 0  min during which time the reaction mixture turned 
yellow. The disappearance o f  the acet imidate [3] was monitored by t.l .c.  
with maximum convers ion to the tit le product in 4 hours. The reaction 
mixture was washed with ice-co ld  50 % sodium bicarbonate solution (3 x 
60 ml) and then with ice-co ld  50 % brine solution (3 x 60 ml). The 
organic layer was dried over MgSC>4 and fi ltered. Removal o f  the CH2 CI2
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in vacuo  gave 3.75 g o f  a ye l low  oil.  Flash chromatography (4 cm,  
gradient, reverse-phase,  100 % water to 80 % MeOH / water) column  
fractions were pooled and the MeOH removed in vacuo .  Addition o f  
CH2CI2 (50 ml) to extract the organic material from the aqueous layer  
plus a re-extraction (50 ml) turned the organic layer ye l low .  Drying o f  
the organic layer over anhydrous MgSCU, filtration and removal o f  the 
CH2CI2 in vacuo  gave the title product as a ye l low  wax (1.57 g, 3.0 
mmol, 55 %).
Rf  0.35 [3:1 MeOH -  water; reverse-phase plates,  anisaldehyde stain and 
UV], acetimidate [3] R f  0.45.
[ a £  + 38.0° (c 1 , CHCI3).
MS (APCI+): m/z = 169 (100 %), 331 (29 %), 547 (16 %, [ M  + N a ] +). 
Found: M+Na, 547 .1796.  C25H32O 12 requires M+Na,  547 .1792  (F.A.B.) .  
vmax (CHCI3): 3024 -  3014 (w),  1751 -  1740 (s), 1454 -  1429 (w),  1369 
(m), 1240 (s) cm '1.
*H NMR (500 MHz, CDC13): 6 1.94 -  19.60 (2H, m, H - 2 ’), 1.96 (3H, s),
2.01 (3H, s), 2 .07 (3H, s), 2.13 (3H, s), 2.45 (2H, t, 8.5 Hz, H - 3 ’),
3.37 (1H, ddd, J  5.7,  6 .6  & 9.7 Hz, H - l ’), 3.72 (1H, ddd, 7  5.7, 6.9 & 9.8 
Hz, H - l ’), 4.05 (1H, ddd, J 5,6a 2.4 J 5;6h 5.3 J 5A 9.6 Hz, H-5),  4.08 (1H,  
dd, J 6a,5 2.4 J 6a,6b 12.3 Hz, H -6 a), 4.25 (1H, dd, J 6b>5 5.3 J 6hM 12.2 Hz, 
H -6 b), 4 .76 (1H, d, J U2 1.7 Hz, H - l ) ,  5.12 (2H, s, H - 4 ’), 5.21 (1H, dd, 
J i , i 1.8 J i , 3 3.3 Hz, H-2) ,  5.24 (1H, t, J  9.8 Hz, H-4) ,  5.29 (1H, dd, J 3>2
3.4 J 3A 10.0 Hz, H-3),  7.34 (5H, s).
13C NMR (100 MHz, CDC13): 6 20 .58 ,  20 .59 ,  20 .62 ,  20 .8 ,  24 .5 ,  30.8,
62.3 ,  66 .0 ,  66.3 ,  67 .1 ,  68 .4 ,  69.0 ,  69 .4 ,  97 .3 ,  128.2,  128.5,  135.8,  169.6,
169.8,  169.9,  170.5 ,  172.7.  Miss ing  1 13C, p oss ib ly  quaternary.
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3.3.2 3 ’-Oxycarbonylpropyl 2 ,3 ,4 ,6 - te tra -0 -ace ty l -a -D -  
mannopyranoside [16]
.OAc
AcO'
AcO
O.
'OH
To a flask containing 3 ’-benzyloxycarbonylpropyl 2 ,3 ,4 ,6 -tetra-O-acety l-  
a-D-mannopyranoside [15] (1 .16g,  2.2 mmol) was added anhydrous  
EtOH (30 ml) and 10% Pd/C (O.lg).  This was hydrogenated under 
standard atmospheric pressure hydrogenation condit ions  over 4 hours in 
the presence o f  an excess  o f  H2 gas. Filtering o f  the mixture through 
Celite and removal o f  the ethanol in vacuo  y ie lded the tit le compound as 
an opaque viscous ye l low oil (0.82 g, 1.89 mmol,  85 %).
R f  0 .6  [1:4 ethanol -  CH2CI2; anisaldehyde and bromocresol green stain],  
compound [15] R f  0.7.
[a]o + 36.0° (c 1 , CHCI3).
MS (ES+): m/z  = 169 (8  %), 331 (5 %), 457 (100  %, [ M  + N a ] +).
Found: M+Na, 557.1316.  C 18H26O 12 requires M+Na, 557 .1322  (F .A.B.) .  
v max (CHCI3): 3024 -  3014 (w),  1757 -  1730 (s),  1429 (w),  1369 (m),  
1252 (s) cm '1.
]H NMR (300 MHz, CDCI3): 6 1.94 -  2 .02  (2H, m, H - 2 ’) 1.98 (3H, s),
2.03 (3H, s), 2.08 (3H, s), 2.13 (3H, s), 2 .44  (2H, t, J  6.9 Hz, H -3 ’), 3 .49  
(1H, dt, J y a,2. 5.9 7 , 9 . 6  Hz, H - l ’a), 3.68 (1H, dt, J y b,2- 5.9 7 rb>1.a
9.6 Hz, H - l ’b), 3.93 -  3.99 (1H, m, H-5) ,  4 .07  (1H, dd, J 6a,5 2.3 J 6a,6b
12.2 Hz, H -6 a), 4 .25 (1H, dd, J 6b,5 5.3 J 6b,6a 12.3 Hz, H-6 b), 4.79 (1H, d, 
J i ,2 1.6  Hz, H - l ) ,  5.21 ( 1H, dd, 7 2,i 1.6 J 2.3 3.0  Hz, H-2) ,  5.25 -  5.31 
(2H, m, H-3 & H-4) ,  7.98 (1H, br, COOH).
13C NMR (100  MHz, CDCI3): 5 20.6 ,  20 .7 ,  20 .8 ,  24 .4 ,  30.7 ,  62.4 ,  66.0 ,
67.0 ,  67 .2 ,  68 .5 ,  69.1 ,  69 .4 ,  97.5,  169.8,  170.1 ,  170 .8 ,  176.7 ,  177.9.
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3.3.3 3 ’-Succinimidoxycarbonylpropyl 2 ,3 ,4 ,6 -te tra-O -acety l -a -D -  
mannopvranoside [17]
HAr.
3 ’ -Oxycarbonylpropyl 2,3,4,6-tetra-O-acetyl-a-D-mannopyranoside [16] 
(1.4 g, 2.7 mmol) was dissolved in anhydrous CH2CI2 (30 ml),  added to a 
flask and then cooled using an ice - water bath. To the reaction mixture  
was added EDCI (1 g, 5.4 mmol,  2 equiv.)  and NHS (0 .62 g, 5.4 mmol,  2 
equiv.) . The reaction was stirred overnight,  a llowing the flask to reach 
room temperature. The reaction mixture was washed with 20 % brine (3 x 
50 ml), dried over N a2SC>4, filtered and the solvent removed in vacuo  to 
obtain the title compound as a pale ye l low  oil (1 .55 g, 2.9 mmol,  107 %) 
with the excess  in yie ld due to the presence o f  urea. This was used  
without further purification.
Rf  0.55 [1:4 ethanol -  CH2CI2; anisaldehyde, PMA and bromocresol  
green stain], butanoic acid [16] R f  0.6.
[or£ 2 + 46.0° (c 0.5,  CHCI3).
MS (ES+): m/z  = 331 (8  %), 554 (100  %, [ M  + N a ] +).
Found: M+Na, 554.1491. C22H29N O 14 requires M+Na, 554.1486 (F.A.B.).  
v max (CHCI3): 3024 -  3014 (w),  1741 (s) ,  1431 (w),  1369 (w),  1229 (s),  
1203 (s) cm '1.
'H NMR (300 MHz, CDCI3): 8 2.01 -  2 .12  (2H, m, H -2 ’) 1.97 (3H, s),
2.02  (3H, s), 2 .08 (3H, s), 2.13 (3H, s), 2.73 (2H, t, J y ,v  7.0 Hz, H -3 ’),
2 .80  -  2 .82  (4H, m, H -4 ’), 3.52 (1H, dt, J Va,2- 5.9 J y a>1-„ 10.1 Hz, H- 
l ’a), 3.81 (1H, dt, Ji -b,2' 6.1 J y b, y a 9.9 Hz, H - l ’b), 3.92 -  3 .96 ( 1H, m, 
H-5) ,  4 .07  (1H, dd, J 6a,5 2.4 y6a,6b 12.3 Hz, H -6 a), 4 .27  (1H, dd, J 6b,5 5.1
o
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/ 6b>6a 12.3 Hz, H -6 b), 4.81 ( 1H, d, J U2 1.4 Hz, H - l ) ,  5.22 -  5.31 (3H, m,  
H-2, H-3 & H-4).
13C NMR (100 MHz, CDCI3): 6 13.9,  13.94, 20 .7 ,  20 .9 ,  24 .5 ,  25 .4 ,  30 .8 ,
62.5,  66 .0 ,  67 .3 ,  6 8 .6 , 69.3, 69 .4 ,  97 .5 ,  169.8 ,  170 .2 ,  170.3 ,  170.9,
172.2,  177.1.  Missing 1 carbonyl, poss ib ly  overlapping for NHS.
3.3.4 Ar-(3-(2 ,3 ,4 ,6 -T etra-0-acety l-a -D -m annopyranosy loxy)-
propylcarbonyl),Ar’- ( / -butyloxycarbonyl)  propane-1 ,3-d iamine  [18]
.OAc
OAc
J -0AcO'
AcO-
N'
H1* 3' NH
To a round-bottomed flask was added 3 ’-succinimidoxycarbonylpropyl
2 ,3 ,4 ,6 -tetra-0 -acetyl-<2 -D-mannopyranoside [17] (1 g, 1.9 mmol,  1.2 
equiv.)  and dissolved in anhydrous CH2CI2 (10 ml).  N -( t -  
butyloxycarbonyl) propane-1,3-diamine [13] (279 mg, 1.6 mmol)  was  
dissolved into anhydrous CH2CI2 (2  ml) and added to the stirred reaction  
mixture at r.t. A further 8 ml o f  anhydrous CH2CI2 was added to the 
reaction vesse l  along with three drops o f  anhydrous TEA. The reaction  
was monitored by t. l .c.  for the disappearance o f  the starting material  
amine (v isuali sed by ninhydrin stain) and appearance o f  a spot o f  
different R f  (v isuali sed by PMA stain). After 2 hours, most o f  the amine  
had disappeared however the reaction was stirred continuously  
overnight.  The reaction was washed with 20 % brine (3 x 50 ml) and the 
organic layer dried over MgSC>4. Removal o f  the so lvent in vacuo  gave  
an oil.  Flash chromatography (4 cm, isocratic ,  ethyl acetate) gave the 
title compound as an oil (0.78 g, 1.31 mmol,  82 %) that crystall i sed in 
part after 16h at 4 °C.
R f  0.35 [1:19 EtOH -  CH2CI2; PMA stain], compound [17] R f  0.30.
[a]“  + 23.2° (c 2.5,  CHCI3).
I l l
MS (ES+): m/z  = 331 (24 %), 629 (100 %, [ M  + N a ] +).
v raax (CHC13): 3024 -  3014 (w), 1745 (s),  1700, 1662 (m), 1512 (m),
1440 -  1433 (br w), 1367 (w), 1230 (s) cm '1.
‘H NMR (300 MHz, CDCI3): 8 1.33 (9H, s), 1.52 (2H, quin, J  5.9 Hz, H- 
5 ’), 1.79 -  1.92 (2H, m, H -2 ’) 1.89 (3H, s), 1.94 (3H, s), 2 .0  (3H, s),
2.05 (3H, s), 2.20 (2H, t, J y X  7.3 Hz, H - 3 ’), 3.05 (2H, q, J 6 . 1  Hz, H - 4 ’ 
or H-6 ’), 3.18 (2H, m, H -4 ’ or H -6 ’), 3 .39  (1H, dt, J V z X  6.2 J VzXh  9.8 
Hz, H-l  ’a), 3.66 (1H, dt, J r b x  6.0 Jrb.i-a 9.8 Hz, H - l ’a), 3 .86 -  3.91  
(1H, m, H-5) ,  3.97 -  4.02 (1H, m, H - 6 a), 4 .18  (1H, dd, J 6b>5 5.2 J6b,6a
12.2 Hz, H-6 b), 4 .70  (1H, d, J U2 1.4 Hz, H - l ) ,  5.11 -  5.22  (3H, m, H-2,  
H-3 & H-4),  6 .44  (1H, m, NH).
I 3 C  NMR (100 MHz, C D C I 3 ) :  8 20 .7 ,  20 .71 ,  20 .8 ,  25 .1 ,  28 .3 ,  30.1 ,  32 .8 ,
62.4,  66.1 ,  67.5 ,  68.5,  69.1,  69 .5 ,  97 .5 ,  169 .7 ,  170.0,  170.1,  170.7,
172.5.  Miss ing 2 C H 2  l 3 C  signals,  poss ibly  overlapped, 1 C =0 signal and 
a quaternary signal.
3.3.5 7V-(3-(2 ,3 ,4 ,6-Tetra-0-acetyl-a-D-mannopyranosyloxy)-  
propylcarbonyl),7V’-(^-butyloxycarbonyl) cystamine [19]
.OAc
OAc
J-QAcO‘
AcO-
N
H1' 3'
H
N
O
To a round-bottomed flask was added 3 ’-succinimidoxycarbonylpropyl  
2,3,4,6-tetra-O-acetyl-Gr-D-mannopyranoside [17] (500 mg, 0.94 mmol,  1.7 
equiv.)  and disso lved into anhydrous CH2CI2 (10 ml).  N-( t -  
butyloxycarbonyl)  cystamine [14] (140 mg, 550 pmol) was d isso lved  into 
anhydrous CH2CI2 (2 ml) and added to the stirred reaction mixture while  
stirring at r.t. A further 8 ml o f  anhydrous CH2CI2 was added to the 
reaction vesse l  along with three drops o f  anhydrous TEA to improve  
solubi lity.  The reaction was monitored by t . l .c.  for the disappearance o f
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amine starting material (visualised by ninhydrin stain) and appearance o f  
a spot o f  different Rf  (visualised by PMA stain). The reaction was stirred 
continuously  overnight. The reaction was then washed with 20 % brine 
(3 x 50 ml) and the organic layer dried over MgSCU. Removal o f  the 
solvent in vacuo  gave an oil. Flash chromatography (4 cm, gradient,  50 
% hexane / ethyl acetate to 10 % hexane / ethyl acetate,  change in 10  % 
hexane every 50 ml) gave the title compound as an oil (244  mg, 363 
pmol,  66  %).
Rf  0.3 [1:9 hexane -  ethyl acetate, PMA stain], compound [17 ]  R f 0.5.
[tfg + 22.4° (c 2.5, CHC13).
Found: M+, 669 .2371 .  C27H44N O 13S2 requires M +, 669 .2363  (F .A.B.) .  
v max (Neat): 3400 -  3100 (s),  2980 -  2900 (s),  1760 -  1650 (s), 1550 -  
1504 (m), 1435 (w),  1367 (w), 1280 -  1220 (m) cm '1.
*H NMR (400 MHz, CDC13): 8 1.38 (9H, s), 1.88 -  1.94 (2H, m, H - 2 ’) 
1.94 (3H, s), 2.0 (3H, s), 2.05 (3H, s), 2 .10  (3H, s), 2.27 (2H, t, J y>2* 7.2 
Hz, H - 3 ’), 2.73 (2H, t, J  6.7 Hz, H - 5 ’ or H -6 ’), 2.79 (2H, t, J  5.9 Hz, H- 
5 ’ or H-6 ’), 3.38 (2H, q, J  6.4 Hz, H - 4 ’ or H - 7 ’), 3.41 -  3 .47 (1H, m, H- 
1’), 3.51 (2H, q, J  6.0 Hz, H - 4 ’ or H - 7 ’), 3.70 (1H, dt, J  5.9 & 9.8 Hz,  
H - l ’), 3 .90 -  3.95 (1H, m, H-5),  4 .02 -  4 .07 (1H, m, H -6 a), 4 .27 (1H,  
dd, J 6b,5 5.2 J 6b,6a 12.2 Hz, H -6 b), 4.75 (1H, d, J  1.5 Hz, H - l ) ,  5.11 (1H,  
br, NH), 5.16 -  5.27 (3H, m, H-2, H-3 & H-4),  6.53 (1H, br, NH).
13C NMR (100 MHz, CDC13): 8 20 .6 ,  20 .7 ,  20 .8 ,  25.0 ,  28 .3 ,  32.5,  37.7,
38.1 ,  38.2,  39 .4 ,  62 .4 ,  66.0,  67.4 ,  68 .4 ,  69 .0 ,  69.4 ,  97 .4 ,  155.9,  169.6,  
169.9,  170.1,  170.6,  172.4.  Miss ing  1 C = 0  13C signal.
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3.3.6 7V-(3-(2 ,3 ,4 ,6-Tetra-0-acetyl-a-D-mannopyranosyloxy)-
propylcarbonyl),A^’-(tri fluoroacetyl)  propane-1,3-diamine [20]
4' 6'
n ^ ^ nh+3 c f3c o o 'H 5
A -(3- (2 ,3 ,4 ,6 -Tetra-0 -acety l -a -D -m annopyranosy loxy)propylcarbonyl) ,  
JV’-( /-butyloxycarbonyl) propane-1,3-diamine [18] (650 mg, 1.1 mmol) was 
added to a flask and dissolved in anhydrous CH2CI2 (20 ml). TFA (2 ml) was  
added slowly to the flask while stirring. After 30 mins the reaction was 
stopped and 10 ml o f  CH2CI2 was added. The reaction mixture turned 
greenish. The solvent and TFA were removed in vacuo  during which time the 
colour gradually disappeared to obtain the title compound as a viscous oil  
(0.7 g, 1.1 mmol, 100 %), contaminated by residual TFA and used without  
further purification.
MS (APCI+): m/z = 491.2  (100%, [ M  -  C F3COO~]+).
v max (CHCI3): 3030 -  3018 (w),  1755 -  1742 (s),  1700 -  1660 (br m),
1530 (br w), 1437 (br w) cm"1.
'H NMR (300 MHz, CDC13): 6 1.80 -  2 .00  (4H, m, H - 2 ’ & H -5 ’) 1.98 
(3H, s), 2 .03 (3H, s), 2.08 (3H, s), 2.13 (3H, s), 2.31 -  2 .37 (2H, m, H- 
3 ’), 3.05 (2H, m, H -4 ’), 3.41 -  3.49 (3H, m, H - l ’ & H - 6 ’), 3.72 -  3.75  
(1H, m, H - l ’), 3.95 -  3.97 (1H, m, H-5) ,  4 .10  (1H, dd, J 6a,5 2.3 J 6a,6b
12.2 Hz, H - 6 a), 4 .24  (1H, dd, J 6b,s 5.2 J6b,6a 12.2 Hz, H-6 b), 4.77 (1H, s, 
H - l ) ,  5.16 -  5 .30 (3H, m, H-2, H-3 & H-4) ,  6 . 8 8  (1H, br, NH),  12.18 (br, 
1H).
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3.3.7 7V-(3-(2 ,3 ,4 ,6-Tetra-0-acetyl-a-D-mannopyranosyloxy)-  
propylcarbonyOv/V’-Ctrifluoroacetyl) cystamine [21]
O A f '
AcO
NH3TFA*
1’ 3' NH 5' S' T
A/r-(3 - (2 ,3 ,4 ,6 -T etra -0 -acety l -a -D -m annop yran osy loxy )propy lcarbony l) ,  
A ’-( /-butyloxycarbonyl)  cystamine [19] (183 mg, 270 pmol) was added to a 
flask and dissolved in anhydrous CH2CI2 (5 ml). TFA (0.5 ml) was added 
s lowly to the flask while stirring. The reaction was monitored by t.l.c. After 
4 hours the solvent was removed in vacuo  and purified by flash 
chromatography (4 cm, isocratic,  10 % EtOH / CH2CI2) to obtain the title  
product as a ye l low  / orange oil (141 mg, 202 pmol,  75 %).
Rf 0.3 [1:9 EtOH -  CH2C12; PMA stain], compound [19] Rf 0.7.
MS (APCI+): m/z  = 569.3 ( 1 0 0 %, [ M  -  C F 3COO~]+).
v max (CHCI3): 3030 -  2930  (br w),  1747 (s),  1662 (br m), 1521 (br w),
1454 _ 1433 (br w),  1371 (m), 1234 (s) cm '1.
lU NMR (300 MHz, CDC13): 6 1.97 (2H, m), 2.03 (3H, s), 2.08 (3H, s),
2.13 (3H, s), 2.31 -  2.33 (2H, m),  2 .79 -  2 .88 (2H, m),  3.06 -  3.13 (4H,
m), 3 .46 -  3.62 (3H, m),  3.66 -  3.73 (1H, m),  3.96 (1H, m), 4 .08 (1H, br 
d, J  12.1 Hz),  4 .26 (1H, dd, J  4.3,  12.1 Hz),  4 .78 (1H, s), 5.20 -  5.45
(3H, m), 7.01 (1H, br, NH). NMR shows the presence o f  /-butyl side
product.
13C NMR (75 .4  MHz, CDC13): 8 18.4,  20 .7 ,  20 .78 ,  20 .82 ,  26 .5 ,  33 .8 ,
35.6 ,  38 .4 ,  39.6 ,  58.4 ,  63.7 ,  67 .3 ,  6 8 .6 , 69 .9 ,  70 .8 ,  79 .6 ,  99.0 ,  171.4 ,
171.6 ,  171.7,  172.4 .  Miss ing 1 C = 0  13C signal.
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3.4 Pepstatin analogues, MPC1, MPC2, MPC5, MPC6
3.4.1 Pepstatin succinimide [22]153
O — Pepstatin
Pepstatin A (176 mg, 260 pmol) ,  EDCI (493 mg, 2.6 mmol,  10 equiv)  
and NHS (296 mg, 2.6 mmol,  10 equiv) were placed in a flask. To this  
was added anhydrous DMF (5 ml) and the reaction stirred overnight.  The 
DMF was removed in high vacuo.  The solid  was loosened from the vesse l  
walls ,  washed with water (20ml) and co l lected  by filtration. The sol id  
was further washed with water (180 ml) and then with ether (50 ml). The 
wet solid  was then dried for 24 hours under vacuum over anhydrous  
phosphorus pentoxide  (1 g). This gave 187 mg (239 pmol,  93 %) o f  the 
title product as a white solid.  Literature compound is not isolated but 
used in s i t u 153.
m.p.: 227 -  229 °C.
MS (APCI+): m/z  = 215 .4  (83 %), 283 .4  (33 %), 511.6  (67 %), 668.7  
(100 %), 783.7  (33 %, [ M  + H J +).
Found: M+Na, 805 .4194 .  C 3 $H66N 6O u  requires M+Na, 805 .4687  (ES).  
v max (KBr): 3500 -  3200 (s),  2959 -  2871 (m), 1818 (w),  1785 (w),  1740  
(s),  1650 -  1617 (s),  1534 (s) cm '1.
'H NMR (DMSO, 300 MHz): 8  0 .50  -  0 .70  (30H, m, CH3), 0.98 (3H, d, J
6.81 Hz),  0.95 -  1.25 (4H, m), 1.25 -  1.40 (2H, m),  1.70 -  1.85 (3H, m),  
1.85 -  1.95 (2H, m), 2.25 -  2.33 (4H, m),  2 .60  (4H, s), 3.55 -  3 .77 (4H,  
m), 3 .90  -  4 .10  (3H, m), 4 .58 (1H, d, J  4 .4  Hz, OH), 5 .04  (1H, d, J  9.6  
Hz, OH), 7.42 (2H, m, NH),  7.73 (1H, d, J  9 .6  Hz, NH),  7.78 (1H, d, J
9.1 Hz, NH),  7 .87 (1H, d, J  6.7 Hz, NH).
13C NM R (DMSO, 75.4 MHz): 8 18.1,  18.2 ,  18.3,  18.38, 18.4,  18.41,  
19.28,  19.33, 21 .6 ,  21.8 ,  22 .3 ,  23 .3 ,  23 .5 ,  24 .2 ,  24 .8 ,  25 .5 ,  25 .7 ,  30 .1 ,
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30.2 ,  30 .3 ,  44 .4 ,  48 .3 ,  50 .5 ,  57 .8 ,  169.2 ,  169.3 ,  169.7 ,  170.2 ,  170.5,
170.6,  171.6,  172.4.  Miss ing several 13C signals  due to overlapping.
3.4.2 Ar-(3-(2,3,4,6-Tetra-0-acetyl-a-D-mannopyranosyloxy)-
propylcarbonyl),7V’-(pepstatinyl) propane-1,3-diamine [23]
n A r
Pepstatin succin imide [22] (30 mg, 38 pmol,  containing significant  
amount o f  pepstatin dimethylamine) and A - (3 - (2 ,3 ,4 ,6 - t e t r a -0 - a c e ty l -a -  
D-mannopyranosyloxy)propylcarbonyl) ,Ar’-(trifluoro acetyl)  propane-1,3- 
diamine [20] (83 mg, 137 pmol , > 5.6 equiv) were both disso lved in 
anhydrous DMF (1 ml), transferred to a flask and the volume o f  DMF  
increased to 5 ml. While the reaction contents were stirred, anhydrous 
TEA (1 ml) was added and the stirring continued overnight.  The DMF 
and TEA were removed in v a c u o , and the crude product d isso lved in 
MeOH and filtered through cotton w ool  to remove the methanol  
insoluble  pepstatin dimethylamine. Purification by reverse-phase  
preparative HPLC (gradient, 60 % MeOH / water to 95 % MeOH / water  
over 25 mins) gave the tit le product (RT 11 min). Removal o f  the MeOH  
in v a c u o , and removal o f  the water by lyophil isat ion gave 2 0  mg (17.3  
pmol,  45 %) o f  the title product as a white  powder.
R f 0.2 [1:9 MeOH -  CH2C12; PMA stain], 
m.p.: 120 -  130 °C, decomposes  > 180 °C.
MS (APCI+): m/z  = 169.0 (100 %), 331 .2  (14 %), 810.7  (5 %, [ M  -  
m a n n o p y r a n o s i d e ] +), 1158.9 (7 % [ M  + H ] +).
Found: M+Na, 1180.6886. C 5 5 H 9 5 N 7 O 1 9  requires M+Na,  1180.6580 (ES).
A c
N
H
N
H
^ P e p s t a t i n
3' 5'
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Vmax (CHCI3): 3400  -  3200 (w, amide),  3024 -  2855 (m), 2401 (w), 1747  
(s),  1647 (s),  1537 (m), 1466 -  1435 (br m),  1371 (w),  1227 -  1213 (s)  
cm '1.
lR  NMR ( C D 3 O D ,  500 MHz): 6 0 .84 -  0.98 (30H, m, CH3), 1.30 - 1.36  
(2H, m, H - l  1 ’ or H - 2 0 ’), 1.37 (3H, d, 7.2 Hz, H - 1 6 ’), 1.54 -  1.65
(4H, m, H - 1 2 ’, H-21 ’ & [H-l 1 ’ or H - 2 0 ’]), 1.69 (2H, quin, J  6 .8  Hz, H- 
5 ’), 1.93 -  1.95 (2H, m, H - 2 ’), 1.95 (3H, s), 2.03 (3H, s), 2.05 (3H, s),
2.13 (3H, s), 2.02 -  2 .10 (3H, m, H - 2 5 \  H - 2 9 ’ & H - 3 3 ’), 2.11 -  2 .14  
(2H, m, H - 3 2 ’), 2 .27 (2H, d, J  6.7 Hz, H - 8 ’ or H - 1 7 ’), 2.31 (2H, t, J  7.4  
Hz, H - 3 ’), 2.34 -  2.36 (2H, m, H - 8 ’ or H - 1 7 ’), 3 .17 -  3.26 (4H, m, H - 4 ’ 
& H -6 ’), 3.51 (1H, ddd, J  5.9,  6.5,  9.8 Hz, H - l ’), 3.75 (1H, ddd, J  6.0,
6.5, 9.8 Hz, H - l ’), 3 .90 -  3.96 (2H, m, H - 1 0 ’ & H - 1 9 ’), 3.98 -  4.03 (3H,  
m, H-5, H - 9 ’ & H - l 8 ’), 4 .09 (1H, dd, J 6a,5 2.5 J 6a,6h 12.2 Hz, H -6 a), 4.13  
(1H, d, J  7.8 Hz, H - 2 4 ’ or H - 2 8 ’), 4.15 (1H, d, J  8.1 Hz, H - 2 4 ’ or H- 
2 8 ’), 4.23 -  4.28  (2H, m, H -6 b & H - 1 5 ’), 4 .82  (1H, d, J Xt2 1-4 Hz, H - l ) ,
4.88  (1H, s, OH), 5.20 -  5.24 (3H, m, H-2, H-3 & H-4).
13C NMR (C D 3OD, 125.7 MHz): 5 18.1 ( C - 1 6 ’), 18.9,  19.1,  19.9, 20 .0 ,
20.6 ,  20 .64 ,  20.7 ,  22 .39 , 22.4 ,  22 .77 ,  22.8 ,  23 .7 ,  23.8 ,  25 .8  & 25 .9  (C- 
1 2 ’ & C-21 ’), 26 .6  (C - 2 ’), 27.5 (C - 3 3 ’), 30.1 ( C - 5 ’), 31 .4  & 31.5 ( C - 2 5 ’ 
& C - 2 9 ’), 33 .7  ( C - 3 ’), 37.8 (2C, C - 4 ’ & C-6 ’), 41 .3 ,  41 .4 ,  41 .6  & 42.0  
(4C, C -8 ’, C - i r ,  C - l 7 ’ & C - 2 0 ’), 46 .0  ( C - 3 2 ’), 51.4  ( C - 1 5 ’), 52.3 &
52.8 ( C - 1 0 ’ & C - l 9 ’), 60.7 & 60.9  ( C - 2 4 ’ & C - 2 8 ’), 63.6  (C -6 ), 67.8 (C- 
4), 6 8 . 6  ( C - l ’), 69.8 (C-5) ,  70.7 ,  70.8 ,  71.1 & 71.5 (4C, C-2, C-3, C - 9 ’ 
& C - l 8 ’), 98 .9  (C - l ) ,  171.5 ,  171.52,  171 .6 ,  172.4,  173.8,  173.9 ,  174.1,
174.2 ,  175.4,  175.5,  174.8.
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3.4.3 A -(3 - (2 ,3 ,4 ,6 -Tetra-0 -ace ty l -a -D -m ani iopyra i iosy loxy)-  
propylcarbonyl),7V’-(pepstat inyl)  cystamine [24]
AcO'
H
N
^ P e p s t a t i nN
H
S
3' 5' T
Pepstatin succin imide [22] (36 mg, 46 pmol,  contains signif icant amount  
o f  pepstatin dimethylamine) and A - (3 - (2 ,3 ,4 ,6 - t e t r a -0 - a c e ty l -a - D -  
mannopyranosyloxy)propylcarbonyl) ,AF-(trif luoroacety l)  cystamine [21] 
(33 mg, 48 pmol ,  > 1 equiv) were both d is so lved  in anhydrous DMF (1 
ml), transferred to a flask and the volume o f  DMF increased to 4 ml. 
While the reaction contents were stirred, anhydrous TEA (1 ml) was  
added and the stirring continued for 16h. The DMF and TEA were  
removed in v a c u o , and the crude product d isso lved  in MeOH and filtered  
through cotton wool  to remove the MeOH insoluble  pepstatin 
dimethylamine. Purification by reverse-phase preparative HPLC 
(gradient, 60 % MeOH / water to 95 % MeOH / water over 25 mins) gave  
the tit le product (RT 11 min). Removal o f  the MeOH in vacuo,  and 
removal o f  the water by lyophil isation gave 28.5 mg (23 pmol,  55 %) o f  
the tit le product as a white powder.
Rf 0.2 [1:9 MeOH -  CH2C12; PMA stain],  
m.p.: 125 -  135 °C, decomposes  > 180 °C.
MS (ES+): m /z  = 1236.6 (30 %, [ M  + H] +), 1258.6  (100 %, [ M  -  H  + 
Na] +).
Found: M+Na,  1258.6237.  C56H97N 7O i9S2 requires M+Na, 1258.6178  
(ES).
vmax (CHC13): 3400 -  3200 (m), 2962 -  28 5 0  (m), 1746 (s) ,  1652 (s),  
1540 (m), 1466 -  1438 (br m),  1370 (w),  1231 -  1225 (s) cm ’1.
’H NM R (C D 3OD, 500 MHz): 8 0 .87  -  0 .98  (30H, m, CH3), 1.28 - 1.35 
(2H, m),  1.38 (3H, d, J  7.2 Hz),  1.54 -  1.64 (4H, m),  1.92 -  1.97 (2H,
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m), 1.95 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.13 (3H, s), 2.02 -  2.12  
(3H, m), 2 .12 -  2 .14  (2H, m),  2 .30  -  2.37 (6 H, m), 2 .82 (2H, t, J  6 .8  
Hz), 2.83 (2H, t, J  6 .6  Hz),  3 .40  -  3.55 (5H, m),  3.73 -  3.78 (1H, m),  
3.90 -  4.03 (5H, m),  4 .10 (1H, dd, J  2.6 & 12.3 Hz),  4 .12  -  4 .16 (2H,  
m), 4.23  -  4 .29  (2H, m), 4 .82 (1H, d, J  1.0 Hz),  4 .89  (1H, s, OH), 5.20  -  
5.26 (3H, m),  7.45 (1H, d, J  9.4 Hz, NH),  7 .67 (1H, d, J  9.1 Hz, NH),
7.96 (1H, d, J  8.4 Hz, NH), 8.01 (1H, d, J  7.9 Hz, NH),  8.06 (1H, t, J  5.6 
Hz, NH),  8.17 (1H, t, J  5.6 Hz, NH), 8.20 (1H, d, J  5.1  Hz, NH).
13C NMR ( C D 3 O D ,  125.7 MHz): 5 18.1,  18.9,  19.1, 20 .0 ,  20.1 ,  20.6 ,  
20.64 ,  20 .66 ,  20 .7 ,  22 .4 ,  22 .7 ,  22 .8 ,  23 .7 ,  23 .8 ,  25 .85 ,  25 .9 ,  26 .5 ,  27 .5 ,
31.4 ,  31.5 ,  33.6 ,  38 .3 ,  38 .6 ,  39.6,  39 .7 ,  41 .3 ,  41 .4 ,  41.6 ,  41 .9 ,  46 .0 ,  51.4,
52.3 ,  52.7 ,  60.8 ,  60 .9 ,  63 .6 ,  67.3,  68.5 ,  69.8 ,  70 .7 ,  70.8 ,  71 .1 ,  71.5 ,  98.9,
171.5,  171.55, 171.6,  172.4,  173.7,  173.9,  174.1,  174.2 ,  175.4 ,  175.6,
175.8.  Miss ing  1 pepstatin CH3, overlapped at 22 .4  ppm.
3.4.4 7V-(3-(a-D-Mannopyranosyloxy)propylcarbonyl),7V’- 
(pepstatinyl)  propane-1 ,3 , -diamine (MPC1) [25]
OH
HO
HO
P ep sta tin
1' 3'
7V-(3-(2 ,3 ,4 ,6 -Tetra-0 -acety l-a -D -m annopyranosy loxy)propy lcarbonyl) ,  
Af’-(pepstatinyl)  propane-1,3-diamine [23] (20 mg, 17.3 pmol) ,  was  
disso lved in MeOH (5 ml) in a 25 ml round-bottomed flask and stirred.  
To this was added LiOH (1M, aq) solution drop w ise  until the reaction  
mixture was pH 11. Stirring was continued for 6 hours before removal o f  
the solvents  in vacuo.  The crude product was  purif ied by reverse-phase  
preparative HPLC (gradient, 20 % M eCN / water to 60 % MeCN / water  
over 25 mins,  RT = 13 mins).  Removal  o f  the M eCN in vacuo  and 
lyophi l isat ion  gave the title product as a white  powder ( 1 2  mg, 70 %, 12  
pmol) .
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m.p.: 120 -  130 °C, decomposes  > 180 °C.
MS (ES+): m/z  = 828.6  (32 %, [ M  -  m a n n o p y r a n o s i d e ] +), 990.7  (100 %, 
[ M  + H ] +), 1012.8 (44 %, [ M  + N a ] +).
Found: M+Na, 1012.6140. C47H 87N 7O 15 requires M+Na, 1012.6157 (ES).  
v max (KBr): 3400 -  3200 (br s), 2960  -  2880  (s),  2500  -  2380  (w),  1685 -  
1632 (s),  1560 -  1542 (m), 1468 -  1437 (m), 1206 -  1187 (s),  1138 (s) 
cm '1.
]H NMR ( C D 3 O D ,  400 MHz): 6 0.86 -  0 .99 (30H, m, CH3), 1.28 -  1.34 
(2H, m), 1.38 (3H, d, J  7.2 Hz), 1.53 -  1.64 (4H, m), 1.68 (2H, m), 1.85 
-  1.92 (2H, m),  2 .02 -  2 .10  (3H, m), 2.12 (2H, d, J  6.5 Hz),  2 .26 -  2.36  
( 6 H, m), 3.20 -  3.23 (4H, m),  3.42 -  3 .52 (2H, m), 3.59 (1H, t, J  9.5
Hz), 3 .66 -  3.75 (3H, m),  3.78 (1H, dd, J  1.7 & 3.3 Hz), 3.82 (1H, dd, J
2.2 & 11.7 Hz),  3.93 -  4.03 (4H, m),  4.11 -  4.15 (2H, m), 4 .26  (1H, q, J
7.1 Hz),  4 .72 (1H, d, J  1.5 Hz),  4.85 (1H, s, OH), 7.47 (1H, d, J  9.4 Hz,  
NH),  7.70 (1H, d, J  9.3 Hz, NH), 7.99 (2H, m, NH).
13C NMR (CD 3OD, 125.7 MHz): 6 18.1,  18.9,  19.2,  20 .0 ,  20 .1 ,  22 .4 ,  22.5,
22.8 ,  22.9,  23 .8 ,  23.9,  25.9 ,  26.0 ,  26.9,  27 .5 ,  30.1 ,  31.5 ,  31.6,  34.0,  37.9,
41.3 ,  41.5 ,  41 .7 ,  42.0 ,  46 .0 ,  51.4,  52.4,  52.8,  60.8 ,  60.9,  63.0,  67.8,  68.7,
71.2,  71.5,  72.2,  72.7,  74.7,  101.7,  173.8,  174.0,  174.1,  174.2,  175.5,
175.7,  175.8.  Missing 1 13C, overlapped at 37.9  ppm.
3.4.5 A^-(3-(a-D-Mannopyranosyloxy)propylcarbonyl),A^’- 
(pepstatinyl)  cystamine (MPC2) [26]
HO
HO
P ep sta tin
N-(3 -  ( 2 ,3 ,4 , 6 -Tetra-O-acety l-a -D-mannopyranosy loxy)propylcarbonyl) ,  
^ ’-(pepstatinyl)  cystamine [24] (25 mg, 20 .2  pm ol) ,  was  d isso lved  in 
MeOH (5 ml) in a 25 ml round-bottomed flask and stirred. To this was
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added LiOH (1M, aq) solut ion drop w ise  until the reaction mixture 
reached pH 11. Stirring was continued for 6 hours before removal o f  the 
solvents  in vacuo.  The crude product was purified by reverse-phase  
preparative HPLC (gradient, 20 % M eCN / water to 60 % M eCN / water  
over 25 mins,  RT = 12.8 mins).  Removal o f  the MeCN in vacuo  and 
lyophil isat ion gave the title product as a white  powder (14.3  mg, 13.4  
pmol ,  66  %).
m.p.: 135 -  145 °C, decomposes  > 180 °C.
MS (ES+): m/z  = 283 .2  (38 %), 906.5  (22 %, [ M  -  m a n n o p y r a n o s i d e ] +),
1068.4  (20 %, [ M  + H ] +).
Found: M+Na, 1090.5787. C48H 89N 7O 15S2 requires M+Na, 1090.5755  
(ES).
v max (KBr): 3600 -  3200 (br s), 2965 -  2930  (w),  1690 -  1630 (s),  1565 -  
1534 (m), 1455 -  1430 (m), 1208 (s),  1146 (s) cm '1.
'H NMR (C D 3OD, 500 MHz): 8 0 .87 -  0 .99  (30H, m, CH3), 1.28 -  1.36 
(2H, m, H - I T  or H - 2 0 ’), 1.39 (3H, d, 8-0 Hz, H - 1 6 ’), 1.58 -  1.63
(4H, m, H - l  I ’ , H - 1 2 ’, H - 2 0 ’ & H - 2 1 ’), 1.85 -  1.92 (2H, m, H - 2 ’), 2.04 -  
2.11 (3H, m, H - 2 5 ’, H - 2 9 ’ & H - 3 3 ’), 2 .14  (2H, d, J 32-,33- 6.7 Hz, H - 3 2 ’), 
2.29 -  2 .38 ( 6 H, m, H -3 ’, H -8 ’ & H - 1 7 ’), 2.83 (4H, t, J  6.7 Hz, H - 5 ’ & 
H -6 ’), 3.47 -  3.53 ( 6 H, m, H-5, H - l ’ , H - 4 ’ & H - 7 ’), 3.61 (1H, t, J  9.6 
Hz, H-4) ,  3 .64 -  3 .72  (3H, m, H-3, H -6 b & H - l ’), 3 .79  (1H, dd, J  1.7 &
3.3 Hz, H-2) ,  3.88 (1H, dd, J 6a>5 2.5 J 6a ,6b 11.5 Hz, H-6 a), 3 .94  -  4 .02  
(4H, m, H - 9 ’, H - 1 0 ’, H - 1 8 ’ & H - 1 9 ’), 4 .12  -  4 .17  (2H, m, H - 2 4 ’ & H- 
2 8 ’), 4 .27  (1H, m, H - 1 5 ’), 4 .74  (1H, d, J U2 1.7 Hz, H - l ) ,  4 .92 (1H, s, 
OH).
13C NMR (C D 3OD, 125.7 MHz): 8 18.1,  19.0, 19.2,  20 .0 ,  20 .1 ,  22.5,
22 .8 ,  22 .9 ,  23 .8 ,  23 .9 ,  25 .9 ,  26 .0 ,  26 .9 ,  27 .5 ,  31 .5 ,  31 .6 ,  33 .9 ,  38.4 ,  38 .6 ,
39.7 ,  39 .74 ,  41 .3 ,  41 .4 ,  41 .6 ,  42 .0 ,  46 .0 ,  51 .4 ,  52 .4 ,  52.8 ,  60 .9 ,  61 .0 ,
63.0 ,  67 .8 ,  68 .7 ,  71.1 ,  71 .5 ,  72 .2 ,  72 .7 ,  74 .7 ,  101.6 ,  173.9 ,  174 .0 ,  174.1,
174.2,  175.5,  175.9 ,  180.9.  Miss ing 1 pepstat in C H 3 , overlapped at 22.4  
ppm.
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3 .4 .6  TV-^-Butyloxycarbonyl^TV’-Cpepstatinyl)  p r o p a n e - 1 ,3 -d ia m in e
[2 7 ]153
H 2 H
P e p s ta t in  
O
iV-(7-Butyloxycarbonyl) propane-1,3-d iamine [13] (111 mg, 640 pmol,  10 
equiv),  pepstatin succin imide [22] (50 mg, 64 pmol)  and anhydrous DMF  
(6  ml) were added to a round-bottomed flask and stirred continuously  for 
2 days.  The solvent was removed in vacuo  and the crude product purified  
by flash chromatography (1 cm 3, isocratic,  10 % M eOH /CFbC^).  T.l .c.  
visuali sat ion was poss ib le  by using either permanganate so lution or by  
dipping in TFA and leaving for ~5 mins (to remove the Boc group),  
heating to remove the TFA and then staining with ninhydrin. The column  
fractions col lected  with Rf 0.5 were pooled  and the solvent removed in 
vacuo  to give an off -white  solid.  This was re-crysta ll ised from 
CHCls /cyc lohexane to obtain a white  powder (48 mg, 57 pmol ,  89 %).
Rf 0.5 [1:9 MeOH -  CHCI3; TFA treatment,  then ninhydrin stain],  
m.p.: 219 -  221 »C (lit. ref. 215 -  217 °C )153.
MS (ES+): m/z = 842.6  (100 %, [ M  + H]+),  864 .6  (27 %, [ M  + N a ] +). 
Found: M+Na, 864.5785.  C42H79N 7O 10 requires M+Na, 864 .5786 (ES).  
v max (KBr): 3400 -  3200 (s, amide),  2960  -  2872 (s) , 2360 -  2331 (m),  
1652 -  1634 (s),  1533 (m), 1465 -  1437 (m), 1171 (m) cm '1.
'H NMR (DMSO, 500 MHz): 8 0 .77  -  0.85 (30H, m, CH3), 1.18 (3H, d, J
7.1 Hz),  1.21 -  1.26 (2H, m), 1.33 -  1.37 (2H, m), 1.36 (9H, s), 1.46 -  
1.52 (2H, m),  1.92 -  1.98 (3H, m), 2 .00  -  2.05 (4H, m), 2.11 (2H, d, J
6.2 Hz), 2 .90  (2H, q, J  6.4 Hz), 2 .97  -  3.05 (2H, m), 3.27 -  3.34  (2H,  
m), 3.75 -  3.83 (4H, m), 4.11 (1H, dd, J  7.2 & 8.9 Hz), 4 .17  (1H, dd, J
7.4 & 8.7 Hz),  4 .24  (1H, quin, J  7.2 Hz),  4 .82  (1H, d, J  4.8 Hz, OH),
4.83 ( 1H, d, J  4.9 Hz, OH), 7.30 (1H, d, J  9 .2  Hz, NH),  7 .43 (1H, d, J
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8 .8  Hz, NH),  7.75 (1H, d, J  8.9 Hz, NH),  7.79 (1H, d, J  8 .8  Hz, NH),
7.89 (1H, d, J  1 A  Hz, NH). NMR data not quoted in the l iterature153.
13C NMR (DMSO, 125.7 MHz): 8 18.1,  18.2,  19.2,  19.3,  21 .6 ,  21 .9 ,  22.2 ,
23.2 ,  23 .4 ,  24 .1 ,  25 .6 ,  28 .2 ,  30 .0 ,  30.3 ,  36.1 ,  37 .5 ,  38 .6 ,  39 .6 ,  39.8 ,  39.9 ,
40.1 ,  40.2 ,  44 .4 ,  48 .3 ,  50.4,  50.7,  54 .8 ,  57 .8 ,  58 .0 ,  69 .0 ,  69.1 ,  77 .4 ,
155.5,  170.6 ,  170.7,  170.78, 170.8 ,  171.1 ,  171.5 ,  172.1.
3.4.7 7V-(*-Butyloxycarbonyl),7V’-(pepstatinyi) cystamine [28]
H 2 4
N,    .P e p s ta t in
V  S  ^  N
1 3 H
O
A-(*-Butyloxycarbonyl)  cystamine [14] (161 mg, 640 jamol, 10 equiv),  
pepstatin succin imide [22] (50 mg, 64 jamol) and anhydrous DMF (6  ml)  
was added to a round-bottomed flask and stirred continuously  for 2 days.  
The solvent was removed in vacuo.  Purification by flash chromatography  
(1 cm 3, isocratic,  10 % MeOH/CH 2Cl2, Rf 0 .55) gave a white powder  
from the pooled fractions,  which was re-crystall ised from hot EtOH to 
obtain a white  sol id (47 mg, 64 jamol, 80 %).
Rf 0.5 [1:9 MeOH -  CHCI3; TFA treatment, then ninhydrin stain],  
m.p.: 244 -  246 °C.
MS (ES+): m/z  = 920.6  (100 %, [ M  + H]+),  942 .6  (53 %, [ M  -  H  + 
N a ] +).
Found: M+Na, 942.5378 .  C43H81N 7O 10S2 requires M+Na, 942 .5384  (ES).  
v max (KBr): 3600 -  3100 (s),  2959 -  2871 (s) ,  1635 (s),  1534 (s),  1466 -  
1437 (m), 1171 (m) cm '1.
•H NMR (DMSO, 500 MHz): 8 0 .77  -  0 .85 (30H, m, CH3), 1.18 (3H, d, 
J i 6M5- 7-1 Hz, H - 1 6 ’), 1.20 -  1.26 (2H, m, H - l l ’ or H - 2 0 ’), 1.33 -  1.38 
(2H, m, H - 1 2 ’ & H - 2 1 ’), 1.36 (9H, s, f-butyl) ,  1.48 -  1.52 (2H, m, H - l l ’ 
or H - 2 0 ’), 1.90 -  1.99 (3H, m, H - 2 5 ’, H - 2 9 ’ & H - 3 3 ’), 2 .00  -  2.08 (4H,  
m, H - 3 2 ’ & [H -8 ’ or H - 1 7 ’]), 2.11 (2H, d, J  6.2 Hz, H - 8 ’ or H - 1 7 ’), 2 .72  
(2H, t, J  6.5 Hz, H-2 or H-3),  2.73 (2H, t, J  6.5 Hz, H-2 or H-3) ,  3.16 -
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3.20  (2H, m, H - l  or H-4),  3.25 -  3.31 (2H, m, H - l  or H-4) ,  3.74 -  3.81 
(4H, m, H - 9 \  H - 1 O’, H - 1 8 ’ & H - 1 9 ’), 4.11 (1H, d, J  7.2 Hz, H - 2 4 ’ or H- 
2 8 ’), 4.11 (1H, d, J  7.3 Hz, H - 2 4 ’ or H - 2 8 ’), 4 .23 (1H, q, 7.0 Hz,
H - 1 5 ’), 4 .82 (1H, d, J  5.3 Hz, OH), 4.83 (1H, d, J  5.2 Hz, OH), 7.32  
(1H, d, J  9.2 Hz, NH), 7.45 (1H, d, J  8 .8  Hz, NH), 7.77 (1H, d, J  9.0 Hz,  
NH), 7.81 (1H, d, J  8.8  Hz, NH), 7.91 (1H, d, J  7.4 Hz, NH).
13C NMR (DMSO, 125.7 MHz): 8 18.2,  18.3,  19.2,  19.3, 21 .6 ,  21 .9 ,  22.2 ,
23.3 ,  23 .5 ,  24.2 ,  25 .7  (C - 3 3 ’), 28 .2  (/-butyl) ,  30.1 & 30.3 ( C - 2 5 ’ & C- 
2 9 ’), 37.1 ,  37 .6 ,  37 .9 ,  38 .0 ,  38.6,  39 .7 ,  39 .8 ,  40.0 ,  40 .1 ,  40 .2 ,  44.3 ,  48.3  
(C - 1 5 ’), 50 .4 ,  50.7,  57.7 & 57.9 ( C - 2 4 ’ & C - 2 8 ’), 69 .0 ,  69.1 ,  77.8 ,
155.5,  170.7,  170.8,  170.9,  171.0,  171.02,  171.6 ,  172.2.
3 .4 .8  A - (P e p s t a t in y l )  p r o p a n e - 1 ,3 -d ia m in e  [2 9 ] 153
2 H
—  P e p s ta tin
1 3
To a flask containing A-( / -butyloxycarbonyl) ,A’-(pepstatinyl) propan el ,3- 
diamine [27] (75 mg, 89 pmol)  was added TFA (4 ml), water (125 pi, 6.9 
pmol) ,  triethylsi lane (125 pi, 0.77 pmol) ,  th ioanisole  (250 pi, 2.1 pmol)  
and phenol (250 pi, 2.8 pmol) and stirred v igorous ly  for 4 hours. The 
TFA was removed in v a c u o , and the resulting sol id purified by  
preparative HPLC (50 % MeOH / water to 100 % MeOH over 25 mins) to 
give  the major product with RT = 14-15 mins (60 mg, 81 pmol,  91 %) as 
a white powder.
Other fractions (RT 12 mins and 16 mins) showed the presence o f  the 
title product but were impure.
Rf 0.2 [1:9 MeOH -  CHCI3; ninhydrin stain], 
m.p.: 214 -  216 °C (lit. ref. 207 -  210 ° C )153.
MS (ES+): m/z  = 742 .6  (100 %, [ M  + H ] +).
Found: M+H, 742.5440. C37H71N 7O8 requires M+H, 742 .5442  (ES).  
v max (KBr): 3500 -  3200 (s),  3079 (w),  2960  -  2872  (s),  2416 (w),  1700  
-  1600 (s) ,  1537 (s),  1467 -  1417 (m), 1204 -  1138 (m) cm '1.
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l¥L NMR ( C D 3 O D ,  500 MHz): 5 0 .86 -  0 .98 (30H, m, CH3), 1.27 -  1.35 
(2H, m, H - l l ’ or H - 2 0 ’), 1.39 (3H, d, JW.is* 7.3 Hz, H - 1 6 ’), 1.55 -  1.64  
(4H, m, H - 1 2 \  H-21 ’ & [ H - l l ’ or H - 2 0 ’]), 1.84 (2H, quin, J  7.0 Hz, H- 
2), 2.02 -  2 .10  (3H, m, H - 2 5 ’, H - 2 9 ’ & H - 3 3 ’), 2 .14  (2H, d, J  6 .8  Hz, H- 
3 2 ’), 2 .30  -  2 .38 (4H, m, H -8 ’ & H - 1 7 ’), 2.98 (2H, t, J 3,2 7.1 Hz, H-3),
3.20  -  3.25 & 3.32  -  3.36 (2H, m, H - l ) ,  3.92 -  3.97 (2H, m, H - 1 0 ’ & H- 
19’), 3.99 -  4.03 (2H, m, H - 9 ’ & H - 1 8 ’), 4 .10  -  4 .14  (2H, m, H - 2 4 ’ & H- 
2 8 ’), 4.21 (1H, q, 7.2 Hz, H - 1 5 ’), 4 .97  (1H, s, OH). NMR data not
quoted in the l iterature153.
13C NMR ( C D 3 O D ,  125.7 MHz): 6 18.0 ( C - 1 6 ’), 18.9,  19.2,  19.9, 20.0 ,
22.3 ,  22 .4 ,  22 .7 ,  22 .8 ,  23 .7  & 23.8 (10C, CH3), 25 .8  & 25.9  ( C - 1 2 ’ & C- 
2 1 ’), 27 .4  (C - 3 3 ’), 28.7  (C-2),  31.3 & 31.4  ( C - 2 5 ’ & C - 2 9 ’), 36.8 (C-3) ,
38.2 ( C - l ) ,  41 .2 ,  41.3 & 41.6  (C -8 \  C - 1 T ,  C - 1 7 ’ & C - 2 0 ’), 46 .0  (C- 
3 2 ’), 51.6 ( C - 15*), 51.9  & 52.7 (C - 1 0 ’ & C - 1 9 ’), 61.0  ( C - 2 4 ’ & C - 2 8 ’),
71.0 & 71.3 ( C - 9 ’ & C - l 8 ’), 173.9,  174.1,  174.3,  174.5,  175.5 ,  175.9.  
Missing  2 13C signals ,  overlapped at 41.6  & 61.0  ppm.
3.4.9 TV-(Pepstatinyl) cystamine [30]157
2 4
To a flask containing 7V-(r-butyloxycarbonyl),A’-(pepstatinyl) cystamine
[28] (6 5  mg, 70  pmol) was added TFA (4  ml), water ( 1 2 5  pi,  6 .9  pmol),  
triethyls ilane ( 1 2 5  pi, 0 . 7 7  pmol) ,  th ioaniso le  ( 2 5 0  pi, 2.1 pmol) and 
phenol ( 2 5 0  pi, 2 .8  pmol) and stirred v igorous ly  for 4 hours. The TFA  
was removed in v a c u o , and purified by preparative HPLC ( 4 0  % MeCN / 
water to 80  % MeCN over 30  mins) to obtain a major product with RT = 
5 mins ( 3 7  mg, 45  pmol,  64  %) as a white  powder. Other fractions (RT 
1 2  mins and 16 mins) showed the presence o f  product but were impure.  
Literature does  not quote any analytical data for com paris ion157.
R f  0 . 2  [ 1 : 9  MeOH -  C H C I 3 ; ninhydrin stain],  
m.p.: 2 1 9  -  221  °C.
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MS (ES+): m/z = 820.5 (100 %, [ M  + H J +).
Found: M+H, 820.5039 .  C38H73N 7O8S 2 requires M+H, 820 .5040  (ES).  
v max (KBr): 3500 -  3200 (s),  2960 -  2872 (m), 1700 -  1600 (s),  1540 (s),  
1470 -  1419 (w),  1203 -  1138 (m) cm '1.
'H NMR (C D 3OD, 400  MHz): 5 0 .86  -  0 .98 (30H, m, CH3), 1.27 -  1.35 
(2H, m), 1.38 (3H, d, J  7.3 Hz),  1.55 -  1.63 (4H, m), 2 .02  -  2 .10  (3H,  
m), 2.13  (2H, d, J  6.5 Hz), 2.28  -  2 .38 (4H, m), 2 .87  (2H, t, J  6.7 Hz),
2.97 (2H, t, J  6 .8  Hz),  3 .24  -  3.32 (2H, m), 3.42 -  3 .62 (2H, m),  3.91 -
4 .04  (4H, m), 4 .10  -  4.17 (2H, m), 4 .23 (1H, q, J  7.3 Hz), 4.93 (1H, s, 
OH), 7 .47 (1H, d, J  9.4 Hz, NH), 7.63 (1H, d, J  9.7 Hz, NH), 7.67 ( 1H, 
d, J  9.1 Hz, NH), 7.97 (1H, d, J  8.3 Hz, NH),  8.05 (1H, d, J  7.6 Hz, NH),
7.6 (1H, s, NH).
13C NMR (C D 3OD, 100.6 MHz): 8 18.0,  18.9,  19.2, 20 .0 ,  20.1 ,  22.4,
22 .7 ,  22 .8 ,  23.7 ,  23.8 ,  25.8 ,  25.9,  27 .5 ,  31 .3 ,  31 .5 ,  35 .6 ,  38 .3 ,  39.4 ,  39.5 ,
41 .2 ,  41 .3 ,  41 .6 ,  41 .9 ,  46 .0 ,  51 .5 ,  52.2 ,  52 .7 ,  60.9 ,  71.0 ,  71.5 ,  173.8,
173.9,  174.2 ,  174.3,  175.5,  175.9.  Miss ing  2 13C signals ,  overlapped at
22 .4  & 60.9  ppm.
3.4.10 Ar-(Iodoacetyl),A^’-(pepstatinyl)  propane-1 ,3-diamine [31]
To a flask was added A-(pepstatinyl)  propane-1,3-diamine [29] (10 mg,
13.5 pmol) .  Any water present was removed by azeotroping with  
anhydrous M eCN ( 3 x 1  ml). The amine was d isso lved in anhydrous DMF  
(3 ml) and stirred while  adding iodoacet ic  anhydride (5.3 mg, 15 pmol,
1.1 equiv).  The flask was covered with aluminium foil  to exclude  all 
light and the reaction stirred continuous ly  for 2 hours. The DMF was  
removed in vacuo  and the crude product stored overnight in a fridge.  The 
next day the flask contents were washed with water containing 1% v/v  
saturated bicarbonate solut ion and 10  % v/v  saturated potassium iodide  
(KI) solution (to stop the poss ib il ity  o f  iodine  exchange) .  The product
H H
Pepstatin
O
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precipitated and was filtered through cotton wool .  The solid  product was  
washed again with the aqueous Kl/b icarbonate  solution (40 ml) and once  
with water before being d isso lved in EtOH and eluted into a round- 
bottomed flask (in an alternative method ethyl acetate was used to both 
crystal l ise  and wash the crude product). Removal o f  the EtOH in vacuo  
gave the tit le compound as a white powder ( 6 mg, 6 .6  pmol,  49 %), which  
was stored in a fridge under argon and used in the next reaction as soon  
as poss ib le .
m.p.: 189 -  191 °C.
MS (ES+): m/z  = 932.3 (83 %, [ M  + N a ] +).
Found: M+Na, 932 .4311.  C39H72IN7O9 requires M+Na, 932 .4334  (ES).  
v max (KBr): 3500 -  3150 (s),  3079 (w),  2959 -  2871 (m), 1700 -  1635 
(s), 1550 -  1507 (s) cm '1.
'H NMR (C D 3OD, 500 MHz): 8 0 .86 -  0 .98 (30H, m, CH3), 1.32 -  1.39  
(2H, m), 1.38 (3H, d, J  7.2 Hz), 1.54 -  1.65 (4H, m), 1.70 (2H, quin, J
6 .8  Hz), 2 .02 -  2 .10  (3H, m),  2.13 (2H, d, J  6.7 Hz),  2.27 (2H, d, J  6.7  
Hz), 2 .34  -  2 .37 (2H, m), 3 .20  -  3 .34 (4H, m), 3.69 (2H, s), 3.93 -  4.01  
(4H, m),  4.13  (1H, d, J  7.9 Hz), 4.15 (1H, d, /  8.1 Hz), 4 .26  (1H, q, J  7.3 
Hz), 4 .89  (1H, s, OH), 7.32 (1H, d, J  9.3 Hz, NH),  7.45 (1H, s, NH),  
7.68 (1H, d, J  9 .0  Hz, NH), 7 .89 (1H, s, NH).
13C NMR (C D 3OD, 125.7 MHz): 8 -2 .0  (CH2-I), 18.1,  18.9, 19.1,  20 .0 ,
20.1 ,  22 .4 ,  22 .7 ,  22 .8 ,  23 .7 ,  23 .8 ,  25 .8 ,  25 .9 ,  27.5 ,  29 .8 ,  31 .4 ,  31.5 ,  37 .8 ,
38.4,  41 .3 ,  41 .4 ,  41 .7 ,  42 .0 ,  46 .0 ,  51.4 ,  52.3 ,  52 .8 ,  60 .7 ,  60.9 ,  71.1,  71.4 ,
171.4,  173.8,  173.9,  174.1,  174.2,  175.4,  175.8.  Miss ing  1 pepstatin C H 3 ,  
overlapped at 22 .4  ppm.
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3.4.11 A^-(Iodoacetyl),A^’-(pepstatinyl)  cystamine [32]
H
N S ^  Pepstatin
N
H
O
To a flask was added A'-(pepstatinyl) cystamine [29] (7 mg, 8.3 pmol).  
Any water present was removed by azeotroping with anhydrous M eCN (3 
x 1 ml). The amine was d isso lved in anhydrous DMF (3 ml) and stirred 
while  adding iodoacetic  anhydride (3.3 mg, 9.4 pmol,  1.1 equiv).  The 
flask was covered with aluminium foil  to exclude all l ight and the 
reaction stirred continuously  for 2 hours. The DMF was removed in 
vacuo  and the crude product stored overnight in a fridge. The next day 
the flask contents were washed with water containing 1% v/v  saturated 
bicarbonate solution and 10 % v/v saturated potassium iodide (KI) 
solution. The product precipitated and was filtered through cotton wool.  
The sol id product was washed again with the aqueous Kl/bicarbonate  
solut ion (40 ml) and once with water before being d isso lved in EtOH and 
eluted into a round-bottomed flask (in an alternative method ethyl  
acetate was used to both crystall i se  and wash the crude product).  
Removal o f  the EtOH in vacuo  gave the tit le compound as a white  
powder ( 6 mg, 6.1 pmol,  83 %), which was stored in a fridge under argon 
and used in the next reaction as soon as possib le .
m.p.: 198 -  201 °C.
MS (ES+): m/z  = 988.2  (56 %, [ M  + H ] +), 1010.3 (100 %, [M  -  H  + 
N a ] +).
v max (KBr): 3600 -  3100 (m), 2959  -  2871 (m), 1700 -  1617 (m), 1540  
(w),  1067 (s) cm '1.
■H NMR (CDjOD, 500 MHz): 6 0.87 -  0 .99  (30H, m, CH3), 1.28 -  1.36  
(2H, m), 1.38 (3H, d, J  7.3 Hz),  1.57 -  1.62 (4H, m),  2.03 -  2.11 (3H,  
m), 2.13 (2H, d, J  6.7 Hz),  2.28 (2H, d, J  6.7 Hz),  2 .34  -  2 .37  (2H, m),
2.83 (4H, t, J  6 . 6  Hz),  3.43 -  3.61 (4H, m), 3.71 (2H, s), 3.91 -  4 .04  
(4H, m), 4 .12  (1H, d, J  7.8 Hz), 4 .15 (1H, d, J  8.0 Hz),  4 .26  (1H, q, J  9.3
129
Hz), 4 .89  (1H, s, OH), 7.43 (1H, s, NH),  7.45 (1H, s, NH),  7.68 (1H, d, J
9.0 Hz, NH).
13C NMR (C D 3OD, 125.7 MHz): 6 -2.1 (CH2-I), 18.1,  18.9,  19.1,  20 .0 ,
20.1 ,  22.4 ,  22 .7 ,  22 .8 ,  23.7 ,  23 .8 ,  25.8 ,  25 .9 ,  27 .5 ,  31 .4 ,  31.6 ,  38 .2 ,  38.3 ,
39 .7 ,  40 .1 ,  41.3 ,  41.4 ,  41 .7 ,  42.0 ,  46 .0 ,  51.4 ,  52 .3 ,  52 .8 ,  60.8 ,  60.9 ,  71.1 ,
71 .4 ,  173.8,  173.9,  174.1,  174.2,  175.4 ,  175.5 ,  175.8.  Miss ing  1
pepstatin CH3, overlapped at 22 .4  ppm.
3.4.12 BSA -  poly(mannose)  conjugate  [33]
■OH
HO'
HO-
AH H BSA
4-Isothiocyanatophenyl a-D-mannopyranoside  [11] (43 mg, 0.14 mmol,  
approx. 60 equiv) and bovine serum albumin (153 mg, ~ 2.3 pmol,  
supplied by Sigma Aldrich) were d isso lved  in NaCl solution (0.15 M, 10 
ml) in a 50 ml round-bottomed flask and stirred v igorously .  The pH was  
adjusted to pH 9 (with the addition o f  0.1M NaOH) and the reaction 
stirred continuously  for 6 hours, maintaining the same pH by addition o f  
NaOH. After this time the reaction mixture was stored overnight in a 
fridge.  Next  day the pH was adjusted to pH 7 and the reaction mixture  
dialysed with 0 .1 5M NaCl solution (1 L) for three days, changing the 
solut ion tw ice  a day and stirring the dia lysis  solution continuously  
within a fridge. The dialysis  tubing contents  were further purified and 
de-salted using centrifugal fi ltration dev ices  (Mill ipore) spun within a 
fixed 35° angle centrifuge at a relat ive centrifugal  force (ref) o f  3000 for 
90 mins,  21 °C (maximum 4 ml solut ion per dev ice )  before re-suspending  
the gelatinous product at the bottom o f  the dev ice  with water (4 ml).
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This was repeated three times to maxim ise  purification. Lyophi li sat ion  
gave 126 mg (74 %) o f  a fine white powder.
m.p.: > 260 °C (decomposes) .
MS (MALDI-TOF): MS peak range = 67 ,000  -  79 ,000 .  Top o f  peak for 
B S A  ~ 66 ,430 .  Compound (35) ~ 74 ,032.
D ifference  = 7602, 24.3  sugar units / B S A  molecule .
228Biochem ica l  analysis:  Analys is  o f  free TNBS reactive  ammo groups  
shows an approximate conjugation o f  23 sugar units. Analys is  o f  
attached sugar units229,230 shows an approximate conjugation o f  22.5  
sugar units.
3.4.13 Poly(mannosyl)  BSA -  pepstatin propane-1 ,3-diamine  
conjugate  (MPC5) [34]
•OH
OH
,1-0
HO-
HO-
BSA
i\i
H
n
^Pepstatin
B SA  -  poly (mannose)  conjugate [33] (30 mg, ~ 3.8 x 10 '7 moles)  was  
placed in a 25 ml round-bottomed flask and d isso lved in 2 ml o f  
phosphate buffer saline (PBS, 1M, pH 8.0) with stirring. To this was  
added iodoacetamide compound [31] (taken from 6 mg / ml stock in 
anhydrous DMF, 350 pg, 3.8 x 10 '7 m oles )  and the reaction was stirred 
continuously  overnight.  The reaction mixture was dialysed once against  
1M PBS solution (1L, pH 7.4) for 24h, changing the solution  once and 
stirring the dialysis  solut ion continuous ly  within a fridge.  Further 
purif ication and de-salt ing was achieved by us ing Mil l ipore  ultrafree-4  
centrifugal f iltration devices  spun within a f ixed 35° angle centrifuge at 
a re f  o f  3000  for 90 mins,  21 °C (crude product made up to 4 ml with
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water and total volume o f  10 % DMSO).  The gelatinous  product at the 
bottom o f  the device  was re-suspended in water (4 ml) and re-centrifuged  
in a new fi ltration device  (3000 ref, 90 mins) and repeated within the 
same device  by re-suspending in water (4 ml). Lyophi li sat ion gave 22 mg  
(73 %) o f  a fine white powder.
m.p.: > 260 °C (decomposes) .
MS (MALDI-TOF): MS peak range = 67 ,500  -  80 ,000.  Top o f  peak for 
compound [33] ~ 74 ,032 , compound [34] ~ 74 ,093 .
Dif ference  = 61. MS appears to show a minimal increase in the value o f  
the top peak, however a shift o f  an increase in the peak range o f  ~ 500 -
1,000 MW.
3.4.14 Poly(mannosyl)  BSA -  pepstat in cystamine conjugate  (MPC6)
B SA  -  poly(mannose) conjugate [33] (30 mg, ~ 3.8 x 10 '7 moles) was  
placed in a 25 ml round-bottomed flask and disso lved  in 2 ml o f  
phosphate buffer saline (PBS,  1M, pH 8.0) with stirring. To this was  
added iodoacetamide compound [32] (taken from 6 mg / ml stock in 
anhydrous DMF, 380 pg, 3.8 x 10 '7 m oles )  and the reaction was stirred 
continuously  overnight.  The reaction mixture was dialysed once against 
1M PBS solut ion (1L, pH 7.4) for 24h, changing the solution once and 
stirring the dialysis  solution continuous ly  within a fridge.  Further 
purif ication and de-salt ing was achieved by using Mil l ipore ultrafree-4 
centrifugal f iltration devices  spun within a f ixed 35° angle centrifuge at 
a ref  o f  3000 for 90 mins,  21 °C (crude product made up to 4 ml with  
water and total volume o f  10 % DMSO).  The gelatinous product at the
[35]
Pepstatin
O
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bottom o f  the device  was re-suspended in water (4 ml) and re-centrifuged  
in a new filtration device  (3000 ref, 90 mins) and repeated within the 
same device  by re-suspending in water (4 ml). Lyophi li sat ion gave 21 mg  
(70 %) o f  a fine white  powder.
m.p.: > 260 °C (decomposes) .
MS (MALDI-TOF): MS peak range = 69 ,000  -  81 ,500. Top o f  peak for 
compound [33] ~ 74 ,032 ,  compound [35] ~ 75 ,163 ,  dif ference = 1,131.  
Iodoacetamide compound [32] - iodine = 861.
MS shows at least the addition o f  one pepstatin derivative to BSA  
derivative,  and a shift in the peak range.
3.5 Attempted synthesis of hexalysyl derivatives MPC3, 
MPC4
Peptides were made under standard peptide synthesis:
The resin (TGT Novasyn , pre-loaded with glycine;  Calbiochem-  
Novabiochem  UK Ltd., Nott ingham, UK) was swel led  in DMF (5 ml) for 
2 0  min in a vial and then transferred to the synthes iser  column ( 1 0  mm 
width).  Fmoc deprotection was carried out us ing a 20 % piperidine  
solut ion in DMF for 5 minutes for standard Fmoc-protected amino acids  
and 10 minutes for the resin. The amino acid cyc les  included a 20  
bubble-cyc le  activation o f  the residues with 0.6 M 1- 
hydroxybenzotriazole  and 0.6 M diisopropyl carbodi imide solut ions,  
both in DMF, fo l lowed by 15-minute coupl ing  cycles  for Fmoc-Lys  
(Boc)-OH or Fmoc-Lys  (ivDde)-OH, carried out twice.  Both the Fmoc  
deprotection and amino acid couplings were monitored quantitatively by  
measuring the U.V. absorbance (X 365 nm). Each double -cyc le  was  
fo l lowed  by a capping cycle  using a 0.3 M solution o f  1-acety l imidazole  
in DMF.
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Several approaches towards MPC3 and MPC4 were attempted but were  
unsuccessful in the time available.  Unfortunately,  due to several  
unforeseen errors, some o f  the derivatives contained a mix o f  Dde and 
ivDde protecting groups. It was later noted that derivatives containing  
the Dde group with free lys ine s -amino groups nearby were condit ions  
that a llowed for the migration o f  the Dde group. As such, some  
compounds were made with two protecting groups attached with Dde  
being attached to any o f  the free s-amino groups.
3.5.1 General  method for cleavage of  peptide from resin and 
purification
To a flask containing the resin (on average 1 g o f  resin was used) with  
attached synthes ised peptide,  was added acetic acid (1 ml),  
trifluoroethanol (1 ml) and CH2CI2 (6  ml) and stirred continuously  for 2 
hours. The resin is f iltered and washed with the peptide cleavage  
mixture.  The solvent o f  the filtrate is removed in vacuo  and the acetic  
acid removed in vacuo  by azeotropic removal using hexane (5 x 30 ml).  
This left an orange oil that was purified by preparative HPLC using a 
MeOH / water gradient. For fu lly  protected amino groups (Boc or Boc  / 
Fmoc) this was typical ly  a 50 % to 90 % MeOH in water gradient over 30 
mins. For peptides with free amino groups,  then a 20 % to 50 % MeOH  
in water gradient over 30 mins is used. Typical  RT was from 15 mins  
(for free amino group peptides) to 30 mins (for fu lly  protected peptides).
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3.5.2 Automated peptide synthesis of  hexalysyl  (ivDde) peptide and 
subsequent Boc deprotection [36a]
Figure 3.1: Hexalysyl (ivDde) peptide [36a]
The tit le compound (with Boc-protected lys ines)  was made using  
automated peptide synthesis under standard condit ions  with a final N-  
terminal Fmoc deprotection stage. The resin obtained from the peptide  
synthes iser (typically  l g  o f  resin was used) was washed with DCM  
through a sinter to remove traces o f  DMF. The resin was transferred to a 
round-bottomed flask (250 ml) contain ing TFA (127.5  ml),  th ioanisole  
(7.5 ml,  63 pmol),  phenol (8 mg, 85 pmol) ,  TES (3.75 ml, 32.1 pmol)  
and H2O (3.75 ml,  208 pmol).  The resin mixture was stirred continuously  
for 4 hours under N 2 before being washed through a sinter with water (50 
ml). All  volati le  solvents  were removed from the filtrate in vacuo  and 
the peptide precipitated on addition o f  ether to obtain a white  solid.  The 
solid was filtered, d isso lved in 40 % AcOH / H2O (50 ml) and 
lyophil ised to obtain a crude white  powder. Preparative HPLC (gradient,  
10 % MeOH / H2O to 40 % MeOH / H2O over 25 mins,  product RT = 5.3 
mins) ,  d is so lv ing  in 40 % AcOH / H2O (20 ml) and lyophi l isat ion gave a 
white powder o f  the titled peptide. On average, an included resin
HO
ivDde
Group
Dde
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quantity o f  1 g (with a loading capacity o f  0 . 2 2  meq / g) will  give  
approximately 150 - 170 mg o f  final product.
Rf at baseline [1:4 methanol -  CHCI3, ninhydrin stain].
MS (ES+): m/z = 526 (100 %, [{M  + 3H}/2] +), 1051 (5.7%, [ M  + 2 H J +).
'H NMR (C D 3OD, 400 MHz): 8 0.97 ( 6 H, d, J 5,4 6.7 Hz, H-5) ,  1.01 ( 6 H, 
s, H - l ) ,  1.50 (12H, m, 6 x H-y), 1.60 -  1.90 (24H, m, 6 x H-P & 6 x H-  
8 ), 2 .36  (4H, s, H-2) ,  2 .90  -  3.05 (12H, m, 5 x H-s) ,  3.03 (2H, d, J  7.0  
Hz, H-3) ,  3.53 -  3.56 (2H, m, H-s  [ ivD de] ) ,  3 .86 -  3.98 (3H, m, g ly  & H-  
a [ i v D d e ] ) ,  4 .34  (5H, m, H -a ) ,  7.92 (3H, br, NH),  8.23 (1H, br, NH),  
8.33 (1H, m, NH), 8 .37 (1H, m, NH).
13C NMR (CDCI3, 100.6 MHz): 8 22 .6 ,  22 .78 ,  22 .8 ,  23 .5 ,  23 .6 ,  23.7 ,
23.8 ,  23 .9 ,  27 .9 ,  28.3 ,  29 .8 ,  30.2 ,  30 .9 ,  32 .0 ,  32 .3 ,  32 .6 ,  38 .4 ,  40 .2 ,  40.4 ,
53.6 ,  54 .5 ,  107.89,  162.5,  162.9,  170.3 ,  172.9,  173.9,  173 .94,  174.0,
174.1,  174.4,  178.3,  200.0 .  Miss ing  multiple  13C signals  due to
overlapping.
3.5 .3  H ex a ly sy l  p ep t id e  d er iva t ives  co n ta in in g  ivD de  and Dde [36b]
Due to synthesis errors, some products contained both ivDde and Dde,  
synthesis and deprotection methods as above [36a]:
MS (ES+): m/z  = 337.2  (100 %, ( [M {D de}  + 2 H ] / 3 f ) ,  351.3 (65 %, 
( [ M ( iv D d e )  + 2 H J /3 )+), 505 .6  (46 %, ([M {D de}  + 2 H ] / 2 ) +), 526.6  (22  
%, ( [ M f iv D d e }  + 2 H ] / 2 ) +).
'H NMR (C D 3OD, 400 MHz): 8  0 .97  ( 6 H, d, J 5A 6.7 Hz, H.-5[ivDde]) ,
1.01 ( 6 H, s, H - l  [D de  & ivD de] ) ,  1.47 -  1.52 (12H, m, 6 x H-y),  1.68 -  
1.73 & 1.82 -  1.89 (24H, m, 6 x H-p & 6  x H -8 ), 2 .36  (4H, s, H-2 [D de  & 
i vD de] ) ,  2 .54  (3H, s, R - 3 [D d e J ) ,  2 .92  -  2 .98  (10H, m, 6 x H-s ),  3.03  
(2H, d, J 3,4 6 . 9 Hz, H -3 [ ivD de] ) ,  3.48 -  3.51 (2H, m, H-s ),  3.88 (2H, d, 
J  3.4 Hz, g ly),  3 .96 (1H, t, Ja,p 6.4 Hz, H - a ) ,  4 .30  -  4 .37  (5H, m, H -a ) .
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13C NMR ( C D 3 O D ,  100.6 MHz): 6 18.5,  22 .6 ,  23 .5 ,  23 .6 ,  23 .7 ,  23 .8 ,
27 .9 ,  28 .0 ,  28 .1 ,  28 .4 ,  29 .5 ,  31.1 ,  31 .9 ,  32 .3 ,  40 .2 ,  40 .4 ,  53 .4 ,  53.9,  71 .3 ,
108.7,  162.9 ,  163.2 ,  170.3,  173.9,  173 .94 ,  174.0 ,  174.1 ,  174.3 ,  175.5,
199.9.  Miss ing  multiple  13C signals due to overlapping.
3.5.4 Boc protected hexalysyl (ivDde)  peptide [37]
HO
NH
Group
HN
DdeBocHN
NH
Boc ivDde
'CH
Figure 3.2: Boc-protected hexalysyl (ivDde) peptide [37]
Hexalysyl  ( ivDde/Dde)  pept ide [36b] (230 mg, 230 pmol)  and anhydrous  
DMF (3 ml) were added to a flask and stirred. Di-J-butyl dicarbonate  
(262 pi, 233 mg, 1.07 mmol,  9 eq.) was d isso lved into anhydrous DMF  
(1 ml) and added drop-wise to the flask fo l lowed by anhydrous TEA (1 
ml). Stirring was continued overnight.  T.l .c.  showed the presence o f  a 
high proportion o f  product ( R f  0.8) and several other minor spots 
(1 .5:8.5  methanol -  CH2 CI2 ; R f  0.7,  0.3 and at the baseline was some  
starting material).  The solvent is removed in v a c u o , re-disso lved in 15 % 
MeOH / 85 % CH2 CI2 and purified by flash chromatography (4 cm,  
gradient, 100 % CH2 CI2 to 50 % MeOH / CH 2 CI2 , 5 % increase in MeOH  
every 100 ml).  Removal o f  the solvent in vacuo  gave the tit le compound  
as an orange oil  (323 mg, 202 pmol,  88 %).
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R f  0.6 [ 1:4  methanol -  CH2CI2; TFA pre-dipping then ninhydrin stain],  
compound [36b] at baseline.
MS (ES+): m/z  = 1631.8 (70 %, ([M {Dde}  + 1H  + N a ) +), 1673.8 (30 %, 
( [M f iv D d e }  + 1H  + N a ) +). Other peaks present with 2 x Dde & 2 x 
ivDde.
‘H NMR (C D 3OD, 400 MHz): 8 0.98  ( 6 H, d, J 5A 6.7 Hz, B - 5 [ iv D d e J ) ,
1.02 (6 H, s, H - l  [D de  & ivD de] ) ,  1.42 -  1.91 (90H, m, /-butyl,  6 x H-y, 6 
x H-p & 6 x H -8 ), 2 .36  (4H, s, H-2 [D d e  & ivDdeJ) ,  2.55  (3H, s, H- 
5[D de]) ,  2 .96  -  3 .04 (12H, m, 5 x H-s  & H-3 [ ivD d e ] ) ,  3.48 -  3.51 (2H,  
t, J e,y 6.7 Hz, H-s) ,  3.89 -  4.01 (2H, m, gly),  4 .07  (1H, m, H -a ) ,  4 .30  -  
4.40  (5H, m, H -a) .
13C NMR (C D 3OD, 100.6 MHz): 6 18.5,  22 .9 ,  23 .8 ,  24.2 ,  26 .0 ,  26 .7 ,
27 .7 ,  28 .1 ,  28.2 ,  28 .4 ,  28.5 ,  28 .6 ,  28 .9  (f-butyl) ,  29 .4 ,  30.5 ,  31.1 ,  31 .7 ,
32.5 ,  34 .7 ,  37.0,  41 .2 ,  53.4,  71.1,  79.7 ,  108.6,  158.3,  158.5,  162.9,
163.3,  164.8,  175.4,  199.8.  Missing multiple  13C signals  due to
overlapping.
3.5.5 Attempted coupling of hexalysyl (ivDde) peptide [36a] and 4- 
isothiocyanatophenyl  a -D-m annopyranoside  [11]
4-Isothiocyanatophenyl a -D-m annopyranoside  [11] (276 mg, 574 pmol,  
15 eq.) was d isso lved in anhydrous MeOH (2 ml), added to a round- 
bottomed flask containing anhydrous TEA (1 ml) and stirred. Hexalysyl  
( ivDde) peptide [36a] (40 mg, 38 pmol)  was d isso lved in anhydrous  
MeOH (3 ml) and s low ly  added to the flask and stirred continuously  
overnight.  The reaction was monitored by t . l .c.  (20 % MeOH / C H C I 3 )  
such that the product had an R f  0.45 (starting sugar R f  0.6,  hexalysyl  
[ivDde] peptide [36a] on baseline) and showed by UV and stained  
strongly by PMA but was not stained by ninhydrin. Purification by flash 
chromatography (4 cm, gradient, C H C I 3  to 30 % MeOH / C H C I 3 )  gave  
major fractions at 20 % MeOH / C H C I 3  and 30 % MeOH / C H C 13 . *H and
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13C NMR o f  both major products shows proton signals  similar to 
compound [1 1 ] (or a derivative),  however  no signals  for the hexalysyl  
( ivDde) compound [36a] were observed. This procedure was also  
attempted with the use o f  a 5:2 mix o f  MeOH:DCM (compound [11] is 
more soluble in DCM) but the desired product was not formed.
3.5.6 Coupling of  hexalysyl  (ivDde) peptide [36a] and 4-isothio-  
cyanatophenyl a -D-m annopyranoside  [11] to form compound
Figure 3.3: Hexalysyl (ivDde) peptide [38] coupled to 4-isothiocyanatophenyl a-D - 
mannopyranoside
4-Isothiocyanatophenyl a -D-m annopyranoside  [11] (452 mg, 940 pmol,  
10 eq.) and hexalysyl ( ivDde)  peptide [36a] (95 mg, 94 pmol) were  
added to a flask and dried in vacuo .  Anhydrous THF (20 ml) and 
anhydrous DCM (10 ml) were added to the flask and stirred. Compound 
[1 1 ] d isso lves  well  in this mixture,  however  the hexalysyl  compound  
[36a] is only  sparingly soluble.  Anhydrous MeOH (10 ml) was added 
s low ly  to the flask to ensure the so lubi l i ty  o f  compound [36] without  
causing the crystal l isat ion o f  the sugar compound [11]. The flask 
contents were stirred for 48 hours before the addition o f  anhydrous TEA  
(2 ml),  and stirred for another 24 hours.  The so lvent  was removed in 
vacuo  and the flask contents dis solved in MeOH to crysta ll i se  sugar [11].
[38]
OAc
NH
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The flask contents were filtered through Celite and the solvent removed  
in vacuo.  T.l .c.  o f  the filtrate (20 % MeOH / CHCI3) shows the presence  
o f  four main products with PMA staining at R f  0.8,  R f  0.7 (ninhydrin 
stain also),  R f  0.6 and R f  0.3 -  baseline.  Flash chromatography (3 cm 3, 
gradient) involved the loading o f  the sample onto a CHCI3 packed  
column, flushing through with CHCI3 (200 ml) and then a gradient o f  10 
% MeOH / CHCI3 to 35 % MeOH / CHC13 with 5 % increase in MeOH  
every 100 ml. At the end o f  the addition o f  35 % MeOH / CHCI3, any 
remaining sample was washed through with 50 % MeOH / CHCI3. The 
column fractions containing the crude product (R f  0.3 -  baseline) were  
pooled and the solvent removed in vacuo  to give 60 mg o f  a white  
powder. Attempts were made using various mass spectrometry methods  
(ES, MALDI-TOF, FAB),  and NMR, to analyse the product, however  
these proved inconclusive .
3.5.7 Coupling of  Boc protected hexalysyl  peptide and pepstatin  
cystamine [39]
r j
s— sr
HN— Pepstatin
HN
NH
HN
BocHN 'CH:
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Figure 3.4: Boc protected hexalysyl peptide and pepstatin cystamine [39]
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Boc protected hexalysy l  peptide [37] (56mg, 35 pmol) ,  NHS (40 mg, 350  
pmol ,  10 equiv.)  and EDCI (33.4  mg, 175 pmol ,  5 eq.) were added to a 
10 ml round-bottomed flask, d is so lved in anhydrous DMF (2 ml) and 
stirred continuously  for 32 hours. The solvent was removed under high  
vacuum and the solid re-disso lved in CH2CI2 20 ml). The organic layer  
was washed with 0 .04M HC1 solut ion (3 x 20 ml),  dried over magnes ium  
sulphate, filtered, and the solvent removed in vacuo  to obtain 85 mg o f  
the crude NHS ester. NMR did not g ive  any additional information so the 
product was used as is in the coupling stage and assumed to be pure and 
quantitative yield.
The crude product (16.9  mg, 9.9 pmol,  1.02 equiv.)  and pepstatin 
cystamine [30] (8 mg, 9.7 pmol) were added to a 10 ml round-bottomed  
flask, d isso lved in anhydrous DMF (1 ml) and stirred for two days. The 
solvent was removed in vacuo  and the crude product purified by  
preparative HPLC (10 % MeOH to 40 % MeOH in water over 30 mins).  
Four major products appeared with the largest at RT 36 -  39 min (HPLC 
run to 100% MeOH from 30 -  35 mins,  then held for 2 mins at 100% 
before a gradient back to 10 % MeOH over 5 mins).  The solvent from the 
product with RT 36 -  39 min was removed in vacuo  and then remaining  
water was removed from the particulate matter by lyophilisat ion to 
obtain the title product as a white  powder (14 mg, 5.8 pmol,  60 %).
R f  0.4 [1:4 methanol -  CH2CI2; TFA pre-dipping then ninhydrin stain].
MS (ES+): m/z = 478.7 (100 %, ([M{Dde} -  5Boc  + 10H )/4+), 494.3 (74 %, 
([M fivDde}  -  5Boc + 9H  + N a ) /4 +), 1055.5 (62 %, ([M{Dde} -  3Boc  + 
5 H ) /2 +). Other peaks present with 2 x Dde.
'H NMR (C D 3OD, 400 MHz): 8 0.86 -  1.01 (m),  1.27 -  1.82 (m),  2.04 -  
2.13 (m),  2.13 (d, J  6 .6  Hz), 2 .29  -  2 .36  (m),  2.45 (t, .7 6 . 8  Hz),  2.55 (s),  
2.79 -  2.85 (m),  2.95 -  3.03 (m), 3.43 -  3 .56  (m),  3 .60  -  3.63 (m), 3 .94  
-  4 .00  (m),  4 .09  -  4.15 (m),  4 .24  -  4 .26  (m),  4.93 (1H, s). Spectra 
assignment not possib le  due to broadness o f  spectrum.
141
Chapter 4
Chemical Synthesis Results and Discussion
The fo l lowing  chapter highlights in more detail some o f  the observations  
and conclus ions  o f  the synthetic work. The designs o f  the inhibitors were  
detailed in chapter 2 and shown in figures 2.7 and 2.8 (page 80),  with  
detailed chemical  structures o f  the final compounds shown in figure 2.14  
(page 87).
4.1 Synthesis of mannose derivatives
4.1.1 Formation of  per -0 -ace ty la ted  1 ,2 ,3 ,4 ,6-penta-O-acety l-a /^-D-  
mannopyranose [1 ]
Complete  acetylation o f  D-mannose211 was accomplished by reacting D-  
mannose with 5 equivalents o f  acetic anhydride and the use o f  TEA as 
both solvent and base.  The exis tence  o f  an anomeric mixture is not a 
problem for further synthetic steps because o f  the inf luence o f  the 
anomeric effect  and neighbouring group participation o f  the C-2 acetoxy  
group, which together help with the formation o f  the a-anomer at the C-l  
posit ion o f  mannose.
4.1.2 Synthesis of  tetra-acetyl  [2], acet imidate  [3] and bromo [4] 
mannopyranosides
The se lect ive  de-acetylation o f  the anomeric pos i t ion  o f  1 ,2 ,3 ,4 ,6 -penta-
0-acety l-a / /?-D-mannopyranose  [1] to form the 2,3,4 ,6-tetra-0-acety l-<z-  
D-mannopyranose [2] (sect ion 3 .1 .2)  has been performed by several  
methods 215>231. i n our hands hydrazine acetate in anhydrous D M F 4,212,213 
gave high yie lds  o f  a single  anomeric, crystall ine  product ( 7 7  % yie ld,  
99 % a-anomer)  (fig.  4.1).
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Figure 4.1: Synthesis of tetra-acetyl, bromo and acetimidate mannopyranosides
Formation o f  2 ,3 ,4,6-tetra-0-acetyl-<2-D-mannopyranosyl trichloro-  
acetimidate [3] from hemiacetal [2 ] is conventional ly  carried out with  
the use o f  trichloroacetonitrile in anhydrous DCM with base,  to give the 
a-anomer.  Potassium carbonate was chosen as an easi ly  available mild 
base,  g iv ing a quantitative y ie ld o f  a pure compound (fig. 4.1).  The 
formation o f  mannosyl bromides208,209 uses a mix o f  per-O-acetylated  
mannopyranose with acetic acid / hydrogen bromide at room temperature 
with complete  formation o f  product within several hours. This procedure  
was fo l lowed (fig- 4 .1 )  to give 2 ,3 ,4 ,6 - te tra -O -acety l -a -D -  
mannopyranosyl bromide [4] from the per-O-acetylated mannose [1] with 
a 97% yield.
4.1.3 Formation of  4-nitrophenyl  2 ,3 ,4 ,6-tetra-0-acety l- /?-D-manno-  
pyranose  [5] and 4-nitrophenyl  2 ,3 ,4 ,6 -tetra-O-acety l-a-D-  
mannopyranose [6 ]
2,3 ,4 ,6-Tetra-O-acety l- t f -D-mannopyranosyl bromide [4] was reacted  
with 4-nitrophenol and tetramethylguanidine as base (sect ion 3 .1 .5 ,  page  
95) g iv ing exc lu s ive ly  the P-anomer [5]. The formation o f  the p-anomer
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was verified by NOE to show correlations between the H - l ,  H-3 and H-5 
protons.  The formation o f  g lycos ide  [6] used BF3.Et20 (fig.  4 .2 )232,233. 
BF 3.Et2 0  was s low ly  added to a mixture o f  per-O-acetylated mannose  
and 4-nitrophenol at 0 °C in CH2CI2 to obtain a high yield o f  crystall ine  
product (89 %) after 24 hours. The suggested mechanism is shown in 
figure 4.2.  The NOE shown in appendix II confirms the formation o f  this 
product.  By addition o f  B F 3.Et20 to the P-anomer [5], it was poss ib le  to 
induced anomerisation to the more stable a-anomer [6].
Me
OAc OAc
0°C, CH2C1:
AcO AcO'
AcO AcO'
OAc
OAc N02
AcO
AcO
O.
[6] 89 %
N02
Figure 4.2: BF3.Et20  catalysed formation of glycoside [6]
4.1.4 Acetyl  deprotection of  4-nitrophenyl  2 ,3 ,4 ,6-tetra-O-acety l-a-  
D-mannopyranose [6 ]
4-Nitrophenyl or-D-mannopyranoside [9] was used in the synthesis o f  
MPC5 and MPC6. It is synthes ised from 4-nitrophenyl 2,3 ,4 ,6-tetra-O-  
acetyl-cu-D-mannopyranoside [6] by deacety la t ion using the addition o f  
LiOH (1M) to pH 11, for several hours (fig.  4 .3 ) 223.
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Figure 4.3: Formation of [9] by acetyl deprotection of [6]
4.1.5 Hydrogenation and formation of  isothiocyanate  derivatives  
from 4-nitrophenyl 2 ,3 ,4 ,6 - te tra-0 -ace ty l -a -D -m anno-  
pyranoside [6 ] and 4-nitrophenyl a -D-mannopyranoside  [9]
The activation o f  acetyl-protected mannopyranoside [6] and deprotected  
mannopyranoside derivative [9] (fig.  4.4) requires the conversion o f  the 
nitro group to an isothiocyanate group. Reduction o f  the
mannopyranosides [6 ] and [9] was by a routine atmospheric pressure 
hydrogenation at room temperature using 10 % Pd / C. Both reactions  
were complete  within 4 hours, with high yields  and easy purification by  
filtration through Celite.
The aromatic amines [7] and [10] were then treated with th iophosgene to 
convert them to the isothiocyanates  (fig.  4 .4 )201,234. Although not as 
poisonous  as the extremely dangerous phosgene, th iophosgene is toxic  
and requires careful handling (the exact precautions used are l isted in the 
experimental in section 3 .1 .9 ,  page 99).  The usual method o f  addition o f  
reagents is to add the amine s low ly  to a large excess  o f  thiophosgene .  
This would  reduce the poss ib le  reaction o f  i sothiocyanate  product with  
unreacted amine. This procedure was used in the formation o f  4-  
i sothiocyanatophenyl 2 ,3 ,4 ,6 - te tra -0 -ace ty l -a -D -m an nopyranos ide  [8],  
using THF as solvent.  However,  addition o f  th iophosgene  to amine [10] 
(but sti ll  with an excess  o f  th iophosgene)  in the synthes is  o f  4-
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isothiocyanatophenyl a-D-mannopyranoside [11] also resulted in a high  
yie ld  o f  product (97 %). The solvent was switched to EtOH / water as the 
solubil ity o f  compound [10] in THF was poor.
H2 over Pd / C
EtOH
H2 over Pd / C
EtOH
Figure 4.4: Formation of isothiocyanate derivatives [8] and [11]
4.2 Synthesis of benzyl 4-hydroxybutanoate and amine 
linkers
4.2.1 Benzyl  4 -hydroxybutanoate  [12]
HO'
O
For the derivatives MPC1 and MPC2, benzyl  4-hydroxybutanoate  spacer
[12] is used. Several methods for its synthes is  have been reported,
including the method published by T h a is r i vo n g s  et  a l  (a hydroboration -
oxidat ion o f  benzyl  3-butenoate)235, and To y o k u n i  a n d  H a k o m o r i  (ring
opening o f  1,4-butyrolactone by benzyl a lc o h o l )4,236, however the
procedure o f  Weber et al  was used here. The method in vo lves  the ring
opening o f  1,4-butyrolactone to form sodium 4-hydroxybutanoate,
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fo l lowed by a phase-transfer catalysed reaction with benzyl bromide  
using tetrabutylammonium bromide as a phase transfer catalyst.
4.2.2 TV-(f-Biityloxycarbonyl) propane-1 ,3-diamine [13] and N - ( t -
butyloxycarbonyl)  cystamine [14]
[13] [14]
di- /-Butyl dicarbonate227 was used in the m ono-Boc  protection o f  
propane-1,3-diamine and cystamine. This proceedure gave high yields  
with a simple purification that required a series o f  aqueous workups.  
After reaction, removal o f  organic solvents  in vacuo  and then the 
disso lv ing  o f  product [13] in s l ightly  acidic aqueous solution (pH 6.5)  
allowed for the complete removal o f  di-protected 1,3-diamino propane 
(as a solid by filtration). Making the aqueous solution more ionic and 
basic (with brine / bicarbonate solution) and extraction o f  organics with 
CHCI3 gives  exc lu s ive ly  the desired product.
A-(f-Butyloxycarbonyl)  cystamine [14] was prepared in much the same 
manner as above with the use o f  di- /-butyl dicarbonate with a few  
differences.  As cystamine is supplied as the dihydrochloride,  a base is 
needed (used sodium bicarbonate) to g ive  the free amine. Solubi li ty  was  
an issue,  and it was found that the best solvent mixture was a roughly  
equal mix o f  water and dioxane. It was essential  to stir the mixture 
vigorous ly  to avoid the production o f  mainly  di-protected Boc-  
cystamine, due to the improved so lubi l i ty  o f  A-(^-butyloxycarbonyl)  
cystamine [14] and di-Z-butyl dicarbonate within dioxane leading to d i ­
substitution o f  Boc towards cystamine. As compound [13], removal o f  
organic solvent and disso lv ing o f  the product [14] in s l ightly  acidic  
aqueous solut ion (pH 6.5) allowed for the removal o f  di -Boc-protected  
cystamine.
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4.3 The synthesis  of  MPC1 / MPC2 precursors
The synthesis o f  intermediates leading to MPC1 / MPC2 (structures 
shown in figure 2.14,  page 87) requires the formation o f  3 ’- 
benzyloxycarbonylpropyl 2 ,3 ,4 ,6 -tetra-O-acety l-a -D-m annopyranose  
[15] (fig.  4 .5),  removal o f  the benzyl  group and activation to an NHS  
ester (fig.  4 .6 ),  so that it may react with either A -^-buty loxycarbonyl)  
propane-1,3-diamine (as used in MPC1) or A-(J-butyloxycarbonyl)  
cystamine (as used in MPC2).
4.3.1 Formation of  3 ’-benzyloxycarbonylpropyl  2 ,3 ,4 ,6 - te tra -0 -  
acetyl-a-D-mannopyranoside  [15]
Initial attempts at the formation o f  the g lycoside  [15] used the 
tr ichloroacetimidate [3] with trimethylsilyl  triflate (TMSOTf) as a 
catalyst.  Multiple conditions were attempted, with the azeotropic  
removal o f  water, the addition o f  TM SOTf in different quantities (from 
0.05 to 1.25 eq, relative to the alcohol)  and reaction times (4 hours to 36 
hours),  however both yields  and purity o f  final product were poor. The 
highest y ie ld  obtained was ~ 30 %, however the purity was insuff ic ient  
as the multiple side products (up to six) could not be separated by flash 
chromatography. The reasons for the poor yie ld and multiple products  
are unclear, but side products derived from either the production o f  the 
acetoxonium intermediate or undesirable reactions o f  the triflate ion may  
be involved. This method (using TMSOTf) was used previously  where  
yie lds  were also low (24 %) which was thought to be due to the use o f  a
9 1 Asecondary alcohol
A second procedure was attempted using BF3.Et20 as a Lewis  acid under 
similar condit ions  as above with azeotropically  dried reagents,  CH2CI2 as 
solvent and 1 to 1.25 equiv.  o f  BF3.Et20 (equivalent to alcohol) .  This 
immediate ly  resulted in higher yie lds  o f  up to 55 % after flash 
chromatography. The proposed mechanism for this reaction is shown in
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figure 4.5.  NMR o f  the product [15] showed that the alkyl chain attached 
at anomeric centre is diastereotopic.  NOESY experiments (see appendix  
I) showed correlation between H-3 and H-5 and no correlation between  
H-5 and H - l ,  veri fying the presence o f  the a-anomer.
,OAc .cci3
Me
OAc
AcO- NH-
AcO'
AcO'
AcO-.CCI3
OR
NH
LA
,OAc
[15] 55 %
AcO'
AcO-
LA = Lewis acid, BF3
HOR = benzyl 4-hydroxybutanoate OR
Figure 4.5: BF3.Et20  catalysed formation of glycoside [15]
4.3.2 Mannose Spacer Linker conjugates of  MPC1 and MPC2
Cleavage o f  the benzyl group requires hydrogenation with a palladium 
catalyst.  This afforded an essentially  quantitative yie ld o f  carboxylic  
acid [16] (fig. 4.6) .  For the synthes is  o f  NHS ester [17], it is important  
to perform the aqueous workup as soon as possib le ,  and to dry the 
compound ef fect ively .  Long-term storage was not considered due to the 
compounds sensi t iv ity  to water,  so the intermediate was used as soon as 
possible .
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H2) Pd/C
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EDCI, NHS, CH2C1;
.OAc
[17] 107 %
(excess due to presence o f urea)
AcO'
AcO'
•O N
OAc
- 1-0
OAc
- 1-0
OAc
-l-Q
Figure 4.6: Formation of NHS ester [17]
The reaction o f  the NHS ester 3 ’-succinimidoxycarbonylpropyl 2,3 ,4 ,6-  
tetra-O-acetyl-o'-D-mannopyranoside [17] with the relevant amine (fig.  
4.7) required the mixing o f  NHS ester and amine in CH2CI2 under 
anhydrous conditions.  A few drops o f  TEA were added to ensure that the 
amine is deprotonated. The reaction was complete  after 4 hours.  
Purification required flash chromatography and yields were high (65 -  
82 %). The final step was the removal o f  the Boc  group (fig. 4.7).  
Although the removal o f  Boc  group with trifluoroacetic acid (TFA) is 
usually performed with the use o f  scavengers  (as for synthesis  o f  amines
[29] and [30]),  this was not used for the derivatives o f  MPC1 and MPC2  
due to purification diff icult ies  in the removal o f  the scavengers.  The free 
amines needed to be reacted with pepstatin -  NHS as soon as possib le  in 
order to avoid degradation. NMR spectra had poorly  resolved signals.
150
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OAc
AcO-
AcO-
[17]
nh2XVo
X = CH2, [13]
X = CH2 SSCH2> [14]•OAc
OAc
AcO-
AcO-
X = CH2, [18], 82%
X = CH2 SSCH2, [19], 6 6 %
.OAc
OAC
AcO-
AcO-
X = CH2, [201,100%
X = CH2 SSCH2, [21], 75%
‘NH3 CF3 COO'
Figure 4.7: Formation of TFA salt derivatives [20] and [21]
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4.4 Synthesis of MPC1, MPC2 and other pepstatin 
analogues
Given the expense o f  pepstatin and the l imited quantities available for 
use,  only  small -scale  reactions were feasible .  The insolubi l i ty  o f  
pepstatin in most so lvents  was an advantage with respect to purification.  
The most useful  analysis for the determination o f  products and reaction  
completion was mass spectroscopy,  in particular electrospray mass  
spectroscopy (ES MS), which always gave pos i t ive  results for product  
ions. NMR was not always useful until final purification o f  known  
products was achieved, due to the d if ficulty  o f  interpreting the data. In 
some situations, the insolubi lity  o f  pepstatin analogues made obtaining  
NMR data difficult .  Some pepstatin derivatives were also difficult  to 
visuali se  by t .l .c. ,  making the progress o f  reactions difficult  to fo llow.
4.4.1 Pepstatin -  NHS
The free carboxyl ic  acid o f  pepstatin may be activated by NHS ester 
formation (fig. 4.8) .  Reaction o f  EDCI, NHS and pepstatin in anhydrous,  
disti l led DMF and vigorous  stirring overnight gave high yields o f  
pepstatin -  NHS. A white suspens ion o f  insoluble pepstatin is present at 
the beginning o f  the reaction but d isso lves  over 4 hours. It was not 
poss ib le  to distinguish pepstatin from product by t .l .c. ,  so at least 16 
hours was allowed for the reaction. The most successfu l purification o f  
compound [22] was to remove o f  the DMF in high vacuo  fo l lowed by  
several washes  o f  the solid  with water (containing a few drops o f  0.1M  
HC1), a wash with ether and drying for 24 hours under vacuum over  
anhydrous phosphorus pentoxide.  The obtained product yie ld  o f  93 % is 
o f  mass recovery, as no indication o f  purity was poss ib le  by analytical  
methods.
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o,v_/V----- N
O— Pepstatin
EDCI, NHS, DMF
Pepstatin [22] 93 %
0
Figure 4.8: Formation of pepstatin NHS [22]
4.4.2 MPC1, MPC2 and their pepstatin precursors
The final four steps in the micro scale  (typically  between 20 -  40 mg)  
synthesis  o f  MPC1 or MPC2 required the coupling o f  pepstatin NHS [22] 
to A-(3 - (2 ,3 ,4 ,6 - te tra -0 -acety l -a -D -m annopyranosy loxy)propy lcarbonyl)  
^ ’-(trifluoroacetyl)  propane-1,3-diamine [20], or 7V-(3-(2,3 ,4,6-tetra-0-  
acety l-a-D-m annopyranosyloxy)propylcarbonyl) ,A’-(trifluoroacetyl)  
cystamine [21], followed by the removal o f  the acetyl groups on mannose to 
give fully deprotected mannose (fig. 4.9).
Coupling o f  pepstatin -  NHS [22] was performed by the combination o f  both 
NHS ester [22] and either o f  the amines [20] or [21] in DMF containing a 
large excess o f  TEA to liberate the free amine from the TFA salt. As 
mentioned above, freshly distilled DMF is needed for synthesis. Initial 
efforts to synthesise [23] and [24] gave lower yields than expected due to the 
presence o f  pepstatin dimethylamide. At least five equivalents o f  the amine 
derivatives [20] or [21] compared to pepstatin NHS [22] were used. 
Purification by reverse-phase preparative HPLC (gradient, 60 % MeOH / 
water to 95 % MeOH / water over 25 mins) allowed easy seperation o f  the 
products [23] and [24] from starting materials due to the significant 
differences in solubility and thus large differences in HPLC retention times.
The final step in the synthesis  o f  MPC1 and MPC2 involved the removal  
o f  the mannose acetyl protecting groups from [23] and [24] (fig. 4.9).  
The method chosen223 was the addition o f  LiOH solution  (1M) to pH 11 
and stirring for several hours. Puri fication by reverse-phase  preparative  
HPLC (gradient, 20 % MeCN / water to 60 % M eCN / water over 25
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mins) al lowed easy seperation o f  the more hydrophilic compounds MPC1 
[25] and MPC2 [26] from their precursors [23] and [24].
.OAc
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AcO
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X = CH2, [2 0 ]
X = CH2 SSCH2) [21]
‘ NH3  CF3 COO'
O— Pepstatin
[221
DMF, TEA
OAc
OAc
AcO'
AcO'
N
.Pepstatin X = CH2l [23] 45 %X = CH2 SSCH2, [24] 55 %
OH
OH
HO'
HO'
N
LiOH, pH 11 
MeOH
.Pepstatin X = CH2, MPC1 [25] 70 %X = CH2 SSCH2i MPC2 [26] 6 6  %
Figure 4.9: Formation of MPC1 and its precursor
4.4.3 Mass Spectroscopy / NMR assignment of  pepstatin analogues
MPC1 precursor [23] has complete  NMR assignments based on !H and 
13C NMR, DEPT135,  COSY and HSQC NM R experiments,  as shown in 
appendices III -  VII, respectively .  MPC1 and MPC2 (fig. 2 .14 ,  page 87),  
and the two immediate precursors,  are the most complex  and largest  
pepstatin analogues upon which reasonable NM R assignment is possible .  
It was essential  to ensure that NMR assignment was poss ib le  for these  
analogues and that these assignments were  consistent with other
154
pepstatin analogues,  and as such the NMR numerical assignment o f  the 
carbon and proton nuclei  within the pepstatin molecu le  fo l low  that o f  the 
largest pepstatin derivative molecule ,  that being the acetyl-mannoside  
derivative [26].
4.4.4 Pepstatin -  l inker conjugates
Af-(7-Butyloxycarbonyl),N’-(pepstatinyl) propane-1,3-diamine [27] and N-(t-  
butyloxycarbonyl), Y ’-(pepstatinyl) cystamine [28] were both synthesised by 
the coupling o f  the respective amine derivatives [13] and [14] with pepstatin 
-  NHS (fig. 4.10). Removal o f  the Boc  group with TFA in the presence o f  
scavengers  (fig. 4.10) was fo llowed by t . l .c. ,  the reactions were complete  
in 4 hours. Solubi li ty  in MeOH or MeCN was sufficient  to allow  
preparative reverse-phase HPLC purification o f  Af-(pepstatinyl) propane-  
1,3-diamine [29] (50 % MeOH / water to 100 % MeOH over 25 mins) and 
iV-(Pepstatinyl) cystamine [30] (40 % MeCN / water to 80 % MeCN over  
30 mins) to obtain pure, high yie lding compounds (60 -  90%).
The final step to synthes ise  N -( iodoacety l ) ,N ’-(pepstatinyl)  propane-1,3-  
diamine [31] and A-(iodoacety l) ,A/r,-(pepstatinyl)  cystamine [32] was  
effected by the addition o f  iodoacetic  anhydride to the respective free 
amines (fig. 4.10).  Reactions  were fast (as measured by t . l .c. ,  visualised  
by ninhydrin stain) and 2 hours was suff icient time for the reaction.  
Initial purification was by an aqueous wash with KI solution included (to 
stop the poss ib i l i ty  o f  iodine  exchange with other halogens),  however in 
one instance purification was attempted with washing in ethyl acetate  
alone. This method appeared to both crysta ll i se  the product more 
e f fect ive ly  and improve the purity, as shown by improved NMR data. 
Yie lds  were in the 50 - 83% range.
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Figure 4.10: Formation of iodoacetamides [31] and [32]
4.5 BSA -  conjugate, MPC5 and MPC6
The use o f  the carrier Bovine  Serum Albumin (BSA) in MPC5 [34] and 
MPC6 [35] meant a different approach was needed for synthesis,  
aqueous reaction condit ions  were n eed ed 185.
4.5.1 BSA -  m annose  con ju g a te  [33]
4-Isothiocyanatophenyl  o'-D-mannopyranoside [11] was coupled to BSA  
in 0 .15M NaCl to give [33] (fig.  4 . 1 1)201. B S A  contains a total o f  59
i q r  #
lys ine s-amine groups , and it was anticipated from previous  mannose  
receptor binding studies that conjugation o f  at least 10 mannose units 
would  allow for significant binding to the mannose  receptor to allow  
uptake by the receptor2,237. Dialys is  and further purif ication with the use  
o f  centrifugal filtration devices  (with 12,000 molecular  weight  cut-off)
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was considered sufficient  to remove free mannosyl derivatives  and salts.  
Analys is  was primarily by the use o f  matrix-assisted laser desorption 
t im e-of-f l ight  mass spectroscopy (MALDI-TOF MS),  which showed that 
approximately 23 mannosyl units were attached to each B SA  (sect ion  
6.3 .1 ,  page 203 and appendix VIII, page 258) .  B iochemical  analysis to 
assess the average number o f  free lys ine residues per B SA  m olecule ,  and 
the average number o f  attached sugar derivatives per B S A  molecule ,  
showed a good correlation with the MS data (section 6 .3 .1 ,  page 205).
4.5 .2  M PC 5 and M PC6 synthes is
Synthesis o f  MPC5 and MPC6 was achieved by the formation o f  a 
thioether bond between a cysteine sulfhydryl with either iodoacetamide  
derivatives o f  pepstatin propane-1,3-diamine [31] or o f  pepstatin 
cystamine [32] (fig. 4 .11).  1M PBS solution was used as the buffer, and 
a maximum o f  20 % DMF was used to solubil ise  the added
iodoacetamide derivatives and to not precipitate the protein (which  
precipitates at approximately 30 % DMF). Protein denaturing, i f  it 
occurs under these condit ions ,  was not considered a problem for the task 
o f  the protein being a carrier or as a delivery mechanism towards the 
mannose receptor. Vigorous  stirring was required to ensure adequate 
mixing o f  the reagents.  D ia lys is  and centrifugal filtration devices  were  
again used to remove free mannosyl derivatives and salts. Quoted yields  
(fig. 4 .11)  are o f  mass recovery. Determination o f  sulfhydryl content  
using E l lm an’s reagent238 with B S A  and compounds [33] -  [35] to assess  
the amount o f  conjugated pepstatin derivative to each BSA molecule  did 
not prove successful.  MALDI-TOF MS showed with MPC6 an increase in 
molecular weight  (measured at the top o f  the peak obtained) o f  at least 
1000 Mr (appendix IX). MS was not so successfu l  with MPC5, which  
showed little increase in peak Mr, but a total peak shift o f  between 500 -  
1000 Mr.
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Figure 4.11: Formation of MPC5 [34] and MPC6 [35]
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4.6 Attempted synthesis of hexalysyl derivatives MPC3 and 
MPC4
MPC3 and MPC4 are based on a hexalysyl backbone, with six mannosyl  
units attached to five  lys ine s-amino groups and one a -am ino  N-terminal  
lysine,  with another lysine containing an ivDde protecting group, the 
non-c leavable  (MPC3) or cleavable  (MPC4) inhibitor moiet ies  be ing  
attached to the C-terminus o f  the peptide (fig. 4 .12).
Pepstatin
HN
Pepstatin - Linker 
attachedAcO- X = CH2 , MPC3 derivative 
X = CH2 SSCH 2 , MPC4 derivative
Ac0‘
AcO-
HN
NH
HN
NH
OAc
, 1-0
Figure 4.12: Structure of MPC3 / M PC4 inhibitors 
4.6.1 Pept ide  synthes is
The initial strategy was to synthes ise  a hexalysy l  carrier on a peptide  
synthesiser,  H -(L y s (B o c ) )5L ys( ivD de)-G ly-O H .  Cleavage from the resin 
and removal o f  the attached Boc groups w ould  thus give a linear peptide  
containing six free amine groups to which  it would  be poss ib le  to attach 
the mannosyl units. Cleavage from the resin and removal o f  the Boc  
groups was done in one step in the presence o f  TFA plus scavengers.  
Vigorous  stirring for 4 hours was suff ic ient to remove the peptide from
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the resin and deprotection o f  the Boc groups.  For all peptides,  removal 
o f  all solvent,  precipitation with ether, and purification by preparative 
HPLC gave the required peptide as a crystall ine white solid.
The experimental procedures in sect ion 3.5 (page 133) give examples  o f  
the peptides upon which the most accurate analytical data was obtained  
at that time. These peptides (the free amino hexalysyl  [36a] and [36b] 
and the fully Boc-protected hexalysyl [37]) were those chosen for 
subsequent steps in the synthesis.  [36a] and [37] were peptides  with  
mixed Dde / ivDde protecting groups, v is ib le  by NMR. In general,  
analysis to show the presence o f  products was diff icult  due to the s ize  o f  
compounds. NMR peaks were often very broad, a llowing only a tentative  
assignment.  Equally,  ES MS was often insuffic ient due to the size  o f  
ions being too large for the detectors. Only mult iply charged ions (i.e.  
from peptides containing free amino groups) gave obvious  ion traces.
It was noted later on that derivatives containing the Dde group with free 
lys ine e-amino groups allowed migration o f  the Dde group to occur239. 
As such, some compounds were made with two protecting groups 
attached with an extra Dde being attached to any o f  the free s-amino  
groups. This served to complicate  the analysis o f  product formation.
4.6.2 Coupling of  mannosyl units to hexalysyl peptide
The coupling o f  the isothiocyanatophenyl derivatives [11] to the 
hexalysyl peptide [36a] (i .e.  that with free lys ine amino groups) was  
attempted several t imes,  ini tial ly  with no success.  It became clear that 
initial problems were solubi li ty  issues .  The mannosyl derivative [11] is 
readily soluble  in CH2CI2, but crysta ll i sed in MeOH. The reverse was  
seen with the peptide. Inclusion o f  THF to a mixture o f  the two solvents  
increased the solubi lity o f  both reagents,  and the reaction proceeded,  
although yields  were low. An alternative solvent such as DMF might
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have proved more successful.  Figure 4.13 shows the structure o f  the 
product [38].
OAc
OAc
-l-Q HOAcO
AcO'
NH
HN
NH
Figure 4.13: Structure of [38]
Two problems existed. Firstly,  the large size and complexity  o f  the 
product made it imposs ib le  to accurately assign the NMR chemical  
shifts, due to s ignificant broadening o f  the spectral peaks. In addition,  
ES MS was unable to observe an ion trace as the size  was too large, and 
no suff ic ient ly  ionisable  groups were present to allow mult iply charged 
ions. At the time, confirmation o f  the presence o f  product was only  
poss ib le  with the rough assignment o f  chemical shifts characteristic to 
each half  o f  the reaction (i .e. observable  proton signals for the lys ine  
CH2 protons, and observable  benzyl signals).  Attempts were made to 
couple this with pepstatin derivatives,  however the dif ficulty in 
observing product formation and the l ikelihood that product formation  
may be difficult  (no evidence showed coupling o f  pepstatin derivatives  
to the mannosyl -  peptide [38]) due to steric interactions,  suggested that 
an alternative approach for the synthesis  o f  MPC3 / MPC4 would be 
desirable.
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4.6.3 Coupling of  pepstatin cystamine derivative [30] to hexalysyl  
peptide [37]
Given the problems with synthesis  caused by attaching the mannosyl  
derivatives first, a different approach, coupling pepstatin -  linker 
derivatives to Boc protected hexalysyl peptide [37] was sought.  The first 
step was the coupling o f  pepstatin cystamine [30] to form compound [39] 
(fig. 4.14) .
The NHS ester o f  the hexalysyl peptide [37] was formed by reaction with  
o f  EDCI and NHS for 32 hours. An aqueous workup (which was mildly  
acidic to reduce the chance o f  hydrolysis )  was used. NMR o f  the crude 
NHS ester was ambiguous,  so the intermediate was used directly.  A 
slight excess  o f  pepstatin cystamine [30] was added (DMF solvent) and 
the reaction stirred for 2 days.  Purification gave a major product (60 % 
yield).  Initially due to a lack o f  an MS ion, (even for MS samples treated 
with TFA to remove the Boc  groups) it was felt that the isolated product  
was a mixture o f  starting materials.  However,  a more careful  
examination o f  the ES MS spectra (once considering the mixed Dde / 
ivDde situation) shows that the product may have actually been present.  
NMR signals were poorly  resolved,  but like mannosyl -  peptide [38], 
there were characteristic peaks o f  each o f  the coupled halves  o f  the 
product [39].
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H-(l_ys(Boc)5) Lys{ivDde/Dde) Gly-OH 
[37]
NHS / EDCI 
DMF
▼ [30]
H-(Lys(Boc)5) Lys(ivDde/Dde) Gly-NHS + h2N S Pepstatin
Figure 4.14: Attempted coupling of pepstatin - cystamine [30] to Boc-hexalysyl derivative [37]
Other attempts at coupling pepstatin -  linker derivatives to carrier 
peptides (pepstatin propane-1,3-diamine [29] and pepstatin cystamine
[30]) were unsuccessfu l for several o f  the previously  ment ioned  
dif ficult ies .  With l imited time and resources available it was not 
poss ib le  to complete  the synthes is  o f  MPC3 and MPC4, however,  several  
factors became apparent from the attempts in synthesis  o f  these  
compounds that will  become useful in future attempts.
o
H-(Lys(Boc)5 )Lys(ivDde/Dde) Gly'
[39] A N
H
S
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Chapter 5
Methods for Biological Study
5.1 Tissue culture media and buffers
All cell s  were incubated at 37 °C, 5% CO2 unless stated otherwise.
Complete RPMI 1640 medium
RPMI 1640 with L-Glutamine (Gibco, Pais ley,  UK)
10% Fetal Calf Serum (FCS; PAA Laboratories, Linz,  Austria)  
lOOU/ml Penici l l in ,  100pg/ml Streptomycin (both from Clare Hall  
Laboratories, ICRF, London, UK)
50pM 2-Mercaptoethanol (2-ME; Gibco)
Complete E4 medium
E4 low bicarbonate (ICRF)
5% FCS, 1% L-Glutamine (2mM, ICRF), 50pM 2-ME  
lOOU/ml Penici l l in ,  lOOpg/ml Streptomycin
Complete Iscove’s medium
I s c o v e ’s Modif ied D u lb e c c o ’s Medium (Gibco)
10% FCS, 1% L-Glutamine, 50pM 2-ME  
lOOU/ml Penici l l in ,  lOOpg/ml Streptomycin
MEM
Modif ied Eagle Medium with HEPES (ICRF) and 2% FCS
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Hanks buffered saline solution (HESS) staining buffer
HBSS (Gibco),  10% rabbit serum
0.1% sodium azide (Sigma-Aldrich, Poole ,  UK)
IL-2 ELISA wash buffer
9.0g  NaCl,  1ml Tween 20 (S igma-Aldrich) ,  H2O to 1L, pH 7.4  
IL-2 ELISA diluent  buffer
PBS, 0.5% BSA (w/v; Sigma-Aldrich) ,  0.1% Tween 20, pH 7.4  
5 x TEE buffer (per 400ml)
2 1 .6g Tris base,  11 g boric acid, 40ml 0.1M EDTA (all from Sigma-  
Aldrich)
5.2 Cells and tissue culture 
A20 cell line
A20 is a murine B-cel l  lymphoma-derived cel l  l ine expressing I -Ad and
I-Ed MHC class-II.  A20 has been shown to express both cathepsin E (CE)  
and cathepsin D (CD), approximately 80% o f  the aspartic proteinase  
activity  can be attributed to CE112. Cel ls  were cultured in complete  E4 
medium. Cells were passaged every 2-3 days and maintained at a density  
o f  between 2 x 105/ml and 5 x 105 ce ll s /m l.
DO11-10
D O 11-10  is a T-cel l  hybridoma with I -A d class  II restriction and with 
spec if ic i ty  for the dominant epitope from chicken egg OVA (p323-p339) .  
Cells were cultured in complete  E4 medium. Cells  were passaged every
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2-3 days and maintained at a dens ity  o f  be tween 2 x 105/ml and 5 x 
105cel l s /m l .
C T LL -2
CTLL-2 (a kind gift  from Dr. B. Stockinger,  NIMR, London, UK) is an 
IL-2-dependent CTL-derived human T-cel l  l ine.  Cel ls  were cultured in 
complete  RPMI 1640 medium without  PS and grown in flasks upright to 
maxim ise  ce l l -ce l l  contact.  Cell  were maintained at a dens ity  o f  1 x 104 
ce l l s /m l  and passaged every 3-4 days or when dens ity  reached 5 x 105 
cell s /m l.
X63
X63 (a kind gift  from Dr. B. Stockinger,  London),  is a murine myeloma  
cell  l ine cont inually  secreting murine GM-CSF from an episomal  vector  
carrying the neomycin  resistance gene. Cells were cultured in complete  
I s c o v e ’s medium and passaged every 3-4  days. X63 were cultured with 
lm g /m l  G418 Sulphate (Gibco) to prevent loss  o f  vector.  To obtain 
medium containing granulocyte-macrophage colony-st imulat ing  factor 
(GM-CSF),  ce l l s  were washed three times in culture medium to remove  
traces o f  G418, and then cultured at 3 x 105 ce l l s /m l  for 24-36  hours.  
The supernatant (s/n) was frozen for long-term storage. For DC cultures,  
10% o f  the s/n was added to the culture medium.
FSDC
FSDC, a kind gift  from Dr. P. Cast ig lioni (Milan) ,  is a transformed  
immature DC cel l  line. Cel ls  were cultured in I s c o v e ’s complete  medium  
and passaged at 3-4 day intervals by vigorous  agitation or mild  
trypsinisation with 0.25% trypsin in versene.
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Generation of  murine bone-marrow derived DC
DCs were grown from murine femur bone marrow from F4-F 8 mice
1_
generated by backcross ing cathepsin D + / -  heterozygotes  expressing I-A 
(a kind gift  from Dr. C. P ieters110) with Balb/c  mice  express ing I -A d. 
These mice  (named B 112  for conven ience)  were hom ozygous ,  
heterozygous  or wild  type for cathepsin D, with low express ion o f  I -Ak 
and high express ion o f  I -A d.
Murine femurs were removed and the bone marrow flushed out with  
MEM using a f ine-gauge  needle .  The red b lood cel l s  were removed by  
re-suspending ce l l s  in 3ml o f  red blood lys ing  buffer (Gibco) for three 
mins and washing three times in MEM. Cells  were cultured at 3-4 x 
105/ml (10ml per flask) in complete  I s c o v e ’s medium containing 10% 
GM-CSF s/n from X63 cel l  culture and 20mM HEPES. On day three, 8ml 
o f  the medium was removed ( s lo w ly  with flask at an angle to avoid  
removing DC clusters) ,  5ml o f  MEM added s lo w ly  and the cell s  washed  
by gentle  agitation. 5ml o f  the s/n containing non-adherent T-cel l s  were  
removed and 8ml o f  fresh complete  I s c o v e ’s medium (with GM-CSF and 
HEPES) added. On day five  the cell s  were removed by s l ight ly  v igorous  
pipetting and placed into fresh I s c o v e ’s complete  medium. The cell s  
were ready for use on day six or seven,  and were harvested by gentle  
pipetting to remove only  non-adherent or s l ight ly  adherent T-cel l s .  This  
cel l  populat ion is def ined as immature dendritic cell s .
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5.3 Antigen processing -  method of study
The majority o f  the b io log ica l  work presented is based upon a cellular  
antigen presentat ion assay. This assay studies the intracellular  
process ing  o f  antigen by aspartic proteinases.  The study o f  cathepsin E 
within the lympoblasto id  B -ce l l  l ine A 20  has been descr ibed previously .  
The majority  (approximate ly  80%) o f  the aspartic protease activity  
within A 20 ce l l s  is attributable to cathepsin E 112.
Figure 5.1 shows a diagrammatic representation o f  the antigen  
presentation assay. In brief,  OVA antigen is added to A20 cell s  that take 
up and then degrade the protein into short pept ides,  a proportion o f  
which are loaded onto class II MHC m olecules .  One o f  these  peptides ,  
the p323 pept ide (known to be produced by cathepsin E), is loaded onto  
the I -A d MHC class-II molecule .  The T-ce l l  hybridoma D O 11-10  
expresses  a T-cell  receptor that recognises  this p323 pept ide /I-Ad 
complex .  R ecogn it ion  stimulates  the production o f  the cytokine IL-2.  
The presence o f  proteolytic  inhibitors such as pepstatin leads to the 
inhibit ion o f  OVA process ing , and thus p323 pept ide production, leading  
to reduced IL-2 production. Secreted IL-2 in the cultures is measured  
either by ELISA or by 3H thymidine incorporation in the indicator  
CTLL-2 cytotox ic  T-cell  l ine (T-ce l ls  that rapidly proliferate in the 
presence o f  IL-2).
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by IL-2 production
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inhibitor CTLL-2
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Figure 5.1: Schematic of antigen presentation assay used to measure cellular aspartic proteinase 
activity
A representative example showing OVA and p323 titrations using this 
standard assay is shown in figure 5.2.  The minimum concentration o f  
ovalbumin protein required to provide a suff ic ient quantity o f  processed  
antigen for MHC-II presentation is 0.5 mg/ml (approximately 10 pM).  
The amount o f  p323 peptide required however is s ignif icantly  lower than 
that for OVA protein (less  than 0.1(ig/ml ,  O.lpM),  presumably because  
p323 peptide does not need uptake or processing, but can bind directly to 
the pept ide-binding site o f  the MHC class-II  molecule .  Subsequent  
sections o f  this chapter describe the methods outlined above.
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Figure 5.2: Response of DO11-10 cells to a) OVA and b) p323 peptide, presented by A20 B-cells. 
DO11-10 hybridoma T-cells (105) and A20 lymphoblastoid B-cells (105) were co-cultured together in 
the presence of a range of antigen concentrations for 24 hours and IL-2 release was measured by 
CTLL assay. Results are expressed as the mean 3H-thymidine incorporation from triplicate 
cultures and are representative of four separate experiments. Graph a) shows the IL-2 standard 
curve
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5.4 OVA and p323 peptide presentation assay
In order to determine the capacity  o f  the APC used throughout the 
fo l low in g  studies to present processed w ho le  antigen or synthetic  
ant igenic  peptides,  IL-2 production was determined fo l low ing  the c o ­
culture o f  murine DCs or A20, with D O 1 1 -1 0  ce l l s  in the presence o f  
OVA or p323 peptide.  All  cell s  were washed in MEM before use.  A20 or 
D O 1 1 -1 0  ce l l s  were added at a concentration o f  5 x 104 ce l l s /w e l l  in 
50pl.  DCs were used at 2.5 x 104 ce l l s /w e l l  in 50pl.  Antigen (ag) was  
included in a volum e o f  50pl ,  inhibitor so lutions in 50pl ,  g iv ing  a total  
volum e o f  2 00p l  for each assay. I f  A20 ce l l s  were  used then complete  E4 
medium was used for all assay components .  I f  DCs were used then 
complete  RPMI 1640 medium was used as the medium.
All  assays were performed in sterile,  96 wel l ,  flat bottomed tissue  
culture plates,  and each condit ion was repeated in triplicate wel ls .  In 
assays where the cell  number was constant, either a range o f  ag doses  or 
inhibitor concentrations  were tested. OVA was d is so lved  in medium  
imm ediate ly  before use to g ive  a stock concentration o f  20mg/m l,  diluted  
further in medium to g ive  the concentration required. OVA-pept ide  was  
disso lved  in H2O to g ive  a stock concentration o f  lm g /m l ,  and diluted in 
medium to g ive  the concentration required. Inhibitor and inhibitor  
control solutions were used at varied concentrations  from 216pM  with  
threefold serial dilutions down to 800nM, or constant at several  
concentrat ions  within this range. Inhibitors were added to D O 1 1 -1 0  & 
APC 30 mins prior to adding OVA or p323 peptide.
Triplicate  w e l l s  containing only APC and D O 1 1 -1 0  but no ag were  
included as a negat ive  control in order to determine the ‘background’ IL- 
2 leve l s ,  and included on all appropriate graphs as the ‘Cells  o n l y ’ 
control.  APC, D O 11-10  & Ag, in the absence o f  inhibitor,  defined the
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pos it ive  control o f  maximum IL-2 production, and included on 
appropriate graphs as ‘p 3 2 3 ’ or ‘O V A ’ control.  For inhibitors that 
included DMSO, a control o f  just DMSO only  was used to assess  the 
effect  o f  DMSO on the assay. For MPC5 and MPC6,  B S A  -  conjugate  
[33] was used as the control (see  sections  3 .4 .12 ,  page 130 and 4 .5 .1 ,  
page 156, for B S A  -  conjugate [33] descript ion).
Cells ,  Ag  and inhibitor were co-cultured for 24 hours at 37°C in 5% CO2. 
Cells  were brie f ly  centrifuged, and 5 0 pil o f  s/n from each wel l  was  
removed and transferred to a new sterile, round-bottomed, 96 wel l  t issue  
culture plate and stored at -2 0 °C  until use. A ssay  plates containing cel ls  
and extra s/n were also frozen and stored, a l lowing the IL-2 
measurements  to be repeated i f  necessary.
I f  a tox ic i ty  assay was performed then lOOjal o f  the cell s  and supernatant  
were kept (thus lOOpl removed from assay plate for IL-2 measurements)  
and used as for the procedure in section  5.7.
5.5 MPC inhibitor concentrations and controls
Pepstatin A (BaChem, Meyerside,  UK), DMSO (S igma-Aldrich)  and all 
synthes ised inhibitors (refer to chapter 3 for chemistry experimental  
procedures)  were stored lyophil ised , but stock concentrations  were  
prepared in different solutions.  Pepstatin A was  stored frozen at - 2 0  °C 
within DM SO, and diluted into dis ti l led H20  for use. Stock solutions o f  
MPC1 and MPC2 were made up with a small  amount o f  DMSO (as % 
required for experiment) before addition o f  dis ti l led H20 .  MPC5 and 
MPC6 were  d is so lved  in dist i l led H20 .  Table 5.1 shows the MW and 
calculated stock concentration o f  inhibitors used within assays.
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Inhibitor MW Stock
concentration
Pepstatin 6 8 6 V75 o f  16 .2mg/m l  
= 216pM
MPC1 990 0 .64m g/m l  
= 2 16pM
MPC2 1068 0 .69m g/m l  
= 216 |liM
MPC5 - 7 5 , 0 0 0 16.2mg/m l  
= 72pM
MPC6 - 7 5 , 0 0 0 16.2mg/m l  
= 72pM
BSA -  
conjugate [33]
- 7 4 , 0 0 0 16.2mg/m l  
= 72pM
Table 5.1: Inhibitor stock concentrations as used for assays
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5.6 Q uantif icat ion  of  IL-2 release with  CTLL-2
In order to remove any exogenous  IL-2, CTLL-2 ce l l s  were washed three 
times in MEM, rested at 37°C in full medium for 90 mins and washed a 
further two times.  50pl o f  comple te  medium containing 5 x 103 CTLL-2  
cell s  were then added to each 50pl o f  supernatant from OVA / OVA-  
peptide presentation assay (see section 5.3).  To quantify the amount o f  
IL-2 produced within a presentation assay, a series o f  three-fold  
dilutions o f  IL-2 standard (from 2 .5ng/m l)  were included, again at 
50p l /w e l l .  The assay was incubated at 37°C in 5% CO2 for 24 hours.  
Cells  were then incubated for a further 16 hours in the presence o f  3.7 x 
10'2 MBq 3H-thymidine /wel l .  Cel ls  were then harvested and thymidine  
incorporation determined using the LKB Wallac-Rack beta liquid  
scinti l lat ion counter.
In some assays  CTLL-2 proliferation / v iabi l i ty  was measured using the 
MTT assay, rather than 3H thymidine incorporation. 20p l  per wel l  o f  
MTT (5m g/ml,  S igma-Aldrich) was added to cell  cultures for the last 4 
hours o f  28 hours culture. Viable  cell s  reduce the ye l low  MTT to a dark 
blue formazan. Cel ls  were lysed by the addition o f  lOOpl o f  10% 
S D S /0 .01M  HC1 and incubated at 37°C overnight.  The opt ical density  
( O D )  at 570nm ( O D 5 7 0 - 6 3 0 )  was determined using a Dynax M R X Tc 
Revela t ion plate reader (Middlesex ,  UK).
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5.7 Q uantif icat ion  of  IL-2 re lease  with  IL-2 ELISA
96-w e l l ,  Maxisorp,  Nunc-Immuno plates (Merch Eurolab, Lutterworth,  
UK) were prepared by coating 100 p l /w e l l  o f  mouse  IL-2 capture 
ant ibody (0 .5m g/m l,  eB iosc ien ce ,  London, UK) diluted 1/400 with PBS,  
pH 7.4. ELISA plates were covered with c ling fi lm and kept overnight  
for 12-18 hours at 2-8°C. The plates were washed three times with wash  
buffer and 3 0 0 p l /w e l l  o f  diluent buffer was  added for two hours at room 
temperature.  If  the plates were not used imm ediate ly  then they were  
stored for up to five  days at 4°C. The plates were washed three times  
with wash buffer and 50pl  o f  supernatant (or diluted supernatant) from 
OVA / OVA-pept ide  presentation assay (sect ion  5.3,  page 168) was  
added per wel l .  Only duplicates o f  each condit ion o f  presentation assay  
were done. For negative  control w e l l s  ( i .e.  ce l l s  only,  medium only) 50pl  
o f  supernatant was added per well .  For w e l ls  containing OVA / OVA -  
peptide then 50pl o f  two dilutions o f  1/4 and 1/10 o f  supernatant in 
diluent buffer were used. A series o f  three-fold  dilutions were also 
included o f  IL-2 from ln g /m l .  ELISA Plates were incubated at 37°C for 
1Vi hours.
The plates were washed three times  with wash buffer and lOOpl/well  o f  a 
biot inylated anti-murine IL-2 ant ibody (0 .5m g/ml;  eB io sc ien ce )  diluted  
1/2 ,000 to 250ng/m l in diluent buffer was added and incubated at 37°C 
for 1 hour. The plates were then washed four times with wash buffer and 
1 00p l /w e l l  o f  streptavadin-horse radish peroxidase  ( lm g /m l ,  
eB io sc ien ce )  diluted 1 /13 ,3000  to 75ng/m l in diluent buffer was  added  
and incubated at 37°C for 45 minutes.  Plates were washed three times in 
wash buffer  and then lOOpl/well  o f  TMB solution (Pharmingen, San 
D iego ,  U S A )  was  added. After 10-15 mins was  added lOOpl/well  o f  1.8N  
H 2 S O 4  to stop development o f  the blue colour. The OD was read at 
450nm using  a Dynax M R Xtc  Revelation plate reader.
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5.8 M easurem ent  of  cell v iab il i ty  w ith in  presentat ion  assay
To determine the tox ic i ty  o f  reagents included in the OVA / OVA-  
pept ide presentation assay (sect ion 5.3,  page 168) cel l  v iabi l i ty  by MTT 
assay was used. 20p l  per wel l  o f  MTT (5m g/m l)  was added to cell  
cultures for 4 hours after 24 hours o f  co-culture.  Cel ls  were lysed by the 
addition o f  lOOpl o f  10% S D S /0 .01M  HC1 and incubated at 37°C  
overnight .  The OD was determined at 570nm (O D 5 7 0 -6 3 0 ) using a Dynax  
M R X t c  Revelat ion  plate reader.
5.9 Measurement of cell viability of CTLL-2 cells
In order to remove any exogenous  IL-2 prior to inclusion in any assay,  
CTLL-2 were washed three times in MEM, rested at 37°C in complete  
RPMI 1640 medium for 90 mins and washed a further two times and 
suspended in complete  RPMI 1640 medium at 105/ml.  lOOpl/well  o f  cell  
suspension was then added to a sterile, 96 w e l l  flat bottomed plate,  to 
which was  added 50pl o f  50 Units/ml IL-2. 50pl o f  inhibitor and 
inhibitor control solut ions were used at varied concentrations from 
216pM  with threefold serial dilutions down to 8pM. In all cases,  the 
e ffec t ive  concentration o f  inhibitors was a quarter on addition to the 
other 150pl o f  assay. Triplicate we l l s  conta in ing CTLL-2 with or without  
IL-2, but no inhibitor,  were included as controls.  Cell  v iabi l i ty  was  
measured by us ing a standard MTT assay as described in section 5.6.
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5.10 D eterm inat ion  o f  ce l lu lar  endocytos is
FSDC or murine bone marrow-derived DC cel l s  were washed in MEM  
before  use. Cell s  were suspended in complete  RPMI 1640 medium at 1 x 
106 ce l l s /m l .  5 0 p l /w e l l  o f  cel l  suspension was added to sterile,  96 well  
round bottomed plates.  For assays with B S A  -  conjugate or MPC5/6  
addition, ce l l s  were pelleted and re-suspended in inhibitor solut ion in 
comple te  RPMI 1640 medium and pre- incubated for 15 mins at 37°C, 5% 
CO2 . For assays  with cytochalasin  D (S igma-Aldrich) ,  cell s  were
pelleted and re-suspended in the appropriate cytochalas in  D 
concentration in complete  RPMI 1640 medium and pre-incubated for 30 
mins at 37°C, 5% CO2. 5 0 p l /w e l l  o f  the y e l lo w  dyes f luoresce in-dextran  
(FITC-DX; Sigma-Aldrich)  or Lucifer Y e l lo w  (LY; Sigma-Aldrich) were  
added either at the fixed concentration o f  2m g/m l or a three-fo ld dilution  
over a range o f  concentrations from 6mg/m l (3mg/ml in assay) and 
incubated at 37°C, 5% CO2 for 1 hour. Background uptake was assessed  
by incubation o f  cell s  with dye at 4°C for 30 mins on ice.  Uptake o f  all
dyes was stopped by adding lOOpl/well  o f  cold PBS,  1% FCS, 0.1%
azide. Cells  were washed three times in cold PBS,  1% FCS, 0.1% azide  
and then re-suspended in cold PBS,  1% FCS, 0.1% azide, cell
f luorescence  was analysed by f low cytometry using a FACScan (Becton  
Dickinson,  Twickenham, UK).
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5.11 Flow cytom etric  analysis  o f  DC phenotype
Express ion o f  C D l l c ,  CD86, DEC-205  and MHC class-II ( I -A d/b) on 
murine DC was analysed by f low cytometry. Murine bone marrow-  
derived DCs were washed and re-suspended at 5 x l 0 5/ml in HBSS  
staining buffer for 15 mins.  Primary antibody was added for 30 mins.  
The cell s  were washed three times with staining buffer and incubated in 
FITC-conjugated rabbit anti-rat IgG antibody (1:50; DAKO A/S,  
Denmark) (or buffer only  i f  using a direct ly  conjugated primary  
antibody) and kept covered from light on ice for 30 mins.  The cell s  were  
washed three times with staining buffer and re-suspended in 150pl o f  
2.5% formaldehyde in PBS and analysed by f low  cytometry using a 
FACScan (Becton Dickinson) .
5.12 Inhibition of cathepsin D / E -  enzymatic studies
A f luorogenic  substrate for cathepsin D and cathepsin E has previously  
been described as part o f  a sensit ive  assay for the detection o f  these  
enzymes.  The substrate M O CAc-G ly-Lys-Pro-I le -Leu-Phe-Phe-Arg-Leu-  
L ys(D n p)y-N H 2 is des igned spec i f ica l ly  to be c leaved by both o f  these  
enzymes.  Under the supervision o f  Prof. T. Kageyama (Kyoto  University,  
Japan) this pept ide substrate was used in enzymatic  competi t ion assays  
to test the activ ity  o f  pepstatin A and the modif ied  MPC inhibitors127. 
Figure 5.3 shows in diagrammatic form how this assay works.
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Figure 5.3: Schematic representation of the enzymatic competition assay used for test of the effect 
of inhibitors on cathepsin E
In i t ia l  te s ts  used  a va r iab le  quan t i ty  o f  f lu o ro g en ic  subs t ra te  with  a f ixed 
q u a n t i ty  o f  enzym e  and inh ib i to r  to ob ta in  da ta  able  to fit into a 
L in e w e a v e r -B u rk  p lo t  (da ta  not shown) .  H o w ev e r ,  the da ta  from th is  
a ssay  w ere  h ig h ly  va r iab le  be tw een  d i f f e ren t  ex p e r im en t s .  An a l te rna t ive  
m e th o d  p ro p o se d  by D ixon  w h e reb y  the in h ib i to r  c o n ce n t ra t io n  is 
c h an g ed  and enzym e  and subs t ra te  c o n ce n t ra t io n s  kep t  co ns tan t  p roved  
m ore  s u c c e s s f u l240. U s ing  the  D ixon  m e th o d  it is p o ss ib le  to acqu ire  data  
tha t  fo l low s  the genera l  equa t ion  shown in f igure  5.4,  and from a g raph  
o f  % a c t iv a t i ty  vs. in h ib i to r  c o n ce n t ra t io n ,  ap p ro x im a te  in h ib i to r  I C 5 0  
va lues  are ob ta inab le .
Fm = maximum fluorescence
(i.e. max. substrate, no inhibitor)
% activation = F- ~  -x 100 C = fluorescence of maximum
Fm substrate concentration alone
Fs = fluorescence at
inhibitor concentration
Figure 5.4: Definition of % activation
Rat and  m o n k e y  C a th ep s in  D / E was a k ind  g if t  o f  Prof.  T. K a g ey a m a  
(K yo to  U n iv e r s i ty ,  Japan) .  S tocks  are s to red  in 0 .05M  sod ium  ace ta te  
b u f f e r ,  50% g lycero l ,  0 .25M  NaCl ,  at -2 0 °C .
"non-fluorescent"
f t  *
v -
peptide substrate
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To 0 .5ml eppendorf  tubes was added 80pl  o f  0 .1M sodium acetate buffer  
(pH 4 .0) .  To each tube was added 5pl o f  100pM (in H2O) o f  a 
fluorogenic  peptide  M OCA c-G ly-Lys-Pro-I le -Leu-P he-Phe-A rg-Leu-  
L ys(Dn p)y-N H 2 (stock ImM in H 2O, 5% DMSO; BAChem, Meyerside,  
UK) known to be c leaved by cathepsin D or E 127. To this was added 5pl  
o f  inhibitor solut ion at a series o f  tw o-fo ld  dilut ions from various  
concentration (dependent on the inhibitor used).  Samples were incubated  
at 37°C for several minutes in a water bath. 10pl o f  enzyme solution  
(0 .01M  sodium acetate buffer, pH 5.5) at 0 .5p g /m l  was added to each  
sample,  and the reaction was a llowed to continue at 37°C for 30 mins  
before adding 2 00p l  o f  5% trichloroacet ic  acid to precipitate the
enzymes. N egat ive  / pos i t ive  controls were included as a sample  without  
enzyme,  or contained no inhibitor,  respectively .  Samples were  
centri fuged at 13,000rpm for a few seconds before reading OD
(excitat ion 328nm, emiss ion  393nm) using a Hitachi f luorescence
spectrophotometer (Hitachi,  Japan).
Data were analysed by the Dixon method240 plotted as fluorescence  
(converted to % activ ity) vs. inhibitor concentration to obtain the I C 5 0  
value for the appropriate inhibitor.
5.13 Assessment of cellular mycoplasma levels by PCR and 
gel electrophoresis
This protocol is based on the Stratagene M ycoplasm a PCR test
(Amsterdam, the Netherlands) for the detection o f  most  Mycoplasm a  
infect ions.  Cells  were assessed for m ycoplasm a infect ion every 4-6  
months.  To external D N A  contamination, all solutions were UV  
irradiated. PCR were run with and without  an internal control to 
approximate  the level  o f  Mycoplasma infect ion ,  the control g iv ing a 
s ing le  band at 420-bp.  A posit ive  control {M yco p la sm a  ora le )  was also
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used. Supernatant from confluent grown cell  cultures grown in the 
absence o f  antibiotic were used.
lOOpl o f  s/n was boi led  for 5 mins before c leaning the D N A  using  
Strataclean Resin  (Stratagene) to prepare a template for PCR (as 
described in stratagene instructions).  Templates can be stored at - 2 0 ° C  
for several days i f  not used immediate ly .  The fo l low ing  stock was  
prepared for PCR; the total volume needed being tw ice  the number o f  
templates (with / without  internal control)  plus three (posit ive  / negative  
/ internal controls only):
2 7 .2p l  H 2O, 0 .4p l  dNTP (25mM stock; Sigma-Aldrich)
0 .4p l  Taq D N A  polymerase (2 .5 U /p l  stock; Promega,  Wisconsin ,  U .S .A .)  
5pl lOx Buffer,  3pl o f  25mM MgCU (both provided with Taq D N A  
polymerase)
2pl Primers (5pM o f  each primer, provided with stratagene mycoplasma  
PCR set)
The stock was divided into controls and two sets per sample to be tested.  
For the Internal control set, 2p l  o f  internal control (provided with  
Stratagene Mycoplasm a PCR set) was added, otherwise  2pl  o f  water was  
added. For the posi t ive  / negative  control set, 10 jllI o f  pos i t ive  control / 
water was added to the appropriate reaction tube, respectively .  10pl o f  
template was added to each sample,  and all samples  covered with a drop 
o f  mineral oil ,  and run using a Perkin Elmer Cetus D N A  thermal cycler  
(refer to Stratagene Mycoplasma protocol) .  PCR samples were mixed  
with loading buffer and run on a 3% agarose gel  at lOOmV for ~30m ins  
in TBE buffer.  The first and last lanes contained lOObp D N A  molecular  
marker set (Promega) .
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5.14 Screen ing  o f  mouse cathepsin  D genotype  by PCR
D N A  was  prepared from B 112  mouse (see  sect ion 6 .5 .1 ,  page 213)  tail  
snips as fo l lows .  Tail snips were placed into Eppendorf tubes containing  
500pl  o f  0.2% SDS, 0.1M Tris pH 8.5,  5mM EDTA, 200m M  NaCl in 
H 2O, and 5pl proteinase K solution ( lOmg/ml Proteinase K in H 2O). The 
tubes were  agitated for 3-4 hours at 55°C, after which they were  
centrifuged for 10 secs  at 13,000RPM, and the s/n was tipped into 500pl  
o f  propan-2-ol.  The solution was mixed by inversion until D N A  
precipitat ion occurred. The D N A  was removed with the tip o f  a 
micropipette  and added to 2 00p l  H20  and incubated at 37°C for 2hrs. 2pl  
o f  each D N A  sample were added to a PCR mixture [ 0 .3 jlxI Taq D N A  
polymerase,  2 .5p l  lOx buffer,  3pl MgCU (all three from promega),  1.2pl  
dNTP (lOmM; Sigma-Aldrich),  0 .5p l  each o f  Primer 1 and 2 (CatD 
forward = TTGGAGAGTTAGCCTGAGCTACTG, CatD reverse = 
CCTCAGCTGTAGTTGCTCACATGA, Sigma-Aldrich) and 12pl o f  
purified H2O]. PCR reaction was run using a Perkin Elmer Cetus D N A  
thermal cycler  with a hot start at 95°C and 35 cyc les  ( l m i n  @ 95°C,  
2min @ 58°C, 3min @ 72°C) and analysed on a 1% agarose / 0.5 M TBE 
gel.
Using  the above primers,  disrupted cathepsin D genes  (that contain a 
neom ycin  cassette ,  and present in heterozygous  or hom ozygou s  cathepsin  
D mice)  gave  a PCR ampli ficat ion product with D N A  bands o f  - 1 . 5  Kb 
in s ize  (see  figure 5.5 for gene  map). These  bands are stronger in 
h om ozygou s  mice.  Wild-type  cathepsin D gene g ives  a - 2 8 0  bp band in 
either heterozygous  or wild-type cathepsin D mice  (stronger band in 
wild-type  mice) .
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Figure 5.5: Map o f wild type and disrupted cathepsin D gene
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Chapter 6
The Use of pepstatin inhibitors in dissecting the role 
of cathepsin E
6.1 Pepstatin A as an inhibitor of the aspartic protease 
cathepsin E
The use o f  pepstatin as a potent inhibitor is restricted because o f  
inadequate solubi lity,  poor cell  permeabi lity ,  lack o f  spec i f ic i ty  for 
either cel l  or protease,  and at high concentrations,  toxic ity .  The effect  o f  
pepstatin A upon antigen process ing  and presentation within the models  
used in this thesis (section 5.3,  page 168) is used as the standard for 
comparison with other modif ied  pepstatin A inhibitors.
6.1.1 The inhibitor pepstatin A is able to inhibit  the enzymatic  
cleavage of  a peptide substrate for rat cathepsin E
Figure 6.1 shows the inhibit ion o f  rat cathepsin E (50 ng/ml) activity  by  
variable concentrations o f  pepstatin A (from 30 -  240 pM). An I C 5 0  o f  
77 ± 4 pM is obtained for pepstatin A based on the results o f  three 
experiments .
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Figure 6.1: Inhibition by pepstatin A of the enzymatic cleavage of fluorogenic substrate MOCAc- 
Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)y-NH2 (5 ng/ml) by rat cathepsin E (50 ng/ml). 
Details of the assay method are listed in section 5.12. Results are representative of three 
experiments and expressed as % activity vs pepstatin A concentration
6.1.2 Pepstatin A can inhibit  DO11-10 response to OVA but not OVA  
peptide p323 when presented by A20 cells
A representative example o f  the e ffect o f  pepstatin A on IL-2 release  
from D O 11-10  ce l l s  upon incubation with A20 cell s  and either OVA or 
OVA pept ide p323 is shown in figures 6.2,  6.3 and 6.4. Pepstatin A 
inhibits IL-2 release by D O 11-10  cell s  in a dose dependent manner when  
in the presence o f  OVA antigen and A 20 cell s  (f ig.  6.2a).  54pM o f  
pepstatin A almost complete ly  inhibits IL-2 release.  Some o f  this ef fect ,  
however,  is due to the presence o f  DM SO, its e ffect  also being dose  
dependent  (f ig .  6.2a).  The difference between the e ffect o f  Pepstatin / 
DM SO and DMSO alone is statis tically  s ignif icant  (fig .  6.4a).  At this 
high concentration o f  pepstatin (54 pM), there is also a major effect  o f  
pepstatin on the presentation o f  p323 pept ide (f ig .  6 .2b) ,  a process  that 
does not require antigen processing.  Much o f  this effect  is due to the 
presence  o f  DMSO (fig.  6.2b).
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Figure 6.2a: Response of DO11-10 cells to OVA (0.5mg/ml), presented by A20 cells with varied 
concentrations of pepstatin A / DMSO or DMSO alone. IL-2 release measured by CTLL assay. 
Results are expressed as the mean 3H-thymidine incorporation from triplicate cultures and are 
representative of six different experiments. Graph includes the IL-2 control for graphs shown in 
figure 6.2a and figure 6.2b. The OVA positive control is cells and OVA protein.
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Figure 6.2b: Response of DO11-10 cells to p323 peptide (0.05pg/ml), presented by A20 cells with 
varied concentrations of pepstatin A / DMSO or DMSO alone. IL-2 release measured by CTLL 
assay. Results are expressed as the mean 3H-thymidine incorporation from triplicate cultures and 
are representative of six different experiments. The p323 positive control is cells and p323 peptide.
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Figure 6.3 shows the effect  o f  Pepstatin and DMSO on v iabi l i ty  o f  OVA-  
treated and p323-treated A20 cell s .  Pepstat in / DMSO or DMSO alone  
are s l ight ly  toxic  at the highest concentrations used (0.33  %, figure 6.3).  
There is an observed cell  death o f  up to 30 % with pepstatin / DMSO,  
and s l ight ly  lower for DMSO (fig.  6.4b) .  Taken together,  these data 
suggest that pepstatin has a signif icant inhibitory effect on antigen  
process ing .  However,  some o f  this e ffect is due to DMSO-related  
inhibition,  and non-antigen process ing  inhibit ion or cellular tox ic i ty  o f  
pepstatin and DMSO. It was not poss ib le  to decrease the amount o f  
DMSO present by increasing the concentration o f  pepstatin A in the 
stock DMSO solution further, since this resulted in the appearance o f  
crystall ine  insoluble  pepstatin aggregates  in the cultures.  The tox ic i ty  o f  
DMSO is substantially  reduced at 0.11 % w hile  pepstatin A (18 pM)  
inhibits by 50 -  60 % (fig .  6.4a).  At this concentration, the e ffect on 
p323 presentation to D O 11-10  cell s  (f ig.  6.4a) and the % assay cell  death 
(fig.  6 .4b)  is minimal
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Figure 6.3: Cell viability of cells in antigen presentation assay (shown in figure 6.2): response of 
DO11-10 cells to a) OVA (0.5mg/ml) and b) p323 peptide (0.05pg/ml), presented by A20 cells with 
varied concentrations of pepstatin A and DMSO. Cell viability measured by MTT incorporation 
and expressed as the mean O.D. (570 -  630 nm) from duplicate cultures. Results are representative 
of six different experiments. The p323 / OVA, cells only and medium only controls are also included
188
Chapter  6
(a)
□  54uM ■  18uM
t  = values lower than 0 % signifies 
enhanced cell proliferation
Pepstatin / OVA DMSO / OVA Pepstatin / p323 DMSO / p323
(b)
□  54uM D18uM
100 - I  
90 - 
80 -
70 -£
W 60 - 0)
Pepstatin / OVA DMSO / OVA Pepstatin / p323 DMSO / p323
Figure 6.4: The effect of Pepstatin on a) OVA or p323 presentation by A20 cells and b) cell viability. 
Both graphs show the results with 54pM Pepstatin and its equivalent DMSO concentration 
(0.33%), and 18pM Pepstatin and its equivalent DMSO concentration (0.11%).
% inhibition of IL-2 release calculated for experimental point as 100 -  [(IL-2 production in 
presence o f inhibitor / IL-2 production in absence of inhibitor) x 100]. Background IL-2 in absence 
of antigen was subtracted from all values before the calculations. % cell death was calculated as 
100 -  [(viability in presence of inhibitor / viability in absence of inhibitor) x 100]. Results show the 
mean +/- SEM of at least four separate experiments. * p < 0.05 versus OVA/DMSO control, ** p < 
0.01 versus OVA/medium control
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6.2 MPC1 / MPC2 aspartic protease inhibitors and effect 
on DO11-10 response to OVA presented by A20 cells
Initial work towards modif ied pepstatin A inhibitors (MPC1 and MPC2)  
contain a s ingle  mannose sugar l inked by a variable length linker to 
pepstatin A. The dif ference between them is that MPC2 contains a 
c leavable  l inker between the mannose and pepstatin A. The structures are 
shown be low  in figure 6.5.  The main aim o f  these inhibitors is to 
increase solubi l i ty  over that o f  pepstatin A alone, enabling the use o f  
either a lower concentration o f  DMSO in v i t r o , or no DMSO at all.
(a)
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HO
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H
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H
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Figure 6.5: Chemical structures of a) MPC1 and b) MPC2
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6.2.1 MPC1 and MPC2 inhibit  the enzymatic  cleavage of  a peptide  
substrate  for rat cathepsin E, at a s imilar level to pepstatin A
U sing  the D ixon  method240, data for the inhibit ion o f  c leavage o f  
fluorogenic  substrate by rat cathepsin E was obtained. Figures 6.6 and 
6.7 show a representative plot o f  this data for MPC1 and MPC2  
respectively .
IC50 values  are in the picomolar range, and similar to that o f  pepstatin.  
MPC1 (n = 3),  IC50 = 133 ± 23 pM. MPC2 (n = 4), IC50 = 86 ± 47 pM.  
This data shows that the attachment o f  a small  l inker and sugar unit does  
not cause any reduction in the inhibitory e ffects  o f  pepstatin A.
100
50 ng/ml rat cathepsin E 
5 mM substrate
80 -
>“5
O<
40 -
20 -
0 100 200 300 400 500 600
C o n cen tra tio n  of MPC1 (pM)
Figure 6.6: Inhibition by MPC1 of the enzymatic cleavage of fluorogenic substrate by rat cathepsin 
E. Results are representative of three experiments and expressed as % activity against MPC1 
concentration
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Figure 6.7: Inhibition by MPC2 of the enzymatic cleavage of fluorogenic substrate by rat cathepsin 
E. Results are representative of four experiments and expressed as % activity against MPC2 
concentration
6.2.2 The effect  of  MPC1 dissolved in water on the DO11-10 response  
to A20 cells pulsed with OVA antigen
It was evident  during synthes is  o f  MPC1 that its so lubi li ty  was  
considerably  greater than that o f  pepstatin A alone. MPC1 had excellent  
so lubi li ty  in organic solvents ,  e sp ec ia l ly  methanol.  The solubi l i ty  in 
water was much higher than that o f  pepstatin.  At high concentrations o f  
MPC1 ( > 0.5 mM) a sl ight c loudiness  was vis ib le ,  but at the lower  
concentrations  used in assays (<54 pM ) the compound appeared to be 
com ple te ly  water soluble.
Figure 6 .8a  shows the effect  o f  MPC1 (s tock solution in water) on IL-2 
release  by D O 1 1 -1 0  T-cell s  upon incubation with A20 ce l l s  and OVA  
antigen. Cell  v iabi l i ty  for this assay is shown in figure 6.8b. The almost  
com plete  inhibit ion o f  IL-2 release observed in figure 6 .8a  at higher  
concentrations  o f  MPC1 (54 pM) is mainly attributed to cellular toxic ity ,
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as shown by figure 6.8b. Observation o f  the w e l ls  o f  the assay containing  
higher concentrat ions  o f  MPC1 showed the presence o f  a crystall ine  
material (f ig .  6.9).  The serial dilution o f  MPC1 direct ly in the culture  
w el ls  o f  an assay or separately before adding to each wel l  did not change  
the outcome.  MPC2 was also tried in a l imited number o f  experiments  
with similar results.
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Figure 6.8a: Response of DO11-10 cells to OVA presented by A20 cells: varied concentrations of 
MPC1 (dissolved in water). IL-2 release by DO11-10 cells, measured by IL-2 ELISA and expressed 
as the mean O.D. (450 nm) from duplicate cultures. Results are representative of six separate 
experiments. Experiment uses lm g/m l OVA
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Figure 6.8b: Cell viability of assay shown in figure 6.8a. measured by MTT incorporation and 
expressed as the mean O.D. (570 -  630 nm) from triplicate cultures. Results are representative of 
six separate experiments
(a) (b)
Figure 6.9: Light microscope pictures at 4,000 x magnification of MPC1 and MPC2 dissolved in 
water (25 %) and E4 culture medium (75 %). a) MPC1, b) MPC2. The solubility of MPC1 / MPC2 
was much reduced in culture medium (containing salts, proteins etc.) compared to its solubility in 
water (not shown) causing dissolved inhibitor to crystallise out of solution in the culture wells
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6.2.3 MPC1 and MPC2 dissolved in DMSO / water inhibit  the D O l l -  
10 response to OVA presented by A20 cells with a similar  
potency to pepstatin A
The addition o f  DMSO helped to d is so lve  the inhibitor in v it ro  when  
added to MPC1 (or MPC2) stock and then diluted with the required 
amount o f  water. Addit ion o f  DMSO to the culture and not to inhibitor  
stock however  did not help to re-d isso lve  insoluble  precipitates o f  
inhibitor.  MPC1 and MPC2 were therefore retested, using a stock 
solut ion containing water/DMSO, but maintaining the final DMSO  
concentration at 1/3 o f  that used with pepstatin A. For example,  54pM  
pepstatin A solut ion contains 0.33 % DMSO. 54 pM MPC1 / MPC2 at
54pM would therefore contain 0.11 % DMSO.
Figure 6 .10a shows the e ffect o f  MPC1, pepstatin A and DMSO on the 
response  o f  D O 1 1 -1 0  cel ls  to OVA presented by A20 cel ls .  IL-2 control  
is not shown for brevity,  but IL-2 release was at leve ls  similar to 
previous  experiments  with approximately 400 pg/ml o f  IL-2 release for
OVA control and 1 ng/ml o f  IL-2 release  for p323 control. MPC1 and
pepstatin A tota lly  inhibited process ing  o f  OVA at 54pM, and partially  
inhibited process ing  (MPC1 more than pepstatin A) at the lower  
concentration o f  18pM. The effect o f  DMSO in this experiment is 
minimal even at the highest  concentration o f  DMSO. Figure 6.10b shows  
the cel l  v iab i l i ty  for the cell s  in the assay shown in figure 6.10a.  MPC1 
showed some toxic i ty  at the highest  dose tested, but DMSO at the same  
concentration had a minimal effect.  The dif ference between pepstatin and 
MPC1 in their effect  to decrease IL-2 release is  l ikely  to be due to 
dif ferences  in cel l  viabi lity,  as shown by comparing figure 6 .10a  to 
figure 6 .10b.
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Figure 6.10: Response of DO11-10 cells to OVA presented by A20 cells in the presence of varied 
concentrations of M PC1, pepstatin A and DMSO. a) IL-2 release by DO11-10 cells, measured by 
IL-2 ELISA and expressed as the mean O.D. (450 nm) from duplicate cultures, b) Cell viability 
measured by M TT incorporation and expressed as the mean O.D. (570 -  630 nm) from triplicate 
cultures. Results for both graphs are representative of four separate experiments. Experiment uses 
3mg/ml OVA, 0.33% DMSO at 54pM pepstatin A, and 0.11% DMSO for MPC1 at 54pM
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Figure 6 .11a  shows the effect  o f  MPC2 and pepstatin A on inhibition o f  
IL-2 release by D O 11-10  cell s .  The data shows a similar trend o f  MPC2  
as MPC1, i .e. complete  inhibit ion o f  OVA process ing  within A20 cel ls  at 
the higher concentration o f  54pM but less than pepstatin A at lower  
concentrations ,  and an effect  that is dose dependent.
DMSO
0.11% DMSO
0.33% DMSO
Inhibitor concentration (pM)
Figure 6.11a: Response of DO11-10 cells to OVA presented by A20 cells in the presence of varied 
concentrations of MPC2, pepstatin A and DMSO. IL-2 release by DO11-10 cells, measured by IL-2 
ELISA and expressed as the mean O.D. (450 nm) from duplicate cultures. Results are 
representative of four separate experiments. Experiment uses 3mg/ml OVA, 0.33% DMSO at 54pM  
pepstatin A, and 0.11% DMSO for MPC2 at 54pM
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Figure 6.11b shows a higher cel l  v iabi li ty  with MPC2 compared with that 
o f  pepstatin A, this trend being similar to MPC1. Like MPC1, the 
difference in inhibitor e ffect between MPC2 and pepstatin upon IL-2 
release is p oss ib ly  due to the dif ference in cel l  viabi li ty .
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Figure 6.11b: Cell viability of experiment presented in figure 6.11a, measured by MTT  
incorporation and expressed as the mean O.D. (570 -  630 nm) from triplicate cultures. Results are 
representative of four separate experiments.
A summary o f  the % inhibit ion o f  release o f  IL-2 and % assay cell  death 
for MPC1, MPC2 and DMSO, at 54pM  and 18pM is shown in figure  
6.12a and 6.12b respectively .  Figure 6 .12a clear ly  shows that the total  
inhibition observed with MPC1 and MPC2 at 54pM is due to inhibit ion  
o f  proteolytic  act ivity  and only  partly due to an e ffect on cell  viabi lity .  
This inhibit ion is statis tically significant.
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Figure 6.12: The effect of MPC1 / MPC2 on a) OVA presentation by A20 cells and b) cell viability. 
Both graphs show the results with 54pM MPC1 / MPC2 and its equivalent DMSO concentration 
(0.11%), and 18pM MPC1 / MPC2 and its equivalent DMSO concentration (0.037%).
Results show the mean +/- SEM of four separate experiments. * p < 0.05 versus OVA/medium  
control, or where specified, OVA/DMSO control. % inhibition of IL-2 release and % cell death 
calculated as described in legend to fig 4.4.
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6.2.4 MPC1 and MPC2 when dissolved with DMSO have minimal  
effect on the DO11-10 response to p323 presented  by A20 cells
A representative example o f  the effect  o f  MPC1, MPC2, pepstatin A and 
DMSO on the D O 11-10  cell  response to p323 pept ide presented by A20  
cell s  is shown in figure 6 .13a and figure 6.13b.  Neither MPC1 nor MPC2 
inhibited pept ide presentation at any concentration tested, confirming  
that the activ it ies  o f  these enzymes was directed primarily at the antigen  
process ing  step, rather than affecting presentation or T-cell  function  
directly.  Figure 6.14 shows the % inhibit ion o f  IL-2 release  for several  
experiments ,  and confirms that MPC1 and MPC2 have a minimal effect  
on the inhibition o f  IL-2 production by p323-treated A 20 cell s .  As 
previous ly  shown (fig.  6.4,  page 189),  pepstatin A (54juM) also inhibits  
the presentation o f  p323 to D O 11-10  cell s  and reduces cel l  viabi lity.
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Figure 6.13a: Response of DO11-10 cells to p323 peptide presented by A20 cells in the presence of 
varied concentrations of MPC1, pepstatin A and DMSO. IL-2 release by DO11-10 cells, measured 
by IL-2 ELISA and expressed as the mean O.D. (450 nm) from duplicate cultures. Results are 
representative of four separate experiments. Experiment uses O.lpg/ml p323 peptide, 0.33% DMSO  
at 54pM pepstatin A, and 0.11% DMSO for MPC1 at 54pM
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Figure 6.13b: Response of DO11-10 cells to p323 peptide presented by A20 cells in the presence of 
varied concentrations of MPC2, pepstatin A and DMSO. IL-2 release by DO11-10 cells, measured 
by IL-2 ELISA and expressed as the mean O.D. (450 nm) from duplicate cultures. Results are 
representative of four separate experiments. Experiment uses O.lpg/ml p323 peptide, 0.33% DMSO 
at 54pM pepstatin A, and 0.11% DMSO for MPC2 at 54pM
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Figure 6.14: The effect of MPC1 / MPC2 on the presentation of p323 by A20 cells. Graph shows the 
effects caused by 54pM of MPC1 / MPC2 and its equivalent DMSO concentration (0.11%), and 
18pM of MPC1 / MPC2 and its equivalent DMSO concentration (0.037%). Results show the mean 
+/- SEM of four separate experiments. % inhibition of IL-2 release calculated for each experiment 
as the % difference in IL-2 production between the p323 control (0 % inhibition of IL-2 
production) and cells only control (baseline or no IL-2 production, thus 100 % inhibition).
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6.3 MPC5 / MPC6 aspartic protease inhibitors and their 
effect on the DO11-10 response to OVA presented by 
A20 cells
Two modif ied  pepstatin A derivatives  that could help overcome some  
exis t ing  problems (such as so lubi li ty  and cell  permeabili ty) were  
synthes ised . The structure o f  these inhibitors,  MPC5 and MPC6 are 
shown in figure 6.15.  These may prove to be useful in the study o f  
antigen process ing  within dendritic cel ls .  These  inhibitors contain  
multiple mannose sugars (est imated to be approximately  23 mannose  
sugars,  see section 6 .3 .1)  attached to bovine  serum albumin (BSA) with  
the inhibitor pepstatin A attached to a s ingle  sulfhydryl residue. MPC6 is 
a c leavable  vers ion o f  MPC5, containing a disulphide l inkage. As  
discussed in chapter 2, it was predicted that these inhibitors would  show  
better solubi l i ty  over MPC1 and MPC2, and introduce a targeting  
element by al lowing increased endocytos is  into dendritic cell s  by  
attachment to the mannose receptor.  Synthesis  o f  the inhibitors MPC5  
and MPC6 is d iscussed fully  in chapter 3. The inhibitors were first tested  
in the enzymatic  and functional assays described for MPC1 and MPC2.
(a)
'P epstatin
(b)
.Pepstatin
Figure 6.15: The chemical structures of a) MPC5 and b) MPC6
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6.3.1 The MPC5 and M P C 6 precursor BSA conjugate  [33] contains  
approximately  23 conjugated mannose sugars
Determination o f  the average amount o f  conjugation o f  
isoth iocyanatomannosyl  sugar derivatives  attached to the B S A  conjugate  
[33] ([33] refers to the numbered synthesis  compound listed within  
chapter 3) is done by three methods,  mass spectrometry (MALDI-TOF),  
biochemical  analysis for total mannose content and free amino groups.  
The first method using MALDI-TOF mass spectrometry gave  a detectable  
average mass for B SA  with a peak at 66 ,430  (appendix VIII).  The mass  
o f  B S A  conjugate [33] gave a peak at 74 ,030  with a peak range between  
67 ,000  -  79 ,000  (appendix VIII).  This range is expected due to the 
varied number o f  conjugated mannosyl compounds, with the median mass  
at 74 ,030 .  The difference between B S A  and B S A  conjugate [33] equates  
to approximately 24.3 mannose units / B S A  molecule .
B iochem ica l  analysis  for the presence o f  sugars is poss ib le  by using the 
phenol -  sulphuric acid method229,230. A graph o f  concentration o f  the 
compound 4-aminophenyl a -D-mannopyranoside  [10] vs absorption (fig.  
6.16) is used as a reference for determining the amount o f  mannose  
sugars attached to the mannosylated B S A  conjugate [33]. Table 6.1 
shows the absorbance values obtained for B S A  conjugate [33] (three 
different experiments ,  two concentrations per experiment) from which an 
est imated number o f  mannosyl units per B S A  are calculated by using the 
l inear equation from figure 6.16.  The mean o f  these g ives  a value o f  23.1  
+ / -  2.5 mannosyl units per B SA  for B S A  conjugate [33].
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Figure 6.16: Selected data from a standard curve of 4-aminophenyl o-D-mannopyranoside [10]. 
Each data point is the mean of three separate experiments, each experiment being run in triplicate, 
and selected as all the data with absorbance between approx 1.0 and 3.5. This selected range fits a 
linear equation, the plot of which is used to help calculate the number of mannose units per BSA  
conjugate [33]
BSA conjugate [33] (mg/ml) 3 6 1.8 3.6 1.8 3 6 1.8
Absorbance (mean O.D. 490 nm) 2 , 15 1,79 1-55 2 .19 1.22
Estimated number mannoses / BSA 23 52 22.31 18.89 26.62 23 97 23.24
Average S.D.
23.1 2.5
Table 6.1: Estimated number of mannosyl sugar units per BSA molecule on BSA conjugate [33]. 
Absorptions of three separate tests of two different concentrations were run as triplicates, and from  
the absorption observed, the mean number of mannosyl sugars per BSA of BSA conjugate [33] was 
calculated from the equation listed in figure 6.16. The mean and standard deviation of these six 
values is calculated as 23.1 +/- 2.5
204
Biochem ica l  analysis for amino groups, such as the number o f  free lysine  
amino acids on BSA conjugate [33],  is poss ib le  by using the 
tr initrobenzenesulfonic  acid (TNBS) method228,241. A standard curve o f  
B SA  and B S A  conjugate [33] (fig.  4 .17)  is obtained by 1 in 2 dilutions  
from 10 mg/m l and 20 mg/ml o f  B S A  and B S A  conjugate [33] 
respectively .  These plots g ive  a correlation that fits an quadratic 
equation (fig.  6 .17) .  From this equation it is calculated that an 
absorbance = 1.0 is equivalent to 5.80 mg/ml (87.1 pM) o f  B SA  and 
10.44 mg/ml (141 pM) o f  BSA conjugate  [33].
To determine i f  all o f  the amino groups on B SA  are able to react with 
TNBS, a test o f  the absorbance o f  B S A  and B S A  under denaturing  
condit ions (addition o f  10% o f  2% w/v  SDS) with a longer duration for 
TNBS reaction (30 mins compared with 5 mins normally) was performed  
with / without a change o f  pH to neutrality after reaction (sometim es  
required to ensure non-reversible  addition o f  TNBS addition by sulfite  
displacement) .  The results (not shown) showed a l imited difference in 
the value obtained for the absorption. It was assumed that all o f  the 
amino groups o f  B S A  were reactable towards TNBS (i.e.  60 including a 
terminal N H 2). As such, it was calculated:
Free amino groups per B S A  = 60
87 .1pM  B S A  x 60 amino groups = 5 .23mM  free amino groups per B SA
5.23mM  / 141 pM B S A  conjugate [33] concentration =
37 amino groups per B SA  conjugate [33]
60 -  37 = 23 attached mannosyl units ner B S A  conjugate [331
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Figure 6.17: Standard curve of BSA and BSA Conjugate [33]. Each data point is the mean of three 
separate experiments, each experiment being run in triplicate. Quadratic equations are included 
for each correlation, from which the number of free lysine amino groups on BSA Conjugate [33] is 
calculated.
6.3.2 Mass spectrometry suggests  that M P C 6 contains a single  
attached pepstatin  A
Determination o f  protein sulfhydryl groups on proteins is traditionally  
accomplished by the use o f  E l lm an’s reagent238. However for unknown  
reasons this method did not g ive  reproducible results.  Alternatively ,  the 
use o f  MALDI-TOF mass spectrometry and enzym olog ica l  data (section  
6 .3 .3 )  help to confirm the presence o f  a s ingle  pepstatin A molecule  
attached to B S A  conjugate [33] within MPC5 and MPC6.
MPC6 shows a peak range = 69 ,000  -  81 ,500 ,  with the median peak for 
MPC6 be ing  ~ 75 ,163 (appendix IX). This is both an increase in median  
peak value  over B SA  conjugate [33] o f  1,131 (pepstatin A analogue MW  
= 861)  and a peak range increase in mass o f  at least 2 ,000  MW, both 
factors indicate  the presence o f  an extra molecu le .  Unfortunately,  the 
mass spectrometry data for MPC5 does not show this and on its own
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would suggest  no change between MPC5 and B S A  conjugate [33]. With 
MPC5 there is at most a sl ight skew in the peak o f  MPC5 towards a 
higher mass but not s ignif icantly  to clear ly  suggest  the inclusion o f  a 
pepstatin analogue l ike that o f  MPC6 (appendix IX).  Although the MS  
data and the enzym olog ica l  data (next section) suggest the inclusion o f  a 
pepstatin m olecu le  onto at least MPC6, there is no concrete ev idence  
without  an analys is  o f  the free sulfhydryl on BSA,  and as such, no 
accurate measurement o f  the percentage o f  pepstatin conjugated via a 
disulphide o f  MPC5 / MPC6 is known. This is d iscussed further in the 
conclus ion.
6.3.3 MPC5 and M P C 6 , but not BSA-conjugate ,  inhibit  the enzymatic  
cleavage of  a peptide substrate  for rat cathepsin £
Using the D ixon  method described in chapter 5240, data for the inhibition  
o f  c leavage  o f  f luorogenic  substrate by rat cathepsin E was obtained for 
MPC5, MPC6 and the precursor BSA conjugate [33]. Figure 6.18 shows  
plots o f  data for B SA  conjugate [33],  MPC5 and MPC6. An accurate 
trend-line could not be applied to the graph o f  B SA  conjugate [33],  
although the data suggested an approx. IC50 value in the 0.5 -  2 pM 
range. This is many orders o f  magnitude higher than the values for 
pepstatin A and MPC1 / MPC2, which have values  in the picomolar  
range. Any inhibition that may be occurring from B SA  conjugate [33] is 
l ikely  to be due to competit ion for c leavage  by cathepsin E enzyme as 
B SA  and mannosylated B SA  have been shown to be c leaved by a 
cathepsin D - l ik e  enzyme most l ikely  to be cathepsin e 242,243.
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Figure 6.18: Inhibition by BSA conjugate [33] of the enzymatic cleavage of fluorogenic substrate by 
rat cathepsin E. Results are the combination of four separate experiments and expressed as % 
activity against BSA conjugate [33] concentration
MPC5 and MPC6 however  showed much more potent inhibition o f  
substrate c leavage  (fig.  6 .19) ,  in the low nM range. Although the I C 5 0  
values are still  an order o f  magnitude higher than pepstatin A, the 
difference in I C 5 0  between BSA-conjugate  [33] and MPC5 / MPC6  
suggests  the presence o f  pepstatin A in the inhibitors. The purif ication  
procedure used for MPC5 and MPC6 makes it unlikely  that any free 
pepstatin is present in the MPC5 or MPC6 solutions,  it is thus unlikely  
that the inhibit ion o f  f luorogenic compound by MPC5 / MPC6 over that 
o f  B SA -conju gate  [33] is due to free pepstatin.  The higher I C 5 0  values  
for MPC5 / MPC6 compared with pepstatin A may suggest  that steric  
factors play a role in reducing the potency  o f  pepstatin A when  
conjugated to BSA. An alternative explanation is that the percentage o f  
conjugated pepstatin molecules  per BSA-conjugate  [33] is low. This  
is sue  is d iscussed  further in the conclusion.
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Figure 6.19: Inhibition by a) MPC5 and b) MPC6 of the enzymatic cleavage of fluorogenic 
substrate by rat cathepsin E. Results are the combination of three separate experiments and 
expressed as %  activity against inhibitor concentration
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6.3.4 MPC5 and MPC6 do not inhibit the D O 1 1 -1 0  response to OVA  
presented by A20 cells
A representative example o f  the inhibition o f  IL-2 release from D O 11-10  
cell s  in the presence o f  OVA-treated A20 cell s ,  with varied  
concentration o f  MPC5, MPC6, and m an nose-B S A  conjugate  [33], is 
shown in figure 6.20.  A summary o f  % inhibition o f  IL-2 release by  
DO 11-10  cell s ,  and % assay cel l  death is shown in figures 6.21a and 
6.21b,  respectively .  There is no signif icant inhibition o f  IL-2 release in 
the presence o f  MPC5 or MPC6, in fact,  MPC5 seemed to cause a 
proliferative response (fig. 6.21a).  However,  m annose-BSA  conjugate  
[33] seemed to cause significant inhibition o f  IL-2 release at the 54pM  
concentration. The reason for this discrepancy is unknown, however may  
be the result o f  competit ion for antigen, and is discussed in the 
conclusion.  The discrepancy between these compounds is not understood.  
Interestingly,  the % assay cell  death (fig.  6 .21b) for all three compounds  
seems to be similar,  with a low effect  on cel l  death.
BSA conjugate ■MPC5 •MPC6 X OVA O Cells only
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Figure 6.20: Response of DO11-10 cells to A20 cells presenting OVA antigen (0.5 mg/ml) with 
varied concentration of BSA conjugate [33], MPC5 and MPC6. IL-2 release measured by 3H- 
thymidine incorporation, and results expressed as the mean from triplicate cultures. Data is 
representative of three different experiments
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Figure 6.21: The effect of MPC5 / MPC6 and BSA -  conjugate [33] within OVA-treated A20 cells 
on a) the %  inhibition of IL-2 production by DO11-10 T-cells and on b) assay cell death. Both 
graphs show the effects caused by 54pM, 18pM and 6pM of the MPC5 / MPC6 inhibitors and their 
control. Results show the mean +/- SEM of three separate experiments. % inhibition of IL-2 release 
calculated for each experiment as the % difference in IL-2 production between the OVA control (0 
%  inhibition of IL-2 production) and cells only control (baseline or no IL-2 production, thus 100 % 
inhibition). % assay cell death calculated for each experiment as the % difference in cell viability 
between the OVA control (0 % assay cell death) and Medium only control (no cells represents 100 
% assay cell death).
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6.4 Aspartic proteases and antigen processing by mouse 
dendritic cells
The life o f  a dendritic cel l  is geared towards antigen process ing  and 
presentation, which requires the uptake and process ing  o f  antigen in 
skin, epithel ia  and other tissues,  fo l low ed  by migration to the T-cell  
zone o f  lymphoid tissue and interaction with appropriate T-cell s .  The 
study o f  aspartic protease inhibitors was therefore extended from A20 B-  
cell s  to murine immature dendritic cell s .
Immature dendritic cell s  are different from the A20 B-ce l l  l ine in several  
ways. Immature dendritic cel ls  are highly  specia l ised  for endocytos is  o f  
antigen, either via  f luid phase (macropinocytosis )  or by receptor  
mediated uptake. In theory, this should equate into a larger uptake o f  
antigen. However  A20 cell s  are considerably  larger than murine ex v ivo  
B-ce l l s ,  and as such have a larger endocytic  capac i ty12. Dendritic cel ls  
also contain a larger quantity o f  proteolytic  enzymes that help them to 
process  large quantities o f  antigen compared with other antigen  
presenting cell s  such as B-cel l s .  Both these factors may inf luence the 
abil ity o f  aspartic protease inhibitors to function effect ive ly .
The remaining sections o f  this chapter describe the generation o f  
cathepsin D defic ient mice that have an I -Ad haplotype, and the 
characteristics o f  bone marrow-derived dendritic cell s  from wild  type  
(adult and 3 week old animals) and cathepsin D defic ient  (3 week old  
animals).  This is fo l lowed by an analysis o f  receptor mediated and fluid  
phase endocytos is  by dendritic cel ls  and the inf luence o f  B S A  conjugate  
[33] on this uptake, and finally some effects  o f  aspartic proteinase  
inhibitors MPC1, 2, 5 and 6 on processing and presentation o f  ovalbumin  
and ovalbumin  peptide p323.
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6.5 Generation of Cathepsin D deficient mice and immature 
dendritic cells
Cathepsin D defic ient mice were obtained as a kind gift  from the 
laboratory o f  Dr. C. P ieters110. The l ine was maintained as a 
heterozygote  co lony  in the B io log ica l  Services  at UCL. The mice  were  
derived from 129 SvJ strain, and expressed MHC o f  H-2 haplotype. It 
was necessary  to introduce the H -2 d MHC haplotype, so the antigen  
presenting cell s  could be used in combinat ion with the D O 11-10  T-cel l  
model  as described previously .
6.5.1 Cathepsin D +/- heterozygous mice with I -A d haplotype
Female  129Sv/J heterozygous mice carrying the inactivated cathepsin D 
gene were backcrossed with male Balb/c  mice  for four generations.  
Heterozygote  breeders from each generation were selected by PCR 
genotyping (section 5.14,  page 182) o f  tail DNA. Forward and reverse  
primers o f  D N A  were situated between exons  3 and 5 o f  the cathepsin D 
gene (fig.  5.5,  page 183).  Disrupted cathepsin D gene contained a 
neomycin  cassette ,  and PCR ampli fication  produced an ~1.5Kb band in 
heterozygous or hom ozygous  mice and an ~280bp band in either  
heterozygous or wild-type mice  (fig .  6 .22).  Like the parental strain110, 
cathepsin D hom ozygous,  F4 generation mice  (from here onwards termed  
B112 mice)  died after three to four weeks.  H om ozygotes  were smaller  
than normal mice  and showed reduced m obil i ty  by three weeks.  100% o f  
the mice  selected as hom ozygotes  for dendritic cell  preparation based  
upon physical appearance were confirmed hom ozygous  by PCR. As  
expected  for the mouse  population, almost 25 % (32 hom ozygous  from a 
total population o f  133 mice) were hom ozygous .
213
C h a p t e r  6
Arrows show homozygous mice as they have the larger ~1.5Kb DNA 
fragment but not the ~280bp (both would signify heterozygous mice)
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Figure 6.22: Example agarose gel of genotyping of mice expressing wild-type or disrupted cathepsin 
D gene
F4 generat ion,  female B112 mice were used to determine the MHC 
haplotype. Tail  bleeds were used to provide blood cells for phenotypic 
analysis o f  the expression of  MHC class-II I-Ad or I -Ab. Antibodies  HB3 
(anti -mouse  I -Ad) and 3TP (ant i-mouse I-Ab) were used for phenotyping. 
Figure 6.23 shows an example of  a f luorescence histogram analysis and 
dot plot for typical I -Ab or I -Ad express ion from whole blood o f  either 
Balb/c  (fig. 6.23a) or 129/SvJ (fig. 6.23b) mice. Mice selected for 
further  generat ion o f  B112 populat ions  were selected from lit ters based 
upon the high expression o f  paternal I -Ad and no expression of  I -Ab. An 
example h is togram and dot plot  o f  a B112 mouse that was I -Ab - v e  and 
I -Ad +ve is shown in figure 6.23c. Of 15 F4 generation mice tested, 8 fit 
the required haplo type and were selected for further  breeding.
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Figure 6.23: Fluorescence dot plot and histogram analysis of I-Ab or I-Ad expression within (a) 
Balb/c mouse whole blood, (b) 129/SvJ mouse whole blood and (c) B112 mouse tail bleed. 
Antibodies used were 1/50 concentration of HB3 (I-Ad) and 1/50 concentration of 3TP (I-A5)
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6.5.2 Generation of  B112 mouse dendritic  cells and phenotypic  
analysis
Murine femurs were extracted from three to four w eek  old B112 mice  
and the bone marrow removed. Cells  were cultured in complete  I s c o v e ’s 
medium containing GM-CSF. On day three, the medium was gently  
removed and replaced with fresh complete  I s c o v e ’s medium with GM-  
CSF. Figure 6 .24a  shows the formation o f  clusters o f  developing  
dendritic cell  progenitors,  and the effect  o f  washing to remove non­
adherent T-cell s  is clearly shown on day five,  the immature dendritic  
cell s  detach from the clusters (fig. 6 .24b, i i ) .  Other cell s ,  poss ib ly  
granulocytes (fig.  6 .24b,i i i )  and a stromal cel l  layer (fig.  6 .24b, iv )  were  
also present. Day five non-adherent T-cel l s  were re-plated into fresh 
medium and were harvested on day six or seven. Figure 6 .24c  show these  
cell s  as non-adherent T-cell s  with an irregular morphology.  N o n ­
adherent or s l ight ly  adherent T-cell s  were used as the cell  population  
containing immature dendritic cells .
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(a)
Figure 6.24: Light-microscope image of developing dendritic cells from murine femur bone 
marrow, a) Day three cells showing clusters of dendritic cell progenitors. Pictures taken before and 
after washing show the reduced number of non-adherent, non-clustered cells after washing. 
M agnification = 4000. b) Day five cells at 4000 magnification and 16,000 magnification respectively. 
These two figures show a decreased amount and density of dendritic cell clusters (i). Immature 
dendritic cells and progenitors are present in culture (ii), along with other larger cells, possibly 
granulocytes (iii). This view also shows clearly the developing stromal/fibroblast T-cell layer (iv). c) 
Day six re-plated cells clearly showing non-adherent immature dendritic cells (arrows)
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Flow cytometry was used to identify cell  surface markers on dendritic 
cell s  cultured from normal Balb/c  mice,  +/+ or +/- B 112  mice  (wild-type,  
WT), or -/- cathepsin D knockout B112 mice.  Figure 6.25 shows  
representative fluorescence histograms for MHC class-II,  C D l l c  (DC 
integrin), CD86 (co-s timulation marker on antigen present ing ce l l s )  and 
DEC-205 (C-type lectin found on DCs) .  In general,  normal Balb/c  mice  
showed much higher expression o f  MHC class-II,  C D l l c ,  CD86 and DEC  
205 than B 112 mouse cel ls ,  suggesting a larger percentage population o f  
dendritic cell s  compared with the B112 mice.  B112 mice were used at 
three to four weeks  o f  age, and as such were s ignif icantly  smaller that 
the normal week seven Balb/c  mice .  There were fewer developing  
clusters o f  B 112  DC progenitor cel ls  and as such, overall  populat ion o f  
dendritic cell s  in the day six or seven cultures o f  B112 ce l l s  may be 
considerably  smaller. Maturation o f  these cel ls  by addition o f  
l ipopolysaccharide  and culture for a further 3 days increased expression  
o f  MHC class-II  and CD86 (data not shown) as expected for mature 
dendritic cel ls .  Later work by Prof. B. Chain showed that culture o f  
these cell s  from these young mice for a total o f  14 -  20 days further 
increased the yie ld  o f  immature DCs.
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Figure 6.25: Flow cytometric analysis of bone marrow cultures from Balb/c, B112 and B112 -/- 
mice. Representative histograms of MHC class-II, C D llc , CD86 and DEC 205 expression. Filled 
histograms show appropriate isotype control or no antibody, while the thick black line shows the 
antibody staining for the particular protein of interest.
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6.6 Mannose receptor mediated endocytosis of BSA conjugate 
[33] into the immature dendritic cell line FSDC
6.6.1 A20 B-cells  have s imilar uptake rates of  the f lu id-phase  marker  
LY and MR-mediated marker FITC-DX
The expression o f  the mannose receptor on A 20 B -ce l l s  has not been  
studied, and indeed there have been no studies that have reported the 
expression o f  the mannose receptor on any B-ce l l s .  Previous studies have  
shown that endocytos is  o f  f luorescein dextran (FITC-DX) by DCs is 
mostly  mediated by the mannose receptor14. Lucifer ye l low  (LY) on the 
other hand is endocytosed by fluid-phase mechanisms independently  o f  
receptor uptake14. In the absence o f  mannose receptor,  therefore  
endocytos is  by A20 cell s  should be the same for LY and FITC-DX.  
Figure 6 .26a shows uptake o f  these two endocytos is  markers by A20  
cel ls  measured by f low cytometry as a function o f  concentration. A 
graphical representation o f  this data is shown in figure 6.26b. Uptake o f  
both tracers continues  to increase with concentration and shows no sign  
o f  saturation that might indicate receptor-mediated uptake. Similarly,  the 
uptake o f  both tracers over time showed a similar pattern between FITC-  
DX and LY (fig.  6 .27).  The presence o f  B SA  conjugate (216 pM) [33] 
did not alter endocytos is  o f  either FITC-dextran or LY, consistent with 
mannose receptor-independent uptake (data not shown).
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Figure 6.26: (a) Top panel: forward scatter / side scatter plot of A20 cells. Bottom panels: FL1 
histogram of A20 cells incubated in the presence of various concentrations of LY and FITC-DX for 
1 hour, (b) Median FL1 taken from histogram plots shown in a) as a function of concentration of 
LY and FITC-DX. Data is a representative example of at least three experiments
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Figure 6.27: (a) Top panel: forward scatter / side scatter plot of A20 cells. Bottom panel: FL1 
histogram of A20 cells incubated in the presence of 1 mg/ml LY or FITC-DX for various times, (b) 
Median FL1 taken from histogram plots shown in a) as a function of time of uptake. Data is a 
representative example of at least three experiments
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6.6.2 BSA conjugate [33] inhibits the uptake of  FITC-DX into FSDC  
cells but does not affect the endocytosis  of  LY
The m yelo id  cell  l ine FSDC shows properties and phenotype o f  immature  
dendritic c e l l s 244,245. In particular, the endocytos is  o f  soluble  
mannosylated antigens by FSDC cel ls  is similar to that o f  murine bone-  
marrow-derived D C s 14,51 and is be l ieved  to be mediated via the mannose  
receptor.  To demonstrate that BSA conjugate [33] was indeed bound by  
mannose receptors,  FSDC cel ls  were incubated in the presence o f  
conjugate [33] and either LY or FITC-DX. Uptake was measured by flow  
cytometry as above.
Figure 6.28 shows uptake o f  different concentrations o f  LY and FITC-  
DX by FSDC cel ls .  Uptake o f  both markers was much more eff ic ient than
for A 20 ce l l s ,  consistent with the known high rate o f  fluid uptake by
12DC . The uptake versus time profiles for the two markers were quite  
different however  (fig.  6 .29).  Uptake o f  Lucifer ye l low  was  
approximate ly  l inear for a three-hour period. In contrast, uptake o f  
FITC-dextran was made up o f  a very rapid early phase,  fo l lowed by a 
much s lower late phase as observed for DC prev ious ly12,14. These  
kinet ics  are consistent with,  though not proof  o f  receptor mediated  
uptake.
The abil ity  o f  B SA  conjugate [33] to compete  for uptake by FSDC with  
either FITC-DX or LY is shown in figure 6.30.  B SA  conjugate had little  
effect  on uptake o f  LY endocytos is  but inhibited FITC-DX in a dose  
dependent  manner at concentrations above 27pM. Inhibition o f  FITC 
dextran is only  partial, even at high concentrations  o f  B SA  conjugate  
[33] ,  suggest ing  that FITC-DX uptake occurs by both fluid phase and 
receptor-mediated uptake.
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Figure 6.28: (a) Top panel: forward scatter / side scatter plot of FSDC cells. Bottom panels: FL1 
histogram of FSDC cells incubated in the presence of various concentrations of LY and FITC-DX  
for 1 hour, (b) Median FL1 taken from histogram plots shown in a) as a function of concentration 
of LY and FITC-DX. Data is a representative example of at least three experiments
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Figure 6.29: (a) Top panel: forward scatter / side scatter plot of FSDC cells. Bottom panel: FL1 
histogram of FSDC cells incubated in the presence of 1 mg/ml LY or FITC-DX for various times, 
(b) M edian FL1 taken from histogram plots shown in a) as a function of time of uptake. Data is a 
representative example of at least three experiments
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Figure 6.30: Uptake of LY and FITC-DX by FSDC cells is inhibited by BSA conjugate [33]. FSDC 
cells were incubated in medium containing LY (1 mg/ml) and FITC-DX (1 mg/ml) and varied 
concentrations of BSA conjugate [33]. After 1 hour the cells were washed, and uptake of fluorescent 
probe measured by flow cytometry. The graph shows median fluorescent intensity of FSDC cells 
versus concentration of BSA conjugate. Data is a representative example of three experiments
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6.7 Processing and presentation of ovalbumin and peptide 
p323 by murine bone marrow DC
A representative example o f  OVA and p323 pept ide presentation by adult 
Balb/c  DC to D O 11-10  cel ls  is shown in figure 6.31.  The amount o f  
ovalbumin protein and p323 peptide required to produce a detectable  
response is in the range o f  0.5 -  1 mg/ml OVA (11 -  23 pM) and less  
than O. lpg/ml  (60 nM) p323 peptide. Similar leve ls  o f  IL-2 release can 
be achieved as A20 cell s  but at lower numbers o f  DCs. This suggests  that 
the process ing  and presentation capacity o f  DCs is greater than that o f  
A20 cell s  under similar conditions .  Bone marrow cell  concentrations o f  2 
x 105 cell s  / ml or 5 x 105 cell s  / ml were commonly  used. O f  this 
population, the total number o f  immature DCs present ranged from 30 % 
to 60 %. Ideally,  a purer population o f  DCs would provide more  
reproducible results.  However,  such an option was not available for this 
initial study.
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Figure 6.31: Response of DO11-10 cells to a) OVA and b) p323 peptide, presented by dendritic cells. 
DO11-10 hybridoma T-cells (106/ml) and adult Balb/c DCs (2 x 105/ml and 5 x 105/ml) were co­
cultured together in the presence of a range of antigen concentrations for 24 hours. IL-2 release 
was determined by CTLL assay. Results are expressed as the mean 3H-thymidine incorporation 
from triplicate cultures and are representative of three separate experiments. Graph a) shows the 
IL-2 control for the data of both graphs
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6.7.1 Pepstatin  A inhibits D O l l - l O  response  to OVA but not OVA  
peptide p323 when presented by Balb/c DCs
The observed effect o f  pepstatin A upon inhibit ion o f  A20 cel l  
processing o f  OVA protein is wel l  characterised (section 6 .1 .2 ,  page  
185).  Using the same model ,  pepstatin A also inhibited  
processing/presentation by bone marrow derived immature DCs (fig.  6.32  
-  6.34).  Figure 6 .32a shows that at 54pM o f  pepstatin A (0.33  % DMSO)  
the inhibition o f  IL-2 release is substantial  (approximately  80 %) (fig.  
6.34).  DMSO at the same concentration had a more l imited e ffect on 
process ing. There is also a l imited tox ic i ty  e ffect o f  either pepstatin A or 
DMSO at these same concentrations (fig.  6 .32b) ,  and importantly,  no 
effect upon p323 presentation (fig. 6 .33).  Figure 6.34 shows the 
percentage inhibition o f  IL-2 release and percentage toxic ity .
Apart from the number o f  DCs used, all other variables in the antigen 
presentation assay are the same as for the use o f  A20 cel ls .  DCs in vivo  
have a larger capacity o f  antigen uptake than B -ce l l s  in v i v o , due to both 
the smaller s ize  o f  these B-ce l l s  and the extra mechanisms used by DCs  
to endocytose .  This may not translate into A20 B-ce l l s ,  which are larger 
than ex v ivo  murine B-ce l l s ,  and as such may have similar levels  o f  
antigen / inhibitor uptake to murine bone marrow derived DCs. As there 
is no e f f ic ient  T-cell  targeting design incorporated into MPC1 or MPC2,  
and g iven  the size  o f  the A20 cel ls  compared to normal B-ce l l s ,  it is 
poss ib le  that the effects  observed with pepstatin A could be comparable  
between A 20 cell s  and DCs.
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Figure 6.32: Response of DO11-10 cells to a) OVA (3mg/ml) and b) p323 peptide (O.lpg/ml), 
presented by DCs with varied concentrations of pepstatin A / DMSO and DMSO alone. IL-2 release 
measured by CTLL assay. Results are expressed as the mean 3H-thymidine incorporation from  
triplicate cultures and are representative of three separate experiments.
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Figure 6.33: Cell viability of antigen presentation assay (shown in figure 4.32a): response of D O ll-  
10 cells to OVA (3mg/ml) presented by Balb/c DCs: with varied concentrations of pepstatin A and 
DMSO. Cell viability measured by MTT incorporation and expressed as the mean O. D. (570 -  
630nm) from triplicate cultures and are representative of three different experiments
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Figure 6.34: The effect of Pepstatin / DMSO and DMSO alone on the OVA presentation by Balb/c 
DCs and cell viability. Graph shows the results with 54pM of Pepstatin along with its equivalent 
DMSO concentration (0.33 %). Results show the mean + /-  SEM of three separate experiments. * p 
< 0.01 versus OVA control. % inhibition of IL-2 release and % cell death calculated as described in 
legend to fig. 6.4
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6.7.2 MPC1 and MPC2 inhibit the D O l l - l O  response to OVA  
presented by DCs with the same efficacy as pepstat in  A
As with the experiments using A20 cell s ,  the quantity o f  DMSO used to 
so lubi li se  MPC1 and MPC2 was one third o f  that used with pepstatin A. 
The effect  o f  54 pM MPC1 and MPC2 on IL-2 release by D O l l - l O  cell s  
when OVA antigen is presented by bone marrow derived DCs from adult 
Balb/c  mice  is shown in figure 6.35a. As for pepstatin A, there is 
inhibition o f  IL-2 release (approximately  80 %) and a more l imited  
effect  o f  DMSO. Figure 6.35b also shows that there is only  a small  effect  
on cell  viabi lity .  Only a l imited series o f  experiments were performed  
with p323 (data not shown) but these experiments  showed that MPC1 and 
MPC2 do not inhibit the presentation o f  p323 peptide to D O l l - l O  cel ls .  
A summary o f  data obtained for MPC1 and MPC2 at 54pM is shown in 
figure 6.36.  In general the effects  observed with MPC1 / MPC2 within  
A20 cell s  is similar (sect ion 6 .2 .3 ,  page 195).  At lower concentrations o f  
MPC1 and MPC2 the inhibition was minimal.
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Figure 6.35: Response of D O ll-lO  cells to OVA presented by Balb/c DCs: varied concentrations of 
M PC1, MPC2 and DM SO added, a) IL-2 release by D O ll-lO  cells, measured CTLL assay. Results 
are expressed as the mean 3H-thymidine incorporation from triplicate cultures, b) Cell viability 
measured by MTT incorporation and expressed as the mean O. D. (570 -  630nm) from triplicate 
cultures and are representative of three different experiments. Results for both graphs are 
representative of at least three separate experiments. Experiment uses 5 x 105 DCs/ml, 3mg/ml 
OVA and 0.11% DMSO at 54pM MPC1 or MPC2
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Figure 6.36: The effect of MPC1, MPC2 (both including DMSO) and DMSO alone on the OVA 
presentation by Balb/c DCs and cell viability. Graph shows the results with 54pM of MPC1 and 
MPC2 along with its equivalent DMSO concentration (0.11 %). Results show the mean + /-  SEM of 
three separate experiments, unless otherwise stated. * p < 0.01 versus OVA control. % inhibition of 
IL-2 release and % cell death calculated as described in legend to fig. 6.4
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6.7.3 The inhibit ion of  the D O l l - l O  response  to OVA presented  by 
WT B112 DCs in the presence of  6pM or higher of  MPC6 is 
mainly due to BSA conjugate [33]
WT B112 DCs were used to stimulate D O l l - l O  cell s  in the presence o f  
MPC6 or B SA  conjugate [33] at 54pM, 18pM and 6pM. Figure 6 .37a  
shows response at different concentrations o f  inhibitor or control.  MPC6  
strongly inhibited presentation o f  OVA (approximately  80%) over the 
range o f  concentrations tested. However,  B S A  conjugate  [33] also  
inhibited quite signif icantly ,  increasing from around 50% at the lowest  
concentration tested to almost 80% at 54pM. MPC6 but not B SA  
mannose [33] had much less  effect  on p323 peptide presentation except  
at the highest concentration o f  54pM).  A more l imited set o f  experiments  
with MPC5 (data not shown) did not display any inhibition above or 
beyond that o f  B SA  conjugate [33].
235
C hap ter  6
(a)
□  MPC6  ■  BSA conjugate [33]
100 i
54 18 6
Concentration (pM)
(b)
□  MPC6  ■  BSA conjugate [33]
a></>
o
2
CM
O
coIS!5
"JE
c
Concentration (pM)
Figure 6.37: The effect of varied concentrations of MPC6 on a) OVA (1 mg/ml) presentation by WT 
B112 DCs, and b) p323 (O.lpg/ml) presentation by WT B112 DCs. Results show the mean + /-  SEM 
of three separate experiments. % inhibition of IL-2 release calculated as described in legend to fig. 
6.4. IL-2 release was measured for each experiment by 3H-thymidine incorporation in triplicate 
cultures.
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6.7.4 MPC6 (2pM) but not BSA conjugate  [33] (2pM) inhibit  the 
D O l l - l O  response to OVA, and does not inhibit  p323 peptide  
presented by WT B112 DCs
As shown in the previous  sect ion, at concentrat ions  above 6pM, B SA  
conjugate [33] has a significant effect  on OVA presentation. Figures  
6.38a and 6.38b show an extension o f  this data to include  2pM MPC6 
and BSA conjugate [33]. 2pM MPC6 inhibits IL-2 release by D O l l - l O  
cel ls  to approximately the same degree as higher concentrations  tested.  
In contrast,  B SA  conjugate [33] has a much-reduced inhibitory activ ity  
at 2pM. Neither MCP6 nor BSA conjugate [33] inhibited p323  
presentation at the lower concentrations (fig.  6 .38b) .
6.7.5 MPC6 but not BSA conjugate [33] (2pM) inhibit the D O l l - l O  
response to OVA, and does not inhibit  p323 peptide presented  
by cathepsin D knockout B112 DCs
Although MPC6 at 2pM inhibits the process ing o f  OVA by WT B112  
DCs, this does not dist inguish the role o f  cathepsin D from cathepsin E 
in this process ing.  Cathepsin D defic ient B112 bone marrow derived  
DCs, however,  should contain cathepsin E as the only  aspartic protease  
within endocytic  compartments.  Inhibition o f  process ing by these cel ls  
using MPC6 would  therefore suggest  a role for cathepsin E. Figure 6.38a  
shows the effect  o f  2pM MPC6 / B SA  conjugate [33] on the processing  
o f  OVA by cathepsin D knockout B 112  bone marrow derived DCs. MPC6  
com plete ly  inhibits OVA process ing by the cathepsin D defic ient DC,  
w hile  B S A  conjugate  has a l imited effect .  Neither 2pM MPC6 nor B SA  
conjugate inhibit  p323 presentation.
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Figure 6.38: The effect MPC6 (2 pM) and BSA conjugate [33] (2 pM) on a) OVA (1 mg/ml) 
presentation by WT B112 DCs and cathepsin D deficient B112 DCs, and b) p323 (O.lpg/ml) 
presentation by WT B112 DCs and cathepsin D deficient B112 DCs. Results show the mean +/— 
SEM of three separate experiments. * p < 0.01 versus OVA control, or where specified versus BSA 
conjugate [33] control. % inhibition of IL-2 release calculated as described in legend to fig. 6.4. IL-2 
release was measured for each experiment by 3H-thymidine incorporation in duplicate cultures.
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Conclusion
The main aim o f  this project was the chemical modif icat ion  o f  a known  
inhibitor o f  cathepsin E (pepstatin A) to improve b ioavai labil ity .  The 
idea was that modif ication o f  the inhibitor to improve solubi li ty ,  a llow  
cellular targeting, and intracellular release o f  inhibitor from carrier, 
would provide a new tool for the study o f  antigen process ing  by  
cathepsin E. It is clear from the work presented within this thes is  that 
this was the case.  The value o f  the inhibitors has been further confirmed  
since the end o f  this PhD project246,247. From this study, it is apparent  
that the enzyme cathepsin E plays a role in the processing o f  at least one  
antigen, in this case the generation o f  a dominant immunogenic  peptide  
from OVA protein. Not only  has this been shown in A20 B-ce l l s ,  that 
express high levels  o f  cathepsin E, but also within dendritic cel ls  that 
contain cathepsin E and no cathepsin D.
C h em ica l  S y nthes is
The first step in synthes is  was to make the MPC1 / MPC2 inhibitors  
(figure 2 .14,  page 87),  those that contained a single  mannose compound  
either with or without a c leavable  linker. As set out in the design o f  
MPC1 / MPC2 (figure 2.7,  page 80),  the synthes is  was broken down into 
several sect ions; the mannose l igands,  a spacer unit, a l inker sect ion, and 
the inhibitor (pepstatin) ligand. There were very l ittle problems  
encountered in the synthesis o f  each o f  these sections,  with most  
reactions a llowing for the isolation o f  pure high y ie ld ing compounds.  
The coupling chemistry used to jo in  these sections  was also successfu l  in 
terms o f  y ie ld  and obtaining pure compounds. The first route for the 
formation o f  3 ’-benzyloxycarbonylpropyl 2 ,3 ,4 ,6 -tetra-0-acety l-<z-D-  
mannopyranoside [15] resulted in sl ightly impure material,  however the  
reaction o f  2,3 ,4,6-tetra-0-acety l-ci '-D-mannopyranosyl trichloro-
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acetimidate [3] with benzyl 4-hydroxy-butanoate  [12] using BF3.Et20  
was both se lec t ive  for the a-anomer and provided moderate ly  high y ie lds  
with little impurities.  The final stages o f  coupling pepstatin to the rest o f  
the MPC1 / MPC2 framework provided some interest ing insights  into the 
physical properties o f  pepstatin.  Pepstatin analogues  were both 
crystall ine and easy to handle in purif ication procedures.
For MPC5 and MPC6 (figure 2.8,  page 80),  a different synthetic strategy  
was used to include an alternative aromatic spacer moie ty ,  based upon  
other studies that showed improved aff in ity  for the mannose receptor.  
The synthesis o f  the mannose -  spacer l igand 4-nitrophenyl 2,3 ,4 ,6-tetra-  
O-acetyl-o'-D-mannopyranoside [6] ( sect ion 3 .1 .6 ,  page 96) was  
improved over the methods used for MPC1 / MPC2, with a shorter 
synthetic pathway to give a higher yie ld ing crystall ine material.  Unlike  
MPC1 / MPC2, pepstatin -  l inker analogues  were synthes ised first, and 
were then coupled to the mannosylated B S A  carrier. It was felt this 
approach would be better for both the synthesis,  purification and 
analysis o f  compounds, espec ia l ly  considering the physical  properties  
learnt about pepstatin that showed pepstatin analogues to be potentially  
easy  to purify.
One key  point regarding the coupling e f f ic iency  o f  the pepstatin  
inhibitor within compound MPC6 was not addressed. Spec if ica l ly ,  there 
is no quantitative data which  analyses  the stoichiometry o f  the 
pepstat in /BSA conjugate for either MPC5 or in particular MPC6.  
However, cons iderable  efforts (both by d ia lysis  and gel chromatography  
purif ication)  were made to remove free pepstatin,  making it unlikely  that 
free pepstatin had a role in the inhibit ion e ffects  observed with MPC6.  
Attempts were made to measure the conjugation e f f ic ien cy  o f  pepstatin  
to B S A  by using E l lm an’s test for the presence o f  free sulfhydryl groups  
on the B SA ,  however  with little success.  This problem needs to be 
looked at again in the future.
240
The synthes is  o f  MPC3 / MPC4 was not completed. The unfortunate  
mixing o f  Dde and ivDde protected lys ine  and the synthesis  o f  hexalysy l  
compounds containing both o f  these groups made it d if f icult  to analyse  
mass spectral data. Although it was felt  that the coupling o f  4- 
isothiocyanatophenyl a-D -m annopyranoside  [11] to the hexa lysy l  carrier 
(starting at section 3 .5 .5 ,  page 138) was successfu l  due to the 
disappearance o f  ninhydrin staining (an indication o f  no free amino  
groups being present), both mass spectra and NMR data were  
inconclusive ,  a problem that also occurred in other attempted synthesis  
steps. One o f  the problems with the synthes is  mentioned above was  
solubility,  an issue  that may be overcome with the use o f  an alternative  
solvent such as DMF. Several alternative approaches may help in the 
synthesis o f  these compounds (see  future work, page 248) .
E n z y m o lo g y
Inhibition by pepstatin A o f  the enzymatic  c leavage o f  a fluorogenic  
substrate by  rat cathepsin E showed an IC50 value within the pM range 
(fig.  6.1,  page 185).  The IC50 values for MPC1 / MPC2 are also in the 
picomolar range, similar to that o f  pepstatin,  suggest ing  that the attached  
ligands do not interfer s ignif icantly  with the binding o f  pepstatin to 
cathepsin E.
MPC5 and MPC6 have an I C 5 0  within the nM range (fig.  6.19,  page 209) .  
This much higher value does suggest an interference in the binding o f  
MPC5 / MPC6 to cathepsin E compared with pepstatin alone. This 
dif ference is l ik e ly  to be due to steric interference by the B SA  carrier or 
the spacer/l inker . However ,  B SA  -  conjugate [33] without  the addition  
o f  pepstat in has an approx. I C 5 0  value o f  inhibit ion o f  rat cathepsin E in 
the 0.5 -  2 pM range. This large di f ference in the I C 5 0  values o f  MPC5 / 
MPC6 compared with B S A  -  conjugate [33] is most  l ikely  due to the 
attachment o f  pepstatin.  It has been shown that the cellular degradation
241
o f  BSA and mannosylated BSA is inhibited by the presence o f  pepstatin  
A 242’243 suggest ing  an involvement o f  aspartic proteinases  in their  
catabolism. This could explain why B SA  -  conjugate has some inhibitory  
effect by i t s e l f  being a target for catabolism by cathepsin E (as opposed  
to the f luorogenic  substrate). This may also be a factor for MPC5 / 
MPC6.
Solubility
DMSO is required to so lubi l ise  pepstatin before it is used in vi tro.  This 
introduces tox ic i ty  effects  on a cel l  assay. The use o f  DMSO is also  
required to avoid crysta ll i sation o f  the inhibitors MPC1 / MPC2. The  
amount required for MPC1 and MPC2, however,  is lower than that 
required by pepstatin A, such that tox ic i ty  is greatly reduced. The 
attachment o f  multiple mannose units to B S A  to form the backbone o f  
the MPC5 / MPC6 inhibitors (figure 2 .14 ,  page 87) greatly improves  
their so lubi l i ty  in water,  such that no DMSO is required. The drawback 
to this is that the s ize  o f  a protein carrier does introduce its own  
problems, for example,  the fact that the protein carrier i t s e l f  was able to 
inhibit at higher  concentrations.  The eventual synthesis o f  the MPC3 / 4 
type o f  inhibitors (i .e.  those with a p o ly - ly s ine  backbone) may overcome  
this type o f  problem.
Targeting -  the effect  of  inhibitors  on A20 cells
As reported previous ly ,  Pepstatin A is a potent inhibitor o f  the 
process ing  o f  OVA antigen within the A 20  cell  l in e 112. MPC1 and MPC2  
are able to com ple te ly  abolish the response  (i .e.  IL-2 release) o f  D O l l -  
lO cel l s  to OVA presented by A20 cel ls .  As shown in figures 6.10 to 
6.14 (page  196 -  201) ,  this e ffect is due to the inhibitors them selves  and 
only  a min imal effect  is due to DMSO, cell  v iabi lity ,  or other cellular  
effects  that could cause inhibition o f  p323 presentation.
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Unlike the inhibit ion o f  IL-2 release when using A 20 ce l l s  and pepstatin,  
MPC1 or MPC2 inhibitors, there is a varied effect  o f  MPC5 and MPC6 
on A20 cel l  process ing  that shows only  a partial inhibit ion o f  IL-2 or in 
some circumstances an increase in IL-2 production, as shown for MPC5  
in figure 6.21a (page 211).  The reason for this varied e ffect is unknown.  
One poss ib i l i ty  for their poor inhibit ion may be l inked to the dif ference  
in IC50 between pepstatin A and that o f  MPC5 and MPC6. Pepstatin A 
has an IC50 on rat cathepsin E within the pM range (fig. 6.1,  page 185).  
This translates into inhibit ion o f  A20 cell  process ing  at approximately  
54pM. In contrast,  MPC5 and MPC6 have an IC50 on cathepsin E within  
the nM range (fig.  6.19,  page 209).  Without any means o f  se lec t ive  
uptake o f  MPC5 or MPC6 into A20 ce l l s  over that o f  pepstatin A, there 
may be a requirement to use over 0 .5mM o f  MPC5 or MPC6 to inhibit  
A20 cell  processing.  Such concentrations  would  not be poss ib le  with the 
MPC5 and MPC6 inhibitors.
Another poss ib i l i ty  for poor inhibition may be due to the dynamics o f  
protein movement and degradation within the A20 B -ce l l  that leads to 
the shuttl ing o f  MPC5 and MPC6 to ly sosom es  before either MPC5 or 
MPC6 can inhibit  OVA c leavage  by its attached pepstatin,  or c leavage  o f  
a pepstatin A analogue from MPC6. This idea is based upon several facts 
on the way B S A  and mannosylated B S A  is degraded in antigen  
presenting cell  endosomes.  The A 20 B -ce l l  contains endosomal
A ftcompartments similar to other antigen present ing cell s  , i.e.  endosomes  
that have a decreased pH gradient towards lysosom al  l ike v e s ic le s  along  
which antigen may travel.  The process  o f  antigen movement towards the 
ly sosom e can be s lower than the speed at which antigen can be c leaved  
in endosom es  to a llow binding o f  ant igenic  pept ides to MHC-II  
m olecu les ,  and as such antigen can be c leaved along any part o f  the 
endosome / ly sosom e  vesicular  pathway. Mannosylated B S A  has been  
shown to be degraded in early ly s o so m e s 248 and is transported to 
l y so so m es  when in the presence o f  pepstatin A 242.
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This suggests  that MPC5 and MPC6 may be able to inhibit  their own  
catabolism , the net effect being the transport o f  MPC5 and MPC6 to the 
ly sosom e with no inhibition o f  antigen process ing  being observed. To 
invest igate  this hypothesis wil l  need more study, outside the scope o f  
this project.
Targeting -  the effect of  inhibitors on DCs
Immature dendritic cell s  are different from the A20 B-ce l l  l ine in several  
ways. Immature dendritic cell s  are h igh ly  specia l ised in endocytos is ,  
either via  fluid phase or receptor mediated pathways.  In theory this 
should equate into a larger uptake o f  antigen. In addition, DC, but not B 
cel ls  or A20 cell s  express members o f  the mannose-binding receptor  
family,  and can therefore take up mannosylated analogues o f  pepstatin 
via receptor mediated endocytos is .  These two factors may impact on the 
ability o f  aspartic protease inhibitors to function ef fect ively .
The development o f  the B112 mice  population (see  sect ion 6.5,  213)  
made it poss ib le  to study the e ffect o f  aspartic proteinases inhibitors on 
wild type and cathepsin D defic ient DCs. It was not felt that the 
inhibitors MPC1 and MPC2 would  be valuable inhibitors for the study o f  
these cel ls .  Unfortunately,  the l imitations with cel l  numbers and project  
duration meant that only  a l imited set o f  MPC5 and MPC6 experiments  
were performed, and in all cases  there were no s ignificant inhibition  
effects  observed with MPC5 compared to its control BSA conjugate [33].  
It would  not be unreasonable to assume that MPC6 would be more potent  
than MPC5 because  o f  its abil ity  to be enzymatically  c leaved  
intracel lularly by thiol  reductases to release an unencumbered pepstatin 
A analogue. The lack o f  MPC5 effect may be an indication o f  this, or as 
mentioned previously ,  some type o f  shuttl ing o f  MPC5 into lysosom es  
where it could be eas i ly  destroyed by the proteolytic  environment.  It is 
l ik e ly  this could  happen to MPC6 also,  how ever  c leavage  o f  the l inker in
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MPC6 may a llow for it to inhibit aspartic proteinase  function. More 
work would  be needed to assess the value o f  the c leavable  l inker.
The effects  o f  pepstatin,  MPC1 and MPC2 upon antigen process ing  using  
murine derived bone marrow DCs (sect ion 6 .7 .1 ,  page 229 and section  
6.7.2 ,  page 232)  are similar to the effects  seen within A20 ce l l s  (sect ions  
6.1, page 184 and sect ion 6.2,  page 190). At lower concentrations  o f  
inhibitor (below 54pM),  the e ffect o f  pepstatin / MPC1 / MPC2 was  
minimal compared with that observed using A20 cel ls .  This may be 
explained by the increased proteolyt ic  abil ity o f  DCs over that o f  A20  
cel ls  such that at 18pM o f  inhibitor enough OVA protein is processed to 
provide a suff icient amount o f  p323 peptide for antigen response by  
D O l l - l O  cel ls .  Very small  amounts o f  antigen are required to provide a 
sufficient T-cel l  response ,  as is evident for the difference o f  dose  
response seen between p323 peptide and OVA protein. It should also be 
pointed out that the MPC1 and MPC2 inhibitors only contain a single  
mannose sugar, and as such are unlikely  to have a high aff inity for the 
mannose receptor to aid in endocytos is .
There were no specif ic  inhibition effect  observed when using high  
concentrations o f  MPC6 (i.e.  6pM or above) (sect ion 6.7 .3 ,  235),  a 
poss ib le  explanation o f  this is as fo l lows .  It has been previously  shown  
that B S A  and mannosylated B S A  are both cleaved by aspartic 
proteases242,243, and it would not be unreasonable to assume that B SA  
should therefore act as a competit ive  inhibitor due to the high  
concentration o f  B SA  conjugate  [33] or MPC6 used, an idea ment ioned  
previously .  A dif ference here with the use o f  DCs is that B S A  conjugate  
[33] displays  a reduced inhibit ion at 6pM, w hi le  MPC6 maintains a high  
inhibit ion (approximate ly  80 %). MPC6 (or even MPC5),  containing an 
inhibitory pepstat in m olecule ,  may inhibit  cathepsin D / E by either BSA  
cataboli sm or pepstatin binding.
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The effect o f  MPC6 (2pM) on B112 WT and cathepsin D def ic ient  DCs  
was also invest igated.  Interestingly, the e ffect o f  the control B SA  -  
conjugate [33] at 2pM is greatly reduced. In consequence,  f igure 6.38  
(page 238) shows that both B112 murine WT and cathepsin D defic ient  
DCs show a statis tically  significant greater inhibit ion o f  OVA process ing  
by MPC6 over that o f  BSA -  conjugate [33]. Importantly,  both MPC6  
and B SA  -  conjugate [33] did not inhibit  the presentation o f  p323  
peptide to D O l l - l O  T-cell s .  The fact that cathepsin D defic ient DCs are 
also s ignif icantly  inhibited in their ability to process  OVA antigen has 
important implications  for the role o f  cathepsin E within the processing  
o f  OVA. Some experiments that used cathepsin D defic ient  DCs actually  
showed inhibition greater that 100 % (fig.  6.38a,  page 238).  Such 
inhibition above that o f  the cell s  only control could poss ib ly  be an 
indication o f  cel l  death or anergy, maybe due to other important effects  
o f  cathepsin E.
Although data was l imited, there was an indication that the levels  o f  IL-2 
release observed with B 112  cathepsin D knockout DCs is general ly  lower  
than that o f  WT B112  DCs. This may be an indication that cathepsin D 
participates in the process ing  o f  OVA antigen within DCs. Antigen that 
enters ly sosom es  would be e f f ic ient ly  c leaved by cathepsin D and may  
re-enter the endosomal pathway for binding onto MHC-II molecules .
Proteolysis  and antigen processing
It is clear from recent literature,  that there is stil l  a lot o f  information to 
be gained for the role o f  proteolytic  enzym es  within antigen processing.  
It can be generally  concluded that at present proteolytic  enzymes such as 
those ment ioned in section 1.7 (starting at page 46) have varied 
functions in antigen presenting cell s .  Although they are all involved in 
the p rocess ing  o f  antigen or important cellular m olecu les ,  it is clear that 
the exact  environment that the enzymes are located, as we l l  as the type
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o f  antigen that they encounter, plays a changing role upon the functions  
o f  each o f  these proteolytic enzymes.  The field is continually  evo lv ing  to 
highl ight the contributions that individual enzymes  play in different  
aspects o f  antigen process ing.
It is traditionally thought that aspartic proteinase  function is not  
essential  for the generation o f  antigens within mice.  However,  our own  
work, and that by others (section 1.7.4,  page 51) has shown that in v it ro  
aspartic proteinase activity  may be important.  This is extended by the 
work presented in this thesis and that has been publ ished247, showing  
that cathepsin E has an important role in the proteolysis  o f  OVA antigen  
within DCs. Watts et al  showed that the presentation o f  myoglobin  
antigen to T -ce l l s  by DCs lacking CD was surprisingly enhanced, and 
that this ef fect  was pepstat in -sensi t ive249. The conclus ion from this work 
indicated opposing functions o f  aspartyl proteinases in antigen  
process ing, whereby cathepsin E may be the important enzyme involved  
in the process ing  o f  m yoglob in  antigen at optimal levels  within DCs,  
whereas cathepsin D may exert destructive effects  upon myoglobin ,  and 
thus reduce the e f f ic ien cy  o f  processing.
In this research, we  show that at least in the case o f  OVA antigen when  
processed either by A20 B -ce l l s ,  or by DCs,  there is non-redundancy for 
the role o f  aspartic proteinases  in the generat ion o f  the p323 fragment  
(amino acids 323 -  339) from OVA protein.  Many other studies,  
however, show redundancy in proteolytic  enzyme function, and this may  
also be true for the aspartic proteinases.  Specif ic  non-redundant  
funct ions,  however,  have also been demonstrated for AEP by Watts et
7 7al  , whereby AEP can destroy a potentia l ly  important T-cel l  epitope, the 
HLA-DR2-restr ic ted encephal i to-gen ic  MBP epitope (MBP 85-99) ,  which  
contains an AEP cleavable  site (Asn-94) .  The fact that AEP and aspartic 
prote inases  are able to direct the immune response  o f  specif ic  antigen
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processing models  may suggest  that other proteinases may also have such  
se lect ive  activi ty  patterns.
The dif ference between these two studies and the general consensus  may  
lie in the complex ity  o f  the antigen process ing  pathway. We have shown  
that with the use o f  a se lect ive ,  so luble,  cel l  and vesicular  targeted  
inhibitor o f  aspartic proteinases,  the recognit ion o f  the p323 fragment o f  
OVA is complete ly  abolished. It may be that future work in the field o f  
antigen processing requires to take into considerat ion the factors that 
guide antigen into a cel l  through to its eventual antigenic peptide.  
Carefully planned experiments that target proteolytic  inhibitors into 
various intracellular compartments may hold the key to unravell ing the 
role o f  proteolyt ic  enzymes on particular antigens or within particular 
intracellular ves ic les .
Future  w ork
There are several areas o f  the synthes is  that need to be improved for 
future work. A method to detect the coupling e f f ic iency  o f  pepstatin to 
B SA  -  conjugate [33] or other MPC inhibitors needs to be addressed.  
One alternative to the E l lm an’s test for measuring free sulfhydryl  
content would  be to use an improved marker for sulfhydryls,  such as an 
iodoacety l analogue o f  a fluorophore, and use to examine the difference  
in its reaction with B S A  -  conjugate [33] and MPC5 or MPC6.  
Alterntively ,  partial tryptic digest ion o f  MPC6 fo l lowed by HPLC-mass  
spectroscopy,  could be used to assay the degree o f  conjugation.
An important area that was very much m issed  in this report was the 
complet ion  o f  the MPC3 / MPC4 inhibitors.  Given the increased affinity  
o f  such mult ivalent l igands for the mannose  receptor, and the l ikelihood  
that they would  be much more potent and less  toxic  that the inhibitors  
tested, the future synthes is  and testing o f  such l igands is very exciting.
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Several lessons  were learnt from the attempted synthes is  o f  MPC3 / 
MPC4. The analysis  o f  products was dif ficult ,  and this needs to be 
addressed. The coupling o f  the sugar units to the hexa lysy l  backbone had 
the additional problem o f  reactant solubil ity .  An alternative approach 
might be to attach the Lysyl ( ivDde) -  l inker -  pepstatin units separately  
from the then pentalysyl and sugar units. Exist ing chemistry could be 
used to obtain a linker -  pepstatin molecule ; attachment o f  an ivDde  
protected lys ine molecule  to pepstatin should be easy,  with purif ication  
and analysis not being a major problem. Subsequent attachment o f  this to 
a Boc-protected pentalysyl framework may aid in the analysis  (no 
complex sugar signals  found in NMR spectra) and in purification (HPLC 
would be ideal to separate the product).  Deprotection o f  Boc groups  
should proceed without problem, leaving attachment o f  the sugar units as 
the last step, with analysis  by MALDI-TOF MS being poss ib le  with such 
a large compound.
Unfortunately,  time l imitations  at the end o f  this project restricted the 
experiments performed. However, it is clear from this study that within  
DCs, cathepsin E plays  a role in the antigen processing o f  OVA. My own  
data showed that even at concentrations  o f  MPC6 below 2pM, significant  
inhibition was  still  observed.  There are several areas o f  research that 
would have s ignif icantly  improved this report. More data using the B112  
mice would  a llow a more detai led and accurate analysis o f  both the role  
o f  cathepsin E and the effect  o f  MPC6. A major l imitation was the 
number o f  ce l l s  obtainable from the B 112  mice  at the early stage o f  l ife  
that they were being used. Another problem was the purity o f  the DC 
population, at most this was ~ 60 %, but it was common to obtain 
populat ions  as low as 30 %. A more accurate analysis  o f  the DC 
populations obtainable from B112 ce l l s  may have helped to explain the 
low yie lds  o f  DCs. Recent  work by Prof. B. Chain has improved the 
y ie lds  o f  ce l l s  obtained by extending the culture duration247. With the 
additional use  o f  FACS cel l  sorting, Prof  B. Chain has been able to
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obtain high yie lds  o f  purer DC populations.  The data obtained from these
247cell s  extends the work presented here
The results presented naturally lead to a w hole  range o f  poss ib le  future 
approaches to study the role o f  cathepsin E. Without a doubt, the use o f  
other antigens would  be important to show i f  cathepsin E has an effect  
on other antigens too.  The se lect ive  targeting o f  particular v e s ic le s  is 
also poss ib le .  As previously  mentioned, the DEC-205 m olecu le  when  
bound by antigen (or antibody) is able to target to late endosomal / 
lysosomal v e s i c l e s 34. The improvements  in cel l  culture o f  human DCs  
over the last decade means that the role o f  cathepsin E within human 
DCs could be explored. The poss ib i l i ty  o f  targeting DCs in v ivo  is also a 
possibil i ty .  Although it has been suggested that it would be dif ficult  to 
synthesis a cathepsin E-specif ic  inhibitor126, this is still  an option that 
could be explored. In fact, some o f  the already synthesised cathepsin D 
inhibitors (see  section 1.7.5,  page 59) may distinguish between these two  
enzymes, and would  be a good starting point.
In conclus ion,  the work presented in this thesis suggests that further 
interdisciplinary collaborations between chemists and immunologists  
wil l  provide a fruitful avenue to approach the molecular dissection o f  
antigen process ing  pathways.  In turn, this wil l  lead not only to improved  
understanding o f  the generat ion o f  the immunological repertoire,  but 
poss ib le  new approaches to therapeutic intervention for the control o f  
cancer, autoimmune disease  or other immune-mediated pathologies.
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Appendix I: NOE of 3-benzyloxycarbonylpropyl 2,3,4,6-tetra-O-acetyl-a-D-mannopyranoside [15]
.OAc
OAc
AcO
AcO
R =
Large H-3 / H-5 NOE
Minimal H-l  / H-3 or 
H-l  / H-5 NOE
H-4 
H - 3 ,  H-2
H-l
H-6 H-6 H-5
ppm
H-5
H-6
W  H-6
H-2
H-4
H-3
5 . 2 5 . 0 85 . 4 4 . 4 . 6 4 . 4 4 . 2 4 . 0 3 . 8 3 . 6 3 . 4 ppm
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Appendix II: NOE of 4-nitrophenyl 2,3,4,6-tetra-O-acetyl-a-D-mannopyranoside [6]
H-4
H-l
H-3 H-2
H-6 H-6
OAc
OAc
. -o ppm
AcO
AcO
OG
4
5 . 4 -
5 . 2 5 . 05 . 6 5 . 4 88 4 . 4 . 65 . 4 . 4 4 . 2 4 . 0 3 . 8
H-5
H-6
H-6
H-4
H-2
H-3
ppm
Appendix III: 'H NMR of acetylated MPC1
H-25'
H-29'
H-32'
H-33'
CH-
H-l 6’,H-2
H-3
H-4
H-l 2' 
H-21'
H-5 
H-9' 
H-6 H -l8' 
H-24’
H-28'
H-4'
H-6'
H-3’ 
H-8' 
H-l T
H-l 1'
or
H-20'
H-l O' 
H-l 9’ H-5H-6
H-15 H-l' H-l H-2
unknown
impurity
— \— •— •— 1— ’— I— '— ’— '— '— I— ' ' ' ' I ' ' ’ ' I ' ' ' 1 1 ' ' '— '— I— '— '— '— ’— I— '— '— '— '— I ' ' ' ' I 1 ' '
5 . 5  5 . 0  4 . 5  4 .0  3 . 5  3 . 0  2 . 5  2 . 0  1 . 5  1 .0  ppm
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4 x acetyl
Appendix IV: 13C NMR of acetylated MPC1
5 x  CH-,
5 x C H
C-33'
C-29
C-17C-2,  C-3 
C-9', C-18'
C-15
C-16'
"T^
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 ppm
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Appendix V: DEPT 135 NMR of acetylated MPC1
C-12
C-21C-29'
C- 6'
C-15
C-33'
C-4'
C-6'
70 65 60 55 50 45 40 35 30 25 20 15 10 ppm
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Appendix VI: COSY NMR of acetylated MPC1
ppm
a .
0 . 5
1 . 0
o
1 . 5
2 . 0
2 . 5
3 . 0
3 . 5
4 . 0
4 . 5
5 . 0
5 . 5
4 . 04 . 55 . 0 3 . 5 3 . 0 2 . 55 . 5 2 . 0 1 . 0  ppm1 . 5
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ppm
1 0 -
2 0 -
3 0 -
50
6 0 -
7 0 -
80
90
1 0 0 -
Appendix VII: HSQC NMR of acetylated MPC
i__A u
I> V
' ' 1 • I ■ ' ■ • I ■ • ■ ■ I ‘ ' J ' 1 •
5 . 5  5 . 0  4 . 5  4 . 0  3 . 5
•rj
I
f-
F-
5 2 . 0  1 . 5  1 . 0  ppm
Appendix VIII: MALDI-TOF MS o f  BSA and BSA  
conjugate [33]
BSA
1 2 0
3 0 0 0 0 4 0 0 0 02 0 0 0 0 5 0 0 0 0 6 0 0 0 0 7 0 0 0 0 m / z
BSA conjugate [33]
500
I " -
4 0 0
3 0 0
20 0
3 0 0 0 0 5 0 0 0 0 7 0 0 0 0
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Appendix IX: MALDI-TOF MS o f  MPC5 and MPC6
1 MPC5
8 0 0  ^
8 0 0 0 0 m / z6 0 0 0 04 0 0 0 0
MPC6
5 0 0 0 0 7 0 0 0 03 0 0 0 0 r a / z
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